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ABSTRACT OF THE DISSERTATION 
 
Contribution of the Microenvironment in Bone Resident Cancer: 
the Role of Thrombospondin-1 in Bone and Risk Loci Contributing to Multiple Myeloma 
 
by 
 
Sarah R. Amend 
 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Genetics and Genomics 
Washington University in Saint Louis, 2014 
 
Katherine Weilbaecher, Chair 
Michael Tomasson, Co-Chair 
 
Cancer growth in bone, a defining characteristic of multiple myeloma and common in 
many solid tumors including breast and prostate cancer, is characterized by the active 
participation of host microenvironment cells.  Tumor cells stimulate the vicious cycle through 
stimulation of bone remodeling by osteoclasts and osteoblasts, resulting in increased release of 
growth factors and cytokines to further promote local tumor growth.  Notably, cancer cells are 
unable to remodel bone independently, and require the metabolically active bone cells for this 
support.   
  A specific role for the bone microenvironment in mediating tumor growth was first 
discussed in 1889 with the introduction of Paget’s seed-and-soil hypothesis that tumor cells will 
only grow in a favorable microenvironment.  This dissertation is focused on investigating the 
properties of a “congenial soil.”  In Chapter 2 we discuss the role of bone-resident 
Thrombospondin-1 (TSP1), a glycoprotein with well-documented roles in promoting cancer 
growth.  Chapter 3 is focused on the identification of genes conferring inherited susceptibility to 
! xi!
multiple myeloma that participate both in malignant cells and in host supportive cells.    
 TSP1 is a large matricellular protein that interacts β3 integrin, CD47, and other receptors 
to regulate cell migration, adhesion, and proliferation with effects on tumor angiogenesis, 
inflammation, and wound healing.  We examined the role of TSP1 in the bone 
microenvironment.  TSP1-/- mice had increased trabecular bone volume and increased cortical 
bone area and thickness compared to wild type controls.  Surprisingly, TSP1-/- mouse bones did 
not resist bending as much as anticipated, and we confirmed a bone materials defect, indicating 
that TSP1 was important for maintaining bone quality.  In addition to the mechanical defects, 
TSP1-/- mice had decreased serum CTX compared to controls, indicating an osteoclast defect.  
Primary osteoclast cultures require TSP1 at early stages of osteoclastogenesis, though exogenous 
TSP1 is dispensable at later stages of maturation.  Interestingly, we found that TSP1-deplete 
osteoclast cultures had a significant and dramatic increase in inducible nitric oxide synthase 
(iNOS) expression.  Moreover, upon administration of a NOS inhibitor to mice, the TSP1-/- bone 
resorption defect was rescued to wild type levels.  To test whether osteoblast-deposited bone-
resident TSP1 inhibits early osteoclast NO signaling, we plated osteoclasts on either wild type or 
TSP1-/- bone and found that only wild type bone was sufficient to block iNOS expression.  Thus, 
we conclude that TSP1 is a paracrine signaling molecule that couples OB activity to OC 
formation and targeting of the TSP1 signaling pathway, currently under investigation for treating 
cancer and modulating blood pressure, may have additional effects on bone. 
 The second part of this dissertation focuses on host susceptibility to multiple myeloma 
(MM) and its requisite precursor, monoclonal gammopathy of undetermined significance 
(MGUS).  The C57Bl/KaLwRij (KaLwRij) mouse strain has increased susceptibility to benign 
idiopathic paraproteinemia (BIP), analogous to human MGUS, and is a common mouse model 
! xii!
for the disease.  Following immunization, KaLwRij mice developed a sustained M-spike at a 
higher frequency than 12 other genetically diverse mouse strains, most notably, the highly 
related C57Bl/6J (B6) strain.  To query the genetic basis for BIP susceptibility in KaLwRij mice, 
we completed SNP analysis to identify variation between KaLwRij and B6.  We found that 
KaLwRij is a unique inbred strain, completely distinct from the closely related B6.  We 
identified several thousand variants between KaLwRij and B6 and compiled a candidate gene list 
of 419 genes.  To ensure that we would pursue genes applicable to human disease, we completed 
whole genome association analysis between MM patients and healthy controls and identified 
SNPs located in 180 gene loci.  Combining these two gene sets resulted in a candidate gene list 
of 5 genes, one of which, Samsn1, is annotated as a negative regulator of B-cell activation.  Upon 
closer examination of the Samsn1 locus, we found that KaLwRij harbored a germline deletion of 
all coding exons of the gene, resulting in absent RNA and protein expression.  Consistent with 
the published role of SAMSN1 in genetically deficient mice, KaLwRij mice had enhanced B-cell 
function as evaluated by B-cell proliferation in primary culture and in vivo IgG2b response.  To 
investigate the role of Samsn1 in host cells, we profiled Samsn1 expression in bone 
microenvironment cells and found that macrophages were high expressers. KaLwRij 
macrophages had enhanced expression of polarization markers, suggesting that they are pre-
activated under homeostatic conditions.  Further, we found that KaLwRij macrophages 
stimulated to a pro-tumorigenic M2 polarization promoted 5TG myeloma tumor growth more 
than B6 control macrophages in mice.  In conclusion, we identified candidate gene lists 
underlying murine and human susceptibility to MGUS and myeloma.  Specifically, we found 
that Samsn1 contributes to KaLwRij susceptibility to BIP, and likely to human MGUS, through 
effects in pre-malignant B-cells and in macrophages. 
! 1!
Chapter 1 
 
Introduction
! 2!
The seed and soil hypothesis of metastasis 
Metastasis is the dissemination of primary tumor cells to a distant site. In 1889, Stephen 
Paget, a physician in the West London hospital, analyzed the autopsies of 735 fatal breast cancer 
patients.  He noted that secondary growth was more often seen in some organs than others, even 
in those with the same potential for metastasis (e.g. liver vs. spleen).  Furthermore, he noted that 
“the bones [of breast cancer patients] suffer in a special way,” more than would be predicted 
based on the circulation of tumor cells alone, based on evidence from other cancer types (Paget, 
1889).   
These observations led to his proposal of the “seed and soil” hypothesis:  “when a plant 
goes to seed, its seeds are carried in all directions, but they can only live and grow if they fall on 
congenial soil.”  Cancer biologists, then, must be “scientific botanists,” concerned not just with 
the malignant seed, but also with the “properties of the soil” that make up a favorable tumor 
microenvironment (Paget, 1889).   
The goal of this thesis is to contribute to the understanding of the “congenial soil.”  First, 
we will address the role of the antiangiogenic Thrombospondin-1 in the “fertile soil” of bone, a 
common site of metastasis.  Second, we will identify genetic risk loci that confer whole-host 
“congeniality” to multiple myeloma (MM) and its precursor syndrome monoclonal gammopathy 
of undetermined significance (MGUS).   
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Part I:  The role of the bone microenvironment in metastasis. 
 
Homeostatic bone remodeling requires coupled bone formation and destruction 
 Bone is a dynamic connective organ that, together with the cartilage, comprises the 
skeleton and provides mechanical, protective, and metabolic support for the rest of the body.  
Cancellous bone is made of a lattice of trabeculae localized to the metaphysis of long bones with 
high surface area for mineral metabolism. Cortical bone forms the outer shell of the metaphysis 
and the diaphysis (shaft) of long bones to provide mechanical support. The bone marrow found 
in the marrow space formed by the cortical bone is made up of hematopoietic and stromal cells 
that give rise to blood cells, platelets, endothelial cells, fibroblasts, adipocytes, osteoblasts (OBs), 
and osteoclasts (OCs) (Baron, 1996).  
 The bone matrix is composed of two compartments: osteoid (primarily collagen type I 
fibers–90%, and non-collagenous proteins–10%) and mineral (calcium-phosphate hydroxyapatite 
crystals). The numerous noncollagenous proteins include growth factors, proteoglycans, and 
adhesion molecules. These molecules contribute to maintenance of homeostatic bone 
remodeling, promoting cell attachment, differentiation, and growth of bone remodeling cells. In 
addition, some molecules aid in osteoid and mineral matrix organization, directly influencing 
bone strength.  
 Bone-forming OB arise from mesenchymal stem cells and express specific markers 
during differentiation including Runx2, alkaline phosphatase, osteonectin, and osteocalcin, 
useful for tracking OB formation in an experimental setting.  To form bone, OBs deposit 
collagen fibers to form the extracellular matrix that is subsequently calcified with hydroxyapatite 
crystals.  Osteoid also contains non-collagenous proteins secreted by the OBs including 
! 4!
thrombospondin-1 (TSP1), BMPs, IGFs, and TGFβ that play diverse roles in maintaining matrix 
structure and as signaling molecules to promote adhesion, survival, and differentiation of cells 
within the bone marrow (Puzas, 1996).  OBs also directly promote OC formation through pre-
OB secretion of MCSF and expression of RANKL, key cytokines necessary for 
osteoclastogenesis. 
 OCs arise from the MCSF- and RANKL-dependent fusion of macrophages.  Following 
fusion, pre-OCs polarize and form the characteristic ruffled membrane necessary for bone 
resorption.  OCs form a contractile actin ring to create a highly acidic sealing zone, the site of 
bone resorption (Baron, 1996; Novack and Teitelbaum, 2008).  Cells committed to the OC 
lineage are TRAP+, useful for in vitro staining.  Furthermore, each stage of OC formation is 
characterized by a unique gene expression signature: early OC precursors express N-FATc1, 
fusing OC express DC-STAMP and CD47, polarized cells express αvβ3 integrin, and mature 
resorbing cells express Cathepsin K.  Dissolving of the mineral and underlying matrix releases 
growth factors and cytokines essential for OB activity, thus recruiting bone formation to a site of 
recent bone destruction. 
 Bone remodeling is a tightly regulated process that requires the coupled activity of bone 
forming OBs and bone resorbing OCs. Bone remodeling is necessary to preserve the integrity of 
the skeleton and to maintain calcium and phosphate levels (Baron, 1996; Hadjidakis and 
Androulakis, 2006).  Misregulation of the basal bone remodeling, as in osteoporosis or bone 
metastasis, leads to decreased bone integrity, resulting in hypercalcemia, nerve-compression, and 
pathologic fracture. 
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Bone is a favorable microenvironment for metastatic invasion and growth 
 Bone metastasis is common to many cancers, including breast (70%), prostate (70%) and 
lung (35%), and bone disease is characteristic of multiple myeloma (Coleman, 2001; Lipton, 
2004; Mundy, 2002). The consequences of bone metastases are devastating and cause pain, 
pathologic fracture, spinal cord and other nerve-compression syndromes, and life-threatening 
hypercalcemia (Roodman, 2004). Both osteolytic lesions and osteoblastic bone metastases are 
associated with increased OC activity and disrupted bone micro-architecture (Coleman et al., 
2005; Lipton et al., 2001). Notably, while cancer cells are unable to resorb bone independently, 
they secrete soluble factors that promote bone remodeling resulting in the release of additional 
bone matrix-bound growth factors which further activates OCs and OBs and promotes tumor 
growth (Bendre et al., 2003; Clines and Guise, 2008; Guise et al., 2006; Hirbe et al., 2006; Hirbe 
et al., 2007; Kakonen et al., 2002; Kingsley et al., 2007; Kozlow and Guise, 2005; Mundy, 2002; 
Pfeilschifter et al., 1987; Roodman, 2004; Yin et al., 1999).  This process of pathologic induction 
of bone remodeling by the cancer cells results in a “vicious cycle” of tumor growth and bone 
destruction (Figure 1.1).  Anti-resorptive therapy, e.g. with bisphosphonates or denosumab, 
significantly decreases skeletal complications of cancer and is a standard of care for patients with 
bone metastases (Body et al., 2009; Fizazi et al., 2009; Hamdy, 2008; Hirbe et al., 2006; 
Roodman, 2004). 
 
Integrins play a critical role in bone metastasis in both tumor cells and host stromal cells  
 The site of metastasis is tumor cell specific depending on adhesion molecule and 
chemokine receptor expression profiles of both the cancer cell and the host organ cells (Kang et 
al., 2003; Marcellini et al., 2006; Wei et al., 2005; Yoneda, 2000).  At the metastatic site, normal 
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physiology is changed towards increased secretion of cytokines and activation of adhesion 
molecules to support recruitment, survival, and growth of tumor cells. Integrins expressed by 
tumor cells, in concert with bone microenvironment chemokine secretion and further adhesion 
molecule activation, determines the osteotropic characteristics of metastasizing cancer cells and 
represent an ideal target for skeletal metastatic cancer therapy.   
Integrins are heterodimeric transmembrane glycoproteins that facilitate cell-cell and cell-
extracellular matrix adhesion and cell migration (Schwartz et al., 1995). Integrins recruit many 
intracellular signaling molecules and can activate survival, proliferation, and motility signaling 
pathways (Hynes, 1992). Tumor cells localize to specific tissues through integrin-mediated 
contacts with extracellular matrix and stromal cells. Integrin expression and signaling are 
perturbed in cancer cells, allowing them to “escape” from cell-cell and cell-matrix tethers, 
invade, migrate, and colonize within new tissues and matrices. Integrin signaling through αvβ3 
and VLA-4 on tumor cells promotes tumor metastasis to and proliferation in the bone 
microenvironment. As described above, misregulated OC-mediated bone resorption is a hallmark 
of bone metastasis and promotes tumor expansion in the marrow space. αvβ3 integrins are 
critical for OC function and development (Faccio et al., 1998; Faccio et al., 2003; Feng et al., 
2001), and β3-/- mice have reduced tumor burden in bone and are protected from tumor-
associated osteolysis due to defective OC (Bakewell et al., 2003; Morgan et al., 2009) 
Integrin-mediated cell signaling plays a critical role in many of these processes during 
bone metastasis, including platelet aggregation (αIIbβ3), hematopoietic/immune cell 
mobilization (VLA-4, osteopontin, TSP1), neoangiogenesis (αvβ3,αvβ5, α6β4, β1 integrins, 
TSP1, CD47) and stromal function (osteopontin, VLA-4) (Figure 1.2). The mechanisms by 
which integrin signaling mediates the pathogenesis of bone metastasis, both from the tumor cell 
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and the host microenvironment, is an area of active research.  Integrin pathway signaling is 
critical in the pathogenesis of bone metastasis at many stages and further study to define integrin 
dysregulation by cancer cells will yield new therapeutic targets for the prevention and treatment 
of bone metastasis. 
 
Integrin signaling is critical for cell adhesion and survival 
There are 8 beta and 18 alpha integrin subunits that assemble into 24 different known 
combinations in different cell types, each characterized by distinct ligand binding specificities, 
signaling abilities, and regulatory mechanisms(Hynes, 2002). Integrins are activated by 
conformational changes in the integrin extracellular domains (“inside-out” signaling). When the 
integrin α and β subunit cytoplasmic and transmembrane domains remain closely juxtaposed, the 
extracellular domains are held in a closed conformation. Activation by intracellular signals to the 
cytoplasmic tails results in separation of the α and β cytoplasmic and transmembrane domains 
and exposure of the extracellular ligand binding domain (Shattil et al., 2010) (“inside-out” 
signaling). In addition to activation by inside-out signaling, ligand binding and integrin 
clustering can be significantly modulated by growth factor receptor interactions and other 
integrin interacting proteins, as reviewed in (Desgrosellier and Cheresh; Hynes, 2002; Shattil et 
al., 2010). The open conformation facilitates high affinity ligand binding and triggers integrin-
mediated cell signaling cascades (“outside-in” signaling) (Offermanns, 2006; Qin et al., 2004), 
critical for growth, migration, adhesion, and survival.  
 Maintaining adhesion to the extracellular matrix, in part through integrin signaling, is 
critical to cell survival (Frisch and Screaton, 2001). Altered cell-cell or cell-matrix interactions 
can result in disruption of downstream survival signaling and anchorage-dependent non-
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transformed cells undergo anoikis (Frisch and Screaton, 2001). Under normal conditions, 
because each cell type expresses a unique set of integrins that recognize underlying extracellular 
matrix ligands, this form of apoptosis ensures that detached cells do not colonize inappropriate 
locations (Frisch and Screaton, 2001). Cells that resist anoikis, such as metastatic cells, take 
advantage of aberrant integrin expression that enables the cell to adhere to a novel extracellular 
matrix (Bissell and Radisky, 2001) and colonize a distant site.  
 
Integrin signaling in tumor cells that metastasize to bone 
Tumor progression, invasion, and metastasis require the activity of many adhesion 
proteins, including the integrin superfamily.  At each stage of cancer progression, subsets of 
integrin heterodimers are activated, providing the necessary signaling pathways for adhesion, 
migration, and cell survival. Metastatic tumor cells show differential integrin heterodimerization 
and activation compared to non-metastatic tumor cells that enable the cell to home to and 
colonize in a metastatic site, such as the bone marrow cavity (Edlund et al., 2001; Yoneda, 
2000). In order for primary epithelial cancers to metastasize, the tumor cells must become 
resistant to anoikis and detach from the primary tumor site extracellular matrix, enter the 
vasculature, and eventually colonize a distant site. Upon reaching a successful metastatic site, 
however, tumor cells use both anoikis and anoikis-resistance to their advantage, in some cases 
forming micro-metastases that are resistant to cancer treatment via integrin binding to the 
underlying bone matrix as reviewed in (Clezardin, 2009). In addition to evading apoptosis, tumor 
cells must also form interactions between the tumor cell and bone stroma to establish and 
maintain skeletal metastasis.  
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The β3 integrin signaling pathway has been implicated in tumor cell-host bone stroma 
interactions during bone metastasis and tumor growth in bone (Figure 1.2).  Breast cancer cells 
that overexpress αvβ3 have increased levels of bone metastasis and associated tumor burden and 
osteolysis (Nakamura et al., 2007; Pecheur et al., 2002; Sloan et al., 2006; Van der Velde-
Zimmermann et al., 1997; Zhao et al., 2007). This overexpression of αvβ3 in the tumor cells 
leads to increased tumor cell adhesion, migration, and invasion to bone as well as enhanced OC 
recruitment within the bone microenvironment (Pecheur et al., 2002; Sloan et al., 2006), 
implicating a role of tumor-specific αvβ3 expression in breast cancer metastasis to bone as well 
as tumor-associated osteolysis.  Likewise, in prostate cancer cells, active αvβ3 is necessary for 
the adherence and migration to bone matrix proteins at early stages of skeletal metastasis.  This 
tumor cell αvβ3 integrin expression allows cancer cells to adhere to the bone matrix and interact 
directly with the native bone cells, OBs and OCs, as well as with the bone matrix itself 
(Nakamura et al., 2007).   
 
CD47 and TSP1 augment αvβ3 integrin signaling  
β3 integrins are activated upon binding to an Arg-Gly-Asp (RGD) protein motif, 
contained in many extracellular matrix proteins including vitronectin, fibronectin, osteopontin, 
bone sialoprotein, and TSP1, among others. Importantly, integrin associated protein CD47 
augments integrin activation and affects the ability of αvβ3 integrin to cluster upon ligand 
binding (Brown and Frazier, 2001).  CD47 augments β3 integrin-dependent adhesion, with 
CD47-deficient β3-expressing cells showing decreased adhesion to vitronectin (Lindberg et al., 
1996).  Notably, TSP1 ligation of CD47 further enhances adhesion (Gao et al., 1996), suggesting 
that TSP1-binding of CD47 mediates the enhancement of β3 function.  Pertussis toxin inhibits 
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these effects, providing evidence that the mechanism likely involves Gαi GTPase activity 
(Frazier et al., 1999; Green et al., 1999).  Investigation of the role of TSP1 in the bone 
microenvironment will be discussed in Chapter 2. 
 
αvβ3 integrin and thrombospondin-1 regulate tumor angiogenesis 
Tumor neovascularization is essential for tumor growth and metastasis, providing the 
cancer cells with host nutrients and access to the circulation for the dissemination for metastatic 
cells.  The ability of tumor cells to activate the normally quiescent vasculature is proposed to be 
controlled by an “angiogenic switch” mechanism, whereby tumor or stromal cells induce 
changes in the relative balance of inducers (VEGF, TGFβ) and inhibitors (TSP-1) of 
angiogenesis (reviewed in (Desgrosellier and Cheresh; Hanahan and Weinberg, 2000; Hodivala-
Dilke, 2008; Hood and Cheresh, 2002; Silva et al., 2008; Stupack and Cheresh, 2004)). 
Many integrins have been implicated in angiogenesis, but one of the best characterized is 
αvβ3.  Integrin αvβ3 is highly expressed on tumor-associated vasculature, and angiogenesis is 
inhibited with β3 neutralizing antibodies.  Interestingly, however, β3-/- mice have enhanced (not 
reduced) tumor-associated angiogenesis in subcutaneous tumors (Reynolds et al., 2002).  In β3 
floxed mice crossed with endothelial-specific Cre mice, depletion of β3 integrin in endothelial 
cells inhibits angiogenesis and tumor growth in a preventative setting, but not in established 
tumors.  Moreover, these tumor effects are transient, and long-term endothelial cell β3 deletion is 
ineffective to reduce angiogenesis (Steri et al., 2014).  Reports that low dose integrin antagonists 
can increase tumor growth and angiogenesis while higher doses suppress tumor growth and 
angiogenesis (Reynolds et al., 2009) (Carmeliet, 2002; Martin et al., 2002; Wang et al., 2001; 
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Zhao et al., 2005) further underscore the complexity of targeting β3 integrins for angiogenesis 
and cancer therapy.  
In some scenarios, β3 integrin influences angiogenesis through interactions with ligand 
TSP1.  TSP1 was the first identified endogenous anti-angiogenic factor (Isenberg et al., 2007a) 
and plays a role in neoangiogenesis in endothelial cells and platelets through its interactions with 
CD47 and β3 integrin. In numerous studies, TSP1 has tumor suppressing effects in the tumor 
microenvironment and many tumors have low expression of TSP1 (reviewed in (Kazerounian et 
al., 2008)). TSP1-/- mice have increased tumor burden and tumor-associated vasculature in a 
primary tumor model, while mice that over-express TSP1 have delayed tumor growth and 
reduced tumor-associated vasculature (Rodriguez-Manzaneque et al., 2001). In contrast, other 
studies demonstrate a role for TSP1 in promoting tumor progression (Dias et al., 2012; John et 
al., 2010; Tuszynski et al., 1987) in part through TSP1 stimulation of endothelial cell migration 
through interactions with the α6 integrin pathway (Dias et al., 2012; John et al., 2010).  Thus, 
TSP-1 can play both pro- and anti-angiogenic roles, depending on its specific integrin 
interaction.  
The role of αvβ3 integrin in tumor-associated angiogenesis is complex, not only 
involving integrin-ligand interactions and associated signaling pathways, but also specific 
temporal regulation and indirect effects through proteins such as TSP1, and are important for the 
progression of angiogenesis and eventual metastasis. 
 
Integrin αvβ3 is necessary for osteoclast function and plays a key role in bone metastasis 
Bone invading metastatic tumor cells co-opt integrin signaling pathways that enhance OC 
function and recruitment. As part of bone remodeling, OC bind to the bone matrix, form an actin 
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ring mediated sealing zone, secrete enzymes and acid to degrade bone, and then migrate to a new 
site.  Each of these functions is regulated in part by integrins located on the membrane surface of 
the OC, interacting with neighboring cells and with the extracellular matrix (Teitelbaum and 
Ross, 2003).  
αvβ3 is the predominant integrin found on OCs and plays roles in multiple components of 
osteoclastogenesis and resorption (Novack and Teitelbaum 2008; Ross and Teitelbaum 2005. 
αvβ3 is responsible for mediating OCbone matrix recognition (Crippes et al., 1996; Liapis et 
al., 1996; Ross et al., 1993; Zambonin Zallone et al., 1989), adhesion (Chellaiah, 2006; Ross et 
al., 1993), formation of the ruffled border, and overall organization of the cytoskeleton (Faccio et 
al., 2003; McHugh, 2000; Rucci et al., 2005; Zhang et al., 2000).  Antibody inhibition of αvβ3 
inhibits OC attachment to the bone matrix and OC-mediated bone resorption(Ross et al., 1993).  
In addition, β3-/- have defective OC function (McHugh, 2000) and are protected from tumor 
associated osteolysis (Bakewell et al., 2003).  
Integrin αvβ3 ligand CD47 also plays important roles in OC formation and tumor-
associated osteolysis, both through augmenting β3 activity, and in an integrin-independent 
manner. CD47-/- mice have increased bone volume due in part to reduced OC number and 
function (Koskinen et al., 2013; Uluckan et al., 2009), and CD47-/- mice are partially protected 
from tumor-associated osteolysis (Uluckan et al., 2009). CD47 in OC include binding to SIRPα 
in hematopoietic cells is an important “self-signal” to prevent phagocytosis.  CD47:SIRPα 
binding is also important for macrophage fusion, an early event in OC formation (Han et al., 
2000; Lundberg et al., 2007; Vignery, 2005).  Interestingly, CD47-/- OCs have increased levels 
of inducible nitric oxide synthase and the CD47-/- OC formation defect is rescued in vitro 
through blockade of nitric oxide signaling (Uluckan et al., 2009).  Notably, in other cell types 
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TSP1-CD47 binding inhibits nitric oxide signaling; we will investigate the role of TSP1 in nitric 
oxide mediated regulation of OC in Chapter 2.  
OC targeted therapy is a standard of care for the treatment of bone metastasis and 
myeloma bone disease. Tumor cells recruit OCs resulting in bone destruction and pain (Clohisy 
and Ramnaraine, 1998; Honore et al., 2000; Mundy, 2002).  Because of its known role in OC 
function and its high expression in skeletal metastatic tumors as discussed above, much research 
has focused on αvβ3 integrin and its ligands in bone.  Elucidating the role of β3 integrin pathway 
member TSP1 is the subject of Chapter 2.   
 
β3-/-, CD47-/-, and TSP1-/- mice have phenotypic overlap suggesting a common pathway  
Mice with genetic deficiency in individual components of the αvβ3 pathway, including 
β3, CD47, and TSP1, show phenotypic overlap in characteristics essential for bone metastasis 
(Table 1.1).  Importantly, both β3-/- and TSP1-/- mice have increased primary tumor growth and 
neoangiogenesis (Reynolds et al., 2002; Rodriguez-Manzaneque et al., 2001), while CD47-/- 
mice have decreased tumor burden with no apparent effect on angiogenesis, suggesting that the 
β3-CD47 signaling pathway may not participate in primary tumorigenesis.  In the bone 
microenvironment, however, β3-/- and CD47-/- mice both have increased bone volume and 
decreased tumor-associated osteolysis (Bakewell et al., 2003; Uluckan et al., 2009), largely due 
to decreased OC activity.  While the TSP1-/- mouse bone phenotype has not been fully 
evaluated, there is some evidence implicating TSP1 in OC activity (Carron et al., 2000; Carron et 
al., 1995).   
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Together, these data led us to hypothesize that the β3 – CD47 – TSP1 signaling axis is 
important in the bone microenvironment, both under homeostatic and pathologic states.  
Investigation of the role of TSP1 in the bone is the topic of Chapter 2.  
 
Thrombospondin-1 is expressed in the bone matrix, but its role remains unknown 
TSP1 is a large matricellular glycoprotein (350 kDa) that is ligand for at least 11 unique 
receptors, including αvβ3 integrin, CD47, and CD36, as well as many extracellular matrix 
proteins, including collagen, calcium, and osteopontin, among others.  It is expressed and 
secreted by all vascular, endothelial, and hematopoietic cells, but is most highly secreted by 
activated platelets as part of wound healing.  As a matricellular protein, TSP1 has dual function, 
both as a member of the ECM and as a signaling molecule.  
TSP1 deficient mice are reported to have mild spine deformation(Crawford et al., 1998) 
and mild growth plate cartilage disorganization (Posey et al., 2008) but detailed analysis of bone 
has not been reported. TSP1 is expressed by OBs and is present in osteoid and mineralized bone 
matrix (Grzesik and Robey, 1994; Kannus et al., 1998; Robey et al., 1989) where it is directly 
deposited by bone-forming OBs (Clezardin et al., 1989; Robey et al., 1989). TSP1 participates in 
OB differentiation in part through activation of latent TGF-β (Bailey Dubose et al., 2012; Ueno 
et al., 2006), and TSP1 receptors CD47 and CD36 also regulate OB (Kevorkova et al., 2013; 
Koskinen et al., 2013). TSP1 has been implicated in OC activity, but its mechanism of action 
remains unknown(Carron et al., 1995). TSP1-CD47 interactions play a role in the formation of 
multiple myeloma-dendritic cell fusions with bone-resorbing capacity (Kukreja et al., 2009), and 
TSP1-CD36 ligation can promote osteoclastic resorption on dentine slices (Carron et al., 2000).  
Together these data led us to hypothesize that OB-secreted TSP1 sequestered in bone matrix will 
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modulate OC function thereby coupling OB activity to OC formation which we will investigate 
in Chapter 2. 
 
Nitric oxide signaling modulates endothelial cell and osteoclast activity 
Nitric oxide (NO) is synthesized by NO synthases (NOSs): eNOS and nNOS synthesize 
low levels of NO(Tsutsui, 2004) while higher levels are produced by iNOS, induced upon 
inflammatory cell activation (Figure 1.2) (Ridnour et al., 2005; Ridnour et al., 2006). NO binds 
sGC to catalyze the reaction of cGMP (Roy and Garthwaite, 2006), responsible for regulating 
signaling that controls proliferation, migration, cell cycle and apoptosis (Thomas et al., 2008). 
NO exerts a biphasic effect with low (<10 nM) levels of NO necessary for maintaining normal 
cell function (Isenberg et al., 2007b), while high (>100 nM) levels of NO are toxic (Lau, 2003) 
(Figure 1.3). Thus, tight regulation of NO is critical for normal cell function and unregulated 
increases in NO is typical of many pathologic conditions, including cancer, and can lead to cell 
toxicity or disrupted cell function.  
NO signaling is a critical signaling pathway during homeostatic bone resorption.  Upon 
stimulation with RANKL, OC precursors upregulate iNOS expression through an NFκB-
dependent mechanism and the subsequent high NO concentration inhibits further OC formation 
(Zheng et al., 2006). iNOS deficient bone marrow macrophages show increased OC formation 
and resorption (Zheng et al., 2006). Misregulation of NO signaling, therefore, may lead to 
aberrant bone remodeling, compromising skeletal integrity. 
TSP1 is a regulator of NO in endothelial cells, platelets, and vascular smooth muscle 
cells(Bergseth et al., 2000; Chen et al., 2000). Notably, only TSP1 receptors CD36 and CD47 
have been implicated in NO regulation. TSP1-/- mice show elevated levels of endothelial cell 
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cGMP compared to wild type, and primary cultures show increased proliferation, migration, and 
adhesion (Isenberg et al., 2005). NO-stimulated endothelial cells and vascular smooth muscle 
cells have increased proliferation and migration and elevated cGMP (Isenberg et al., 2005). 
These responses are blocked upon addition of TSP1, CD47-binding peptide, or CD36-binding 
peptide (Isenberg et al., 2005). Vascular outgrowth is increased in TSP1-/- mice, an effect that is 
augmented with NO stimulation (Isenberg et al., 2006). Interestingly, while addition of TSP1 
inhibits the NO-stimulated vascular outgrowth in CD36-/- mice, it has no effect in CD47-/- mice 
(Isenberg et al., 2006), indicating that CD47 is necessary for NO-mediated endothelial cell 
function. Despite identification of CD36 as a regulator of eNOS (Isenberg et al., 2007b), the 
direct mechanism of action for CD47 inhibition of NO has not been identified. Our lab reported 
that CD47 suppression of NO signaling in OCs plays an important role in pathologic osteolysis 
(Uluckan et al., 2009), but the CD47-activating ligand in OCs has not been defined.  We will 
explore the role of TSP1-regulation of NO signaling in OC in Chapter 2.  We hypothesize that 
TSP1 is a negative regulator of NO signaling in OC, promoting early stages of OC formation.  
 
Goals of the present study 
 The seed-and-soil hypothesis of cancer metastasis has been accepted for decades, and the 
field of cancer biology acknowledges the necessity of host support for tumor growth.  While 
many molecules have been implicated in host-cell support of tumor growth, the components of 
“congenial soil” remain incomplete.  Therapeutic targeting of the host cells, specifically the 
uncoupling of the “vicious cycle” within the bone microenvironment, represents a promising site 
of intervention for the treatment of bone metastasis. 
! 17!
In Chapter 2, we elucidate the role of potent anti-angiogenic TSP1 in bone in order to 
better understand the impacts of TSP1-pathway directed therapeutics.  While many receptors of 
TSP1 are known to be important for bone integrity, both in the bone matrix and in metabolically 
active bone cells, the role of the matricellular ligand is unclear.  We demonstrated that TSP1 
played both structural and signaling roles to maintain bone homeostasis.  Using TSP1-null mice, 
we showed that TSP1 contributed to bone quality and that it was essential for OC formation.  We 
found that pharmacologic inhibition of NO signaling in TSP1-/- mice restored OC activity, 
placing TSP1 upstream of NO regulation of OC formation.  Importantly, we present strong 
evidence for TSP1 as a paracrine signaling molecule, coupling OB activity to OC formation, thus 
building upon the literature of critical bone remodeling factors. 
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Part II:  Genetic susceptibility to monoclonal gammopathy of undetermined significance, 
the requisite precursor to multiple myeloma 
 
Monoclonal gammopathy of undetermined significance is a common disorder of aging 
Monoclonal gammopathy of undetermined significance (MGUS) is a common syndrome 
of aging, with a prevalence of 3.2 – 5.2 percent in 50 – 70 year olds, respectively (Kyle et al., 
2006; Landgren et al., 2009).  MGUS is characterized by the presence of a constant serum level 
of monoclonal paraprotein (less than 3 g/dl) termed “M-spike” as detected by a persistent band in 
the gamma region of a serum protein electrophoresis (SPEP, Figure 1.4a) in the absence of end-
organ damage.  While largely benign, MGUS is associated with increased fracture risk and 
osteoporosis (Melton et al., 2005), and MGUS patients have elevated serum levels of OC-
activating (MIP1α) and OB-inhibiting (DKK1) factors (Ng et al., 2011).  Importantly, MGUS is 
the requisite precursor to multiple myeloma (MM), and progresses to overt malignancy at a rate 
of 1% per year. Due to the largely asymptomatic state and low rate of transformation to myeloma 
(lifetime risk of 10-30% (Kyle et al., 2010; Sirohi and Powles, 2006; Zingone and Kuehl, 2011)), 
MGUS is not clinically treated, though patients are monitored with annual blood chemistry tests.   
 
Step-wise transformation from MGUS multiple myeloma 
 MM is the second most common hematological malignancy and is invariably fatal with a 
~6 year median survival (Kumar et al., 2013).  MM is a malignancy of plasma B-cells that is 
clinically diagnosed by an M-spike of >3 g/dL and the presence of CRAB syndromes: 
hypercalcemia, renal insufficiency, anemia, and lytic bone lesions, highlighting its dependence 
on the bone microenvironment (Figure 1.4b).   
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 Normal plasma B-cell development results in a long-lived non-proliferative antibody-
producing cell. One of the hallmarks of B-cell differentiation is a DNA rearrangement for 
increased variation:  VDJ recombination in immunoglobulin (Ig) heavy and light chains, somatic 
hypermutation, and Ig heavy change switch recombination.   In the bone marrow, pro- and pre-
B-cells undergo Ig heavy and light chain recombination, respectively.  Immature B-cells that 
undergo receptor editing and express IgM receptor leave the bone marrow and travel to the 
spleen or lymph nodes as antigen-presenting cells.  Upon encountering an antigen, the B-cell will 
endocytose the antigen and presents the antigenic peptides as part of the MHC II complex.   
These activated B-cells enter a germinal center and undergo somatic hypermutation of both the 
heavy and light chains.  Cells that express high-binding antigen-receptors undergo Ig class 
switch recombination then home to the bone marrow as mature, antibody producing plasma B-
cells.   
The affected cell in MGUS and MM is the typically non-proliferative terminally-
differentiated post-germinal center B-cell.  In MGUS, there is a clonal expansion of one or more 
of these plasma cells, resulting in an elevated level of immunoglobulin in the serum.  MM is 
characterized by a further expansion of one or more of these clones to fill the marrow space, 
again resulting in an elevated immunoglobulin level, but now accompanied with more significant 
end-organ damage.      
 
The bone microenvironment contributes to MGUS and MM pathology 
 Differentiation and function of normal plasma cells is dependent on the bone marrow 
microenvironment.  Bone marrow stromal cells and OBs support B-cell lymphopoiesis, 
proliferation, and plasma cell homing to the marrow.  Likewise, MM::microenvironment 
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interactions parallel normal B-cell::microenvironment cross-talk, with similar mechanisms 
identified for homing (CXCR4/SDF1 gradient) and proliferation (IL-6, IGF1, TGFB) (reviewed 
in (Kuehl and Bergsagel, 2002)).  In addition, myelomas further modulate the bone 
microenvironment and produce OC-stimulatory (Basak et al., 2009; Esteve and Roodman, 2007; 
Oyajobi et al., 2003) and OB-inhibitory factors (Giuliani et al., 2005; Yaccoby, 2010) that 
deregulate the coupled process of healthy bone remodeling (Mundy, 2002; Weilbaecher et al., 
2011). This results in osteolytic lesions in 70-80% of MM patients (Terpos et al., 2007) (Figure 
1.4b). Such pathologic bone resorption releases tumor growth factors stored within the bone 
matrix. Bone marrow stromal cells, a heterogeneous population including mesenchymal stem 
cells, support myeloma growth through adhesion-dependent mechanisms (VLA-4/VCAM) and 
the production of soluble growth factors including IL-6(Terpos et al., 2007). MM causes 
significant bone destruction, hypercalceimia, bone pain, and facture. 
 
Tumor associated macrophages promote myeloma progression 
In addition to the crucial role of bone remodeling cells, there is a growing literature 
implicating tumor-associated macrophages (TAMs) in the pathogenesis of MM (reviewed in 
(Asimakopoulos et al., 2013; Berardi et al., 2013; Ribatti et al., 2013)).  TAMs are typically 
categorized as classically-activated pro-inflammatory macrophages (M1) or alternatively-
activated anti-inflammatory macrophages (M2), though the distinction between the two classes 
likely represents a spectrum rather than specific identity. M1 macrophages, activated by bacterial 
lipopolysaccharide (LPS) and interferon-gamma (IFNg), promote a strong host immune 
response.  In contrast, M2 macrophages, activated by IL-4, IL-13, and TGFβ, suppresses Th1-
mediated inflammation and promotes wound healing, including angiogenesis and destruction of 
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the extracellular matrix.  Thus, even within their normal physiologic roles, M1 macrophages are 
inherently anti-tumor while M2 macrophages promote tumor progression. 
MM patients with active disease have higher percentage of macrophages in the bone 
marrow than either MGUS patients or patients with non-active disease (Scavelli et al., 2008).  In 
addition, these macrophages are functionally distinct from non-affected patients and contribute to 
angiogenesis through vasculogenic mimicry (Scavelli et al., 2008).  MM TAMs have increased 
pro-MM factor secretion such as IL-6 (Kim et al., 2012; Zheng et al., 2009) and higher levels of 
pro-angiogenic VEGF expression compared to non-MM macrophages (Ribatti et al., 2006; 
Scavelli et al., 2008; Vacca and Ribatti, 2011).  The role of Samsn1 in macrophages will be 
explored in Chapter 3. 
 
Genetic risk factors contributing to MGUS and MM susceptibility 
Human population studies suggest that genetic risk factors underlie susceptibility to 
MGUS and MM.  Interestingly, however, the majority of plasma-cell intrinsic genetic events in 
MM cells are present in MGUS-affected B-cells (Davies et al., 2003), though not in normal 
plasma B-cells. Epidemiological studies have identified a higher incidence for MM in African 
Americans and that this is the result of elevated risk to MGUS, rather than an increased rate of 
conversion from MGUS to MM (Kyle et al., 2010; Kyle et al., 2006; Landgren et al., 2006).  In 
addition, studies in affected families showed a higher risk of MM in patients with an MGUS-
affected relative (Jain et al., 2009; Kyle et al., 2004; Vachon et al., 2009). 
Genome wide significance studies of MM have identified seven SNPs that confer a 
significant increase in MM risk (Broderick et al., 2012; Chubb et al., 2013).  Interestingly, a 
recent study in an MGUS patient population showed that these SNPs also conferred increased 
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risk to MGUS (Weinhold et al., 2014), providing further evidence that increased MM risk is due 
to increased MGUS risk.  These studies highlight the need for a better understanding of the 
genetic predisposition to MGUS that will be the subject of Chapter 3. 
 
C57Bl/KaLwRij is a spontaneous mouse model of MGUS and MM 
One of the most common experimental models for MGUS and MM is the 
C57BL/KaLwRij mouse (KaLwRij).  KaLwRij was first identified to have a high frequency of 
benign idiopathic paraproteinaemia (BIP), the murine counterpoint to human MGUS, in 1974 
(Radl and Hollander, 1974).  KaLwRij mice have increased serum levels of homogeneous 
immunoglobulin by SPEP, similar to the M-spike observed in MGUS and MM patients, by 12 
months of age with a penetrance of ~45% (Radl et al., 1978).  Affected mice progress to overt 
malignancy at a rate of approximately 1% with similar clinical features as human MM, including 
severe bone pathology (Radl et al., 1978).   
5T myeloma cell lines were generated from spontaneous myelomas in KaLwRij mice, 
and can be transplanted into KaLwRij mice to propagate the myeloma (Alici et al., 2004; 
Asosingh et al., 2000; Vanderkerken et al., 2003).  Intravenous injection into KaLwRij mice 
yields robust bone marrow-disseminated myeloma with significant osteolytic bone lesions and 
increased monoclonal paraprotein (M-spike) within 28 days (Dallas et al., 1999; Edwards et al., 
2009; Garrett et al., 1997).  Importantly, the 5TMM cell lines will not engraft in the closely 
related C57Bl/6 (B6) strain (Asosingh et al., 2000), highlighting the requirement of a supportive 
host microenvironment for establishment of early disease.  Notably, while KaLwRij represents 
an ideal model for MGUS and for a MM-supportive host microenvironment, the genetic basis of 
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BIP susceptibility in these mice remains largely unknown.  We characterized the genetic 
variation between KaLwRij and B6 using SNP mapping which is presented in Chapter 3.   
 
Mouse genetic mapping to identify genetic susceptibility loci for BIP 
 The KaLwRij mouse strain is an ideal model to dissect genetic risk loci contributing to 
the complex trait of BIP susceptibility, analogous to human MGUS.  Importantly, identifying 
germline risk alleles will encompass genes at play in all cell types participating in the step-wise 
progression from a normal plasma cell to overt MM, including host stromal cells predicted to 
contribute to MGUS and MM.  In our studies presented in Chapter 3 we use a variety of genetic 
techniques to identify MGUS risk alleles using KaLwRij mice and human MM samples. 
 The BIP-prone KaLwRij strain has been interbred since approximately 1978, and we 
demonstrated that it is distinct from, but closely related to, the commonly used wild type (and 
BIP-resistant) strain, B6 (Chapter 3, Figure 3.1).  We used SNP analysis, also known as linkage 
disequilibrium mapping, to identify candidate loci underlying risk to MGUS.  Haplotype 
analysis, while uncommon in the genomic era, is used to narrow quantitative trait loci regions 
and to characterize regions of interest contributing to phenotype in recombinant inbred strain 
analysis (Burgess-Herbert et al., 2008).   
Linkage disequilibrium is the non-random assortment of alleles based on physical 
proximity.  Loci that are physically proximal to each other are more likely to be inherited 
together than expected by random assortment, due to low rates of recombination in short 
physical space.  Contiguous loci that are inherited together represent a haplotype. Therefore, by 
identifying regions which are shared in “high” phenotype mouse strains and not in “low” 
phenotype mouse strains allows for the identification of candidate gene loci. Traditional 
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haplotype block analysis assumes that any variation between strains is a result of ancestral 
variation rather than recent variation, resulting in large DNA regions that are identical by 
descent.  We modified the approach to identify smaller units of variation between the closely 
related KaLwRij and B6, and therefore used a lower threshold than is typical for this analysis. 
In our analyses presented in Chapter 3, we identified candidate lists of genes underlying 
susceptibility to (1) murine BIP, (2) human MM/MGUS, and (3) both murine BIP and human 
MM/MGUS.   
 
Goals of the present study 
 Epidemiological evidence points to genetic risk to MGUS and subsequent progression to 
MM, representing a “congenial soil” for malignant cell transformation, both inherent to the pre-
malignant B-cell and to the non-cancerous host cells contributing to disease progression. 
 In Chapter 3, we focus on whole-host “congeniality” to MGUS and MM.  We identify 
genetic risk loci contributing to susceptibility to microenvironment-dependent MGUS.  Using a 
combinatorial approach, we compiled candidate gene lists derived from mouse SNP analysis and 
human MM patient association studies to ultimately identify a shared candidate list of five genes 
and focused our studies on Samsn1.  We show that the most common murine model for human 
MGUS and myeloma, KaLwRij mouse strain, has a germline deletion for the B-cell inhibitor 
Samsn1.  We present compelling evidence that Samsn1 confers genetic risk to B-cell malignancy 
through effects both in pre-malignant cells inn cooperating cells of the host microenvironment, 
namely TAMs.  Therefore, Samsn1 represents a single tumor-suppressor gene contributing to 
myeloma progression through two mutually exclusive mechanisms. 
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Figure 1.1.  The “vicious cycle” of bone metastasis. 
In the bone marrow space, metastatic cells secrete factors (including PTHrP, IL-6, VEGF, TNF, 
and MMPs) to  stimulate bone resorption, through both direct and indirect effects on osteoclasts.  
In turn, osteoclasts releases bone-sequestered growth actors (including TGFβ and IGFs) that 
further stimulate tumor growth.   
Reproduced from (Weilbaecher et al., 2011). 
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Figure 1.2. 
Expression of integrins in tumor cells and host microenvironment cells during metastasis. 
Reproduced from (Schneider et al., 2011).  
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Figure 1.3.  Nitric oxide (NO) exerts a biphasic (or “Goldilocks”) effect on cell activation.   
In the absence of nitric oxide, cells remain inactive or fail to differentiate.  Under tonic levels 
of NO, synthesized by the constitutive nitric oxide synthases (NOSs) endothelial NOS and 
neuronal NOS, cells are activated or differentiate.  High levels of NO, produced by inducible 
NOS, results in cell toxicity. 
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Figure 1.4.  Clinical diagnosis of MGUS and multiple myeloma. 
(a) Serum protein electrophoresis (SPEP).  Arrowhead indicates band in the gamma 
region, indicative of an accumulation of monoclonal paraprotein (M-spike).  Negative 
(left) and positive (right) M-spike. 
(b) X-ray of a multiple myeloma patient with characteristic “hole-punch” bone lesions 
(arrows).  Reproduced from the American Academy of Orthopedic Surgeons.!
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Table 1.1.  Integrin β3-/-, CD47-/-, and TSP1-/- mouse model phenotypic overlap 
!
! ! ! ! ! ! !Mouse 
model 
Primary tumor Bone metastasis Homeostatic bone 
Tumor Angiogenesis Tumor Osteolysis Bone volume Osteoclasts 
β3-/-! ! ! " " ! " 
CD47-/- " !#!#!#!! " " ! " 
TSP1-/- ! ! ? ? ? ? 
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!Chapter 2 
 
Thrombospondin-1 regulates bone homeostasis through effects on bone matrix integrity 
and nitric oxide signaling in osteoclasts 
42
!Abstract 
 
Thrombospondin-1 (TSP1), an endogenous antiangiogenic, is a widely expressed 
secreted ligand with roles in migration, adhesion and proliferation and is a target for new 
therapeutics. While TSP1 is present in the bone matrix and several TSP1 receptors play roles in 
bone biology, the role of TSP1 in bone remodeling has not been fully elucidated. Bone turnover 
is characterized by coordinated activity of bone-forming osteoblasts (OB) and bone-resorbing 
osteoclasts (OC). TSP1-/- mice had increased bone mass and increased cortical bone size and 
thickness compared to wild type (WT). However, despite increased size, TSP1-/- femurs showed 
less resistance to bending than expected, indicative of diminished bone quality and a bone 
material defect. Additionally, we found that TSP1 deficiency resulted in decreased OC activity in 
vivo and reduced OC differentiation. TSP1 was critical during early osteoclastogenesis, and 
TSP1 deficiency resulted in a substantial overexpression of inducible nitric oxide synthase 
(iNOS). Importantly, administration of a NOS inhibitor rescued the OC functional defects of 
TSP1-/- mice in vivo. To investigate the role of bone-derived TSP1 in osteoclastogenesis, we 
found that wild type (WT) pre-OCs had defective iNOS expression when cultured on TSP1-/- 
bone compared to WT bone, suggesting that TSP1 in bone plays a critical role in iNOS signaling 
during OC development. These data implicate a new role for TSP1 in bone homeostasis with 
roles in maintaining bone matrix integrity and regulating OC formation. It will be critical to 
monitor bone health of patients administered TSP1-pathway directed therapeutics in clinical use 
and under development. 
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!Introduction 
 
Bone is a dynamic tissue, characterized by balanced bone resorption and formation. This 
bone remodeling is necessary to preserve the structural integrity of the skeleton and to maintain 
calcium and phosphate homeostasis (Baron, 1996; Hadjidakis and Androulakis, 2006). Bone is a 
matrix composed of two compartments: osteoid (primarily collagen type I fibers) and mineral 
(calcium-phosphate hydroxyapatite crystals). The bone matrix also contains numerous 
noncollagenous proteins including growth factors, proteoglycans, and adhesion molecules. These 
molecules contribute to maintenance of homeostatic bone remodeling, promoting cell 
attachment, differentiation, and growth of bone remodeling cells. In addition, some molecules 
aid in osteoid and mineral matrix organization, directly influencing bone strength.  
Mesenchymal osteoblasts (OBs) form bone by depositing collagen and other molecules to 
form osteoid and subsequently calcify this matrix to form rigid bone. Osteoclasts (OCs), 
polarized multi-nucleated hematopoietic cells formed from the fusion of macrophages, resorb 
bone through protease- and acid-dependent processes. The formation and activity of OCs and 
OBs is a tightly coupled process. OCs are activated by OB-derived cytokines such as M-CSF and 
RANK-L. In turn, OCs promote osteoblastic bone formation by releasing stored growth factors 
including bone morphogenic proteins, TGFβ, and insulin growth factor from the bone matrix. 
Misregulation of healthy bone remodeling, as in cancer metastasis, arthritis, or osteoporosis, 
leads to decreased bone integrity, pathologic fracture, nerve-compression syndromes, and 
hypercalcemia (Weilbaecher et al., 2011). While many factors that individually regulate OC and 
OB formation and activity have been identified, our understanding of the role of OB-deposited 
bone matrix-sequestered proteins in homeostatic OC activity remains incomplete. 
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!Thrombospondin-1 (TSP1) is a large secreted protein that binds at least 11 distinct 
receptors, including β3 integrin, CD47, and CD36, thereby influencing downstream pathways. 
By regulating migration, adhesion and proliferation, TSP1 participates in diverse processes 
including angiogenesis, inflammation, and wound healing. TSP1 was the first identified 
endogenous antiangiogenic molecule, and TSP1 mimetics have entered clinical trials as cancer 
therapeutics (Taraboletti et al., 2010). Antibodies against the TSP1 receptor CD47, used to 
induce macrophage phagocytosis of cancer cells, have completed pre-clinical studies(Tseng et 
al., 2013; Weiskopf et al., 2013), and a humanized antibody is under clinical development. In 
addition, nitric oxide (NO) signaling, a pathway regulated by TSP1, is being therapeutically 
targeted for vasodilation (NO donors) or hypotension (NO synthase inhibitors)(Deshpande et al., 
2012). As these TSP1 pathway-targeted therapies enter broad clinical use, it is important to 
consider the action of TSP1 in other systems, including the skeleton, where TSP1 receptors 
CD47, β3 integrin, and CD36 (Faccio et al., 2003b; Kevorkova et al., 2013; Koskinen et al., 
2013; McHugh et al., 2000; Schneider et al., 2011; Uluckan et al., 2009) are involved in OC and 
OB signaling. Bone-related off-target effects will be especially crucial to consider in advanced 
cancer patients at risk for skeletal metastasis and post-menopausal women who are at risk for 
osteoporosis.  
TSP1 deficient mice are reported to have mild spine deformation (Crawford et al., 1998) 
and mild growth plate cartilage disorganization (Posey et al., 2008) in addition to enhanced 
angiogenesis (Smadja et al., 2011) but detailed analysis of bone has not been reported. TSP1 is 
expressed by OBs and is present in osteoid and mineralized bone matrix (Grzesik and Robey, 
1994; Kannus et al., 1998; Robey et al., 1989) where it is directly deposited by bone-forming 
OBs (Clezardin et al., 1989; Robey et al., 1989). TSP1 is involved in OB differentiation in part 
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!through activation of latent TGF-β (Bailey Dubose et al., 2012; Ueno et al., 2006), and TSP1 
receptors CD47 and CD36 also regulate OB (Kevorkova et al., 2013; Koskinen et al., 2013). 
TSP1 is a regulator of nitric oxide (NO) in endothelial cells, platelets, and vascular smooth 
muscle cells (Chen et al., 2000; Isenberg et al., 2009), but only receptors CD36 and CD47 have 
been implicated in NO regulation (Isenberg et al., 2009; Isenberg et al., 2006; Isenberg et al., 
2005). TSP1 has been implicated in OC activity, but its mechanism of action remains unknown 
(Carron et al., 1995). TSP1-CD47 interactions play a role in the formation of multiple myeloma-
dendritic cell fusions with bone-resorbing capacity (Kukreja et al., 2009), and TSP1-CD36 
ligation can promote osteoclastic resorption on dentine slices (Carron et al., 2000). CD47-/- mice 
have a bone resorption defect (Koskinen et al., 2013; Lundberg et al., 2007; Uluckan et al., 
2009), which we have shown is due to increased iNOS in OCs (Uluckan et al., 2009). Together 
these data led us to hypothesize that OB-secreted TSP1 sequestered in bone matrix will modulate 
OC function thereby coupling OB activity to OC formation.  
In this study, we describe the role of bone-sequestered TSP1 in the maintenance of bone 
homeostasis, both as a structural protein contributing to bone strength and as a signaling ligand 
promoting OC formation. Here we have used mice genetically deficient in TSP1 and neutralizing 
anti-TSP1 antibody to investigate the role of TSP1 in bone homeostasis. Together, these data 
implicate a novel role for TSP1 in bone homeostasis, both in mediating bone matrix integrity and 
by regulating OC formation as a matrix-derived paracrine signaling molecule. Our findings 
provide an important rationale to monitor the effects on bone health of TSP1 pathway-directed 
therapeutics, currently in clinical use and under development, especially in patients affected by 
bone pathology such as osteoporosis and skeletal metastasis.  
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!Materials and Methods 
 
Animals 
TSP1-/- mice were originally obtained from Jack Lawler (Lawler et al., 1998) and backcrossed 
over 20 times to C57BL/6J. TSP1-/- and TSP1+/+ mice were housed in shared pathogen-free 
conditions according to the guidelines of the Division of Comparative Medicine, Washington 
University School of Medicine. The animal ethics committee approved all experiments.  
Reagents 
Anti-TSP1 function blocking antibody, clone A4.1 (IgM, mouse anti-human)(Annis et al., 2006) 
was purchased from Thermo Scientific (Waltham, MA). TSP1 is highly conserved among 
species and clone A4.1 has cross-species reactivity with mouse and bovine TSP1. IgM istoype 
control was purchased from eBioscience (San Diego, CA).  
Micro-computed tomography 
Tibiae and femurs from TSP1-/- and WT sex-matched mice were suspended in agarose and tibial 
metaphyses and femoral mid-diaphysis were scanned by micro-computed tomography (uCT-40; 
Scanco Medical) as described previously (Heller et al., 2012; Uluckan et al., 2009). For image 
acquisition, the long bones were placed in a 13-mm holder and scanned. The cancellous region 
was selected using contours inside the cortical shell on each 2d image. The growth plate was 
used as a marker to determine a consistent location to start analysis and 40 slices were analyzed. 
A 3-dimentional cubical voxel model of bone was built and calculations made: relative 
trabecular bone volume over total volume, trabecular number, and trabecular spacing. The 
cortical region was selected using contours outside the cortical shell at the mid-diaphysis and 50 
slices were analyzed. The average cross-sectional geometry measurements were calculated for 
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!cortical thickness and total cross-sectional area. The bending moment of inertia was determined 
using standard engineering parallel-axis theory as previously described (Brodt et al., 1999; Silva 
et al., 2006). 
Bone biomechanics 
Immediately following dissection, femurs were frozen at -20OC for a minimum of 12 hours. 
Femurs were thawed in phosphate-buffered saline for 1 h prior to use, and testing was carried out 
at room temperature using a servohydraulic testing machine (8841 Dynamite, Instron, Norwood, 
MA). Femurs were positioned on two supports 7 mm apart, and the central loading point was the 
mid-diaphysis. Displacement was applied transverse to the long axis of the bone at a rate of 0.03 
mm/s until failure. Force-displacement data were recorded at 60 Hz and analyzed to determine 
stiffness (a measure of elastic resistance to bending), yield force (a measure of the force required 
to permanently deform the bone), ultimate force (the highest force attained prior to failure), post-
yield displacement (a measure of ductility) and energy-to-fracture (a measure of overall 
resistance to fracture) (Brodt et al., 1999; Silva et al., 2006). Estimated material properties 
(elastic modulus, yield stress, ultimate stress) were calculated using standard engineering beam 
theory that normalizes for bone size.  
Reference point indentation 
Femurs were subjected to reference point indentation as previously described (Randall et al., 
2009). A 25 µm testing probe was placed on the cortical bone surface and a preload force of 
0.1N and a waveform of 10 cycles of 2N force was applied as a frequency of 2 Hz (Biodent, 
Active Life Sciences, Santa Barbara, CA). Each bone was subjected to 3 indents 1 mm apart. 
Measurements were made for each indent: initial indentation distance and indentation distance 
increase (cycle 1 – cycle 10). 
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!Serum CTX assay  
Carboxy-terminal telopeptide collagen crosslinks (CTX) was measured in the serum of overnight 
fasted mice by ELISA (RatLaps; Immunodiagnostic Systems, Scottsdale, AZ) according to the 
manufacturer’s instructions. 
Serum P1NP assay 
N-terminal propeptide of type I procollagen (P1NP) was measured in serum of overnight fasted 
mice using ELISA (Immunadiagnostic Systems, Scottsdale, AZ) according to the manufacturer’s 
instructions. 
L-NAME administration 
L-NAME (Sigma Aldrich, St. Louis, MO) was administered in the drinking water of 8 week old 
mice for 6 weeks, changed every 2 days (40 mg/kg/day). 
In vitro osteoclast differentiation 
To generate macrophages, whole bone marrow cells were cultured in αMEM, 10% FBS, 1% 
penicillin-streptomycin, 100 ng/ml MCSF for 3 days as previously described (Morgan et al., 
2010). To generate OCs, 9x104/ml were plated on plastic or bone powder as indicated and 
cultured in αMEM, 10% FBS (on plastic), 1% penicillin-streptomycin, 50 ng/ml MCSF, 50 
ng/ml RANKL, refed every 48 hours. Where indicated, macrophages were cultured with 5 µg/ml 
antibody. TRAP staining was performed according to the manufacturer’s instructions (Sigma-
Aldrich, St. Louis, MO). 
In vitro osteoblast differentiation 
To generate bone marrow stromal cells (BMSCs), whole bone marrow cells were cultured in 
ascorbic-acid free αMEM, 10% FBS, 1% penicillin-streptomycin for 7 days.  For OB 
differentiation, 2x105 BMSC/ml were cultured in αMEM, 10% FBS, 1% penicillin-streptomycin, 
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!10 mM β-glycerophosphate, 50 ug/ml ascorbic acid for 14 days, refed every 7 days.  Cultures 
were fixed in 10% neutral buffered formalin and stained with Alkaline Phosphatase (Fast Blue 
RR salt, Sigma Aldrich) and 0.4% Alizarin Red.  Chromogenic alkaline phosphatase was 
quantitated according to manufacturer’s instructions (Sigma-Aldrich, St. Louis, MO).  Alizarin 
red stain was measured using the Osteogenesis Quantitation Kit according to manufacturer’s 
instructions (Millipore, Billerica, MA). 
Bone powder coated plates 
Plates were coated with bone powder as previously described(Cremasco et al., 2012) with 
modifications. Bone marrow was flushed from the long bones of WT and TSP1-/- mice, and the 
bones were frozen at -20OC. Frozen bones were crushed to powder using a Bullet Blender Bead 
Lysis Kit (Midsci, St. Louis, MO), and the powder was washed 3 times in 70% ethanol. Plates 
were coated with 1:20 bone powder:PBS + 4 ug/ml poly-l-lysine for 4 hours at 68OC. Plates were 
sterilized under UV light and experiments completed as described. 
Quantitative reverse-transcription PCR 
RNA was extracted using RNeasy Mini kit (Qiagen, Venlo, Netherlands) and cDNA generated 
using iScript (Bio-Rad, Hercules, CA). Quantitative PCR was completed using SsoFast EVA 
Green Supermix (Bio-Rad, Hercules, CA).  
qRT-PCR primer sequences (forward/reverse) 
NFATc1:  
GGTAACTCTGTCTTTCTAACCTTAAGC / GTGATGACCCCAGCATGCACCAGTCA 
DC-STAMP: ACAAACAGTTCCAAAGCTTGC / TCCTTGGGTTCCTTGCTTC 
TRAP: CAGCTGTCCTGGCTCAAAA / ACATAGCCCACACCGTTCTC 
β3 integrin: TGGTGCTCAGATGAGACTTTGTC / GACTCTGGAGCACAATTGTCCTT 
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!Cathepsin K: GAGGGCCAACTCAAGAAGAA / GCCGTGGCGTTATACATACA 
iNOS: GGCAGCCTGTGAGACCTTTG / GCATTGGAAGTGAAGCGTTTC 
cyclophilin: AGCATACAGGTCCTGGCATC / TTCACCTTCCCAAAGACCAC 
In vivo calcein labeling 
Calcein labeling was completed as previously described (Su et al., 2012).  Briefly, mice were 
injected 8 and 2 days prior to sacrifice with 20 mg/kg calcein (Sigma-Aldrich, St. Louis, MO) in 
a 2% sodium bicarbonate solution i.p.  Calveria were fixed in 70% ethanol and embedded in 
methylmethacrylate and sectioned. 
Bone histomorphometry 
Bones were prepared and analyzed as previously described.  Mouse tibiae were fixed in 10% 
formalin for 24 hours and decalcified in 14% EDTA solution for 2 weeks.  Paraffin embedded 
sections were stained with TRAP.  Sections were analyzed by a blinded operator according to 
standard protocol using Bioquant Osteo V7 10.10 (Bioquant Image Analysis Corp.). 
Statistical analysis 
All experiments were analyzed using Student’s t-test. In calculating two-tailed significance 
levels for equality of means, equal variances were assumed for both populations. Results were 
considered to reach significance at p<0.05. *p<0.05; **p<0.01; ***p<0.001.  
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!Results 
 
TSP1-/- mice had increased cancellous and cortical bone mass 
We have previously shown that mice deficient in the TSP1-receptor CD47 have modestly 
increased bone mass (Koskinen et al., 2013; Lundberg et al., 2007; Uluckan et al., 2009). To 
determine if TSP1-/- mice would similarly display increased bone volume, we performed 
microCT analysis on WT and TSP1-/- mice to evaluate cancellous and cortical bone. We 
observed a significant increase in trabecular bone volume in 8 week-old (+32.6%), 16 week-old 
(+112.1%), and 32 week old (+158.8%) TSP1-/- mice (Figure 2.1 A-B). Coordinately, 
trabecular number was increased and trabecular spacing was decreased in TSP1-/- mice (Figure 
2.2). This dramatic increase in trabecular bone volume is in contrast to the modest bone volume 
phenotypes of TSP1-receptor deficient mice (CD47, CD36, β3 integrin-/- (Faccio et al., 2003a; 
Kevorkova et al., 2013; Koskinen et al., 2013; McHugh et al., 2000; Uluckan et al., 2009)), and 
is consistent with TSP1 binding to multiple receptors. TSP1-/- mice also had significantly 
increased cortical bone thickness and total cortical area at 12 weeks (Figure 2.1 C-E), indicating 
a geometrically larger bone in TSP1-/- compared to WT mice. Therefore, TSP1-/- mice had both 
increased size and increased relative bone mass compared to WT mice.  
 
TSP1 improved bone strength through effects on the bone material properties 
Because TSP1 null mice showed enhanced cortical thickness and cross-sectional area 
(Figure 2.1 C-E), and because TSP1 is a known component of the bone matrix (Clezardin et al., 
1989; Robey et al., 1989), we hypothesized that TSP1 deletion may influence bone mechanical 
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!properties. Bone mechanical properties are influenced by many factors including overall 
structural morphology and the material properties (“quality”) of the bone matrix.  
MicroCT analysis of the femoral mid-diaphysis showed a striking increase in moment of 
inertia in TSP1-/- mice (+67.1%), predicting increased strength based on morphology (Figure 
2.3 A). Interestingly, however, direct measurement of mechanical strength by 3-point bending 
did not recapitulate these results. Bone is permanently deformed upon reaching its yield force 
and eventually fractures after reaching its highest (ultimate) force. TSP1-/- femurs showed only a 
modest increase ultimate force (+16.7%) and no difference compared to WT in yield force 
(Figure 2.3 B-C). Notably, a normalized measure of yield force that accounts for differences in 
morphology (yield stress) is significantly decreased in TSP1-/- femurs (Figure 2.3 D). This 
suggests a bone material defect in TSP1-/- mice that offsets the morphological size advantage.  
To directly evaluate the local material properties of the bone matrix, we performed 
reference point indentation by applying a repetitive force on the cortical bone surface through a 
small probe. TSP1-/- femurs had increased initial indentation distance and a larger increase in 
indentation at the end of 10 cycles (Figure 2.3 E-F). These data indicate that TSP1-/- bone 
material had less resistance to microfracture compared to WT control. Dynamic 
histomorphometric analysis to quantitate bone formation rate and mineral apposition rates were 
difficult to perform because of fuzzy and poor bone mineral labeling in the TSP1-/- mice (Figure 
2.4 B), consistent with a bone mineral defect. Taken together, these mechanical and material 
properties demonstrate that TSP1 plays a role in maintaining the matrix quality necessary for 
normal bone strength. 
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!TSP1-/- mice had decreased bone resorption and OC formation 
  While we identified differences in long bone size and bone material properties that 
contribute to reduced bone quality, the underlying mechanism leading to the increased bone mass 
in TSP1-/- mice remained unclear. The progressive increase in trabecular bone volume with age 
in TSP1 null animals (Figure 2.1 A-B) is consistent with a failure in bone resorption. To test 
this, we measured serum markers of bone turnover, which include CTX (carboxy-terminal 
telopeptide collagen crosslinks), a measure of osteoclastic bone resorption and P1NP (pro-
collagen type I N-terminal telopeptide), a measure of OB function. There were no statistically 
significant differences in serum P1NP at 8, 16, or 32 weeks of age (Figure 2.4 A) and no 
differences in ex vivo OB formation assays (Figure 2.4 C-E). We did observe significant 
decreases in serum CTX levels in TSP1-/- mice compared to WT controls at 8 weeks and 16 
weeks of age (Figure 2.5 A) consistent with a defect in OC resorption. Histomorphometric 
analysis of mouse tibiae showed that TSP1-/- mice did not have significantly different OC 
number/bone surface at 8 or 32 weeks of age (Figure 2.6). To investigate the role of TSP1 in 
osteoclastogenesis and function, we differentiated WT primary OCs from bone marrow 
macrophages in vitro. TSP1 is secreted by activated platelets, leading to high levels of the 
protein in blood serum. Fetal bovine serum (FBS), necessary in OC culture media, contains 
approximately 100 ng/ml TSP1 (data not shown). To neutralize FBS-derived TSP1, we treated 
cultures with TSP1 neutralizing antibody (clone A4.1). Notably, in control cultures, TSP1-/- OCs 
were indistinguishable from WT OCs, indicating that exogenous, FBS-derived TSP1 was 
sufficient to maintain normal OC formation (Figure 2.7). In contrast, OC differentiation in the 
presence of anti-TSP1 antibody was dramatically reduced, while cells treated with the IgM 
control antibody developed large multinucleated TRAP+ OCs (Figure 2.5 B, left panels; Figure 
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!2.7). Interestingly, while there was no change in NFATc1, a marker of OC lineage commitment, 
RT-qPCR analysis showed decreased expression of OC differentiation markers (DC-STAMP, 
TRAP, β3 integrin, Cathepsin K) in anti-TSP1 antibody treated cultures, consistent with reduced 
osteoclastogenesis (Figure 2.5 C).  
To define the temporal requirement of TSP1 in OC formation, we treated early (d0-2), 
mid (d3-4), or late (d4-5) stage OC cultures with A4.1 to neutralize TSP1 at different times 
during OC formation. We found that neutralizing TSP1 in early OC precursors (d0-2) was 
sufficient to decrease OC differentiation, while mid- or late-stage TSP1 neutralization had no 
effect (Figure 2.5 B). These data indicate that TSP1 promotes early-stage OC formation while it 
is dispensable for later maturation.  
 
Inhibition of NOS rescued TSP1-/- bone resorption phenotype 
TSP1 is an established mediator of NO signaling in endothelium and inflammatory 
macrophages (Chen et al., 2000; Isenberg et al., 2009), and we have previously shown that 
TSP1-receptor CD47 null mice show reduced OC formation due to increased levels of iNOS 
transcription (Uluckan et al., 2009). In primary OC cultures treated with TSP1 neutralizing 
antibody, we saw a dramatic elevation of iNOS expression compared to isotype control (Figure 
2.8 A). Neither nNOS nor eNOS were elevated in anti-TSP1 antibody treated cultures (data not 
shown). To test whether the bone resorption defect in TSP1-/- mice was attributable to elevated 
NO signaling, we inhibited NO production in vivo by administration of the pan-NOS inhibitor L-
NAME in the drinking water of TSP1-/- and WT mice (40 mg/kg/day) for six weeks. L-NAME-
treatment increased the serum CTX level of TSP1-/- mice to that of their WT counterparts, 
demonstrating that osteoclastic bone resorption was restored (Figure 2.8 B). Together, these data 
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!indicate that aberrant NO signaling in TSP1-/- mice was in part responsible for decreased OC 
function in vitro and in vivo. 
 
TSP1 in bone was sufficient to inhibit OC iNOS 
It is well established that TSP1 is secreted by OBs and is present in the bone matrix 
(Clezardin et al., 1989; Robey et al., 1989). We found that TSP1 contributes to maintaining bone 
strength (Figure 2.3), but its role as matricellular signaling molecule in the bone remained 
unknown.  
We hypothesized that bone-sequestered TSP1 signals to immature OCs to inhibit RANK-
L-induced iNOS. We therefore differentiated WT bone marrow macrophages into OC on plates 
coated with bone powder derived from WT or TSP1-/- mice. The osteoclastogenic culture 
medium was serum free to ensure that the bone was the only source of TSP1. OCs plated on 
TSP1-/- bone powder had increased iNOS expression compared to the same cells plated on WT 
bone after 24 hours of differentiation (Figure 2.9 A). Notably, the lineage marker NFATc1 was 
unchanged between cells plated on WT and TSP1-/- bone, indicating that osteoclastogenic 
signaling was initiated equally (Figure 2.9 A). Together, these data indicate that bone-
sequestered TSP1 plays a critical role in iNOS signaling during early osteoclastogenesis.  
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!Discussion 
 
We demonstrate here that TSP1 is critical for the maintenance of bone homeostasis, 
contributing both to matrix material integrity and regulation of OC formation (Figure 2.9 B). 
TSP1-/- mice were protected from age-associated bone loss and had increased cross-sectional 
area, but failed to show proportional resistance to bending. Instead, we found that TSP1 null 
mice had a bone material properties defect, resulting in decreased bone material quality and 
reduced strength. The increased trabecular bone mass in TSP1-/- mice was due to decreased 
osteoclastic resorption that was rescued upon in vivo pharmacologic inhibition of NO signaling. 
We demonstrated that TSP1 inhibition of iNOS was necessary for early OC formation, but was 
dispensable for later OC maturation. Finally, we showed that bone-sequestered TSP1 modulated 
OC iNOS levels, indicating TSP1 as a novel paracrine signaling molecule, coupling OB function 
to OC formation.  
The bone matrix is composed of two compartments: mineral of calcium-phosphate 
hydroxyapatite crystals and osteoid of collagen (90%) and other non-collagenous proteins (10%, 
NCP). Many diseases including osteogenesis imperfecta and rickets impact bone quality through 
modification of the osteoid tissue or mineralized matrix leading to increased risk of fragility 
fracture. Notably, TSP1 binds many components of the bone matrix, including collagen and 
hydroxyapatite, as well as numerous NCPs including osteonectin, fibronectin, osteopontin, and 
proteoglycans, among others (reviewed in (Tan and Lawler, 2009)). These NCPs are critical for 
bone matrix organization, both for collagen organization and hydroxyapatite deposition (Termine 
and Robey, 1996). In osteogenesis imperfecta patient OBs, secretion of TSP1 and its NCP 
binding partners are misregulated, suggesting that TSP1 participates with collagen and other 
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!NCPs for osteoid organization (Fedarko et al., 1995). Our data indicate that TSP1 is critical for 
maintaining the material properties of bone necessary for high bone quality. We postulate that 
TSP1 mediates the proper physical organization and protein stoichiometry of the bone matrix 
through its interactions with other bone matrix components. Further work is necessary to 
understand the role of the matrix proteins that interact with TSP1 to mediate bone quality. 
The TSP1-/- bones had both cancellous and cortical bone phenotypes. The increased area 
and cortical thickness of the TSP1-/- bones suggest an effect of TSP1 loss on OB bone 
formation. Assessment of bone formation rate and mineral apposition rates by dynamic 
histomorphometry in the TSP1-/- mice were hampered by the lack of double labels and diffuse 
single labels (Figure 2.4 B). These labeling abnormalities are consistent with a bone matrix 
defect. Ex vivo OB formation assays were not abnormal in the TSP1-/- cells or in WT cells in the 
presence of TSP1 neutralizing antibody (data not shown). It is possible that there was a 
compensatory increase in bone mineral formation due to defects in bone quality or that there are 
effects of TSP1 on osteocyte and OB formation and function that may be present early in 
development. Experiments are underway to explore the role of TSP1 in OBs. 
In addition to its role in maintaining bone matrix material integrity, we also found that 
TSP1 binding to early OC precursors promotes differentiation. While our data supports the 
hypothesis that bone-resident TSP1 regulates iNOS in early OC, it is also possible that TSP1 
modulation of the matrix, including stoichiometry of NCPs and protein presentation, may 
indirectly influence NO signaling. As ongoing research better characterizes the protein 
interactions in the bone matrix, the impact of matricellular TSP1 on cell signaling will be 
elucidated. Our data shows that exogenous TSP1 promotes osteoclastogenesis through 
modulation of NO signaling in OC precursors, similar to its function in endothelial cells, 
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!platelets, and vascular smooth muscle cells through CD36 and CD47 (Chen et al., 2000; Isenberg 
et al., 2009; Isenberg et al., 2006; Isenberg et al., 2005). The dramatic OC phenotype of TSP1 
deficiency, in contrast with the modest effects reported for receptors CD47 and CD36 (Carron et 
al., 2000; Kevorkova et al., 2013; Koskinen et al., 2013; Lundberg et al., 2007; Uluckan et al., 
2009), suggests that TSP1 binds multiple receptors to influence OC formation. We have 
previously reported that CD47 promotes OC formation through inhibition of iNOS (Uluckan et 
al., 2009). In the setting of bone homeostasis, OCs sense increased NO produced by iNOS early 
in differentiation as negative feedback to regulate the extent of osteoclastic bone resorption 
(Zheng et al., 2006). We demonstrated in vitro that TSP1 inhibits iNOS expression in OC 
precursors, thereby permitting OC formation. Notably, inhibition of NO synthesis in vivo 
rescued the TSP1-/- bone resorption defect, consistent with TSP1’s influence on OC through 
modulation of NO signaling.  
We present data to support novel roles of TSP1 that place it as a critical member of the 
bone microenvironment. We propose the following model: TSP1 is directionally secreted by OB 
into the matrix during bone formation (Clezardin et al., 1989; Robey et al., 1989). In the bone, 
TSP1 promotes matrix material integrity through interactions with other essential bone matrix 
proteins. Moreover, the matrix-derived TSP1 acts as a paracrine signaling molecule to promote 
OC formation via inhibition of iNOS, thus linking OB function to OC formation via the bone 
matrix (Figure 2.9 B). 
Due to its pleiotropic nature, with roles in inflammation, angiogenesis, and bone health, 
the TSP1-signaling axis represents a promising therapeutic target for many disease states. NOS 
inhibitors, including the compound L-NAME used in our study, are under clinical investigation 
to modulate blood pressure. Their converse, nitric oxide donors, have been in clinical use for 
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!decades to relieve angina and hypertension. Given our data of elevated OC activity upon 
administration of L-NAME to TSP1-/- mice, it will be important to monitor the bone health of 
patients administered these NO-targeted drugs long-term, especially in an elderly patient 
population with common bone pathological comorbidities such as osteoporosis and 
osteoarthritis.  
Bone pathologies such as osteoporosis and bone metastasis are characterized by a 
disruption of healthy bone turnover leading to pathologic fracture, hypercalcemia, and nerve 
compression. Modulation of OCs and OBs represent an attractive point for therapeutic 
intervention with agents such as bisphosphonates and anti-RANKL antibody (denosumab) in 
clinical use (Weilbaecher et al., 2011). Our findings provide further rationale to target the TSP1-
pathway, especially in comorbidities such as osteoporosis and bone metastasis. Importantly, we 
showed that TSP1-/- mice are protected from age-associated bone loss, but the increased bone 
mass was accompanied by a loss in bone quality. This provides important rationale to monitor 
bone health, both bone density and bone quality, as part of studies investigating TSP1-pathway 
directed therapeutics for bone-related and other indications. As targeted drugs, including anti-
CD47 antibodies, TSP1 mimetics, and NOS inhibitors, enter development and clinical use, it will 
be important to further investigate the role of TSP1, its receptors, and its downstream signaling 
molecules in bone health, to identify and monitor both harmful and positive bone effects.  
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Figure 2.1. 
TSP1-/- mice had increased bone mass.  
MicroCT analysis for calculation of bone morphological parameters: (A) Trabecular 
bone volume of 8-, 16-, and 32-week-old WT and TSP1-/- mice tibiae (8- and 32-week 
n=6/group; 16-week n=5/group). (B) Representative images of three- dimensional 
microCT reconstruction. (C) Cortical bone thickness and (D) total area of 12-week-old 
WT and TSP-/- mice femurs (WT n=5; TSP1-/- n=4). (E) Representative images of 
three-dimensional microCT reconstruction. (scale bars = 500 um) 
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Figure 2.2. 
TSP1-/- mice had altered trabecular morphology.   
MicroCT analysis for calculation of bone morphological parameters: (A) Trabeculae 
number and (B) trabecular spacing of 8-, 16-, and 32-week-old WT and TSP1-/- mice 
tibiae (8- and 32-week n=6/group; 16-week n=5/group).  
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Figure 2.3. 
TSP1 improved bone strength through effects on bone material properties.  
12-week old WT and TSP1-/- femurs were evaluated for structural and material 
strength. (A) MicroCT analysis of WT and TSP1-/- mice femurs for minimum moment 
of inertia. Femurs were subjected to three-point bending to evaluate structural 
mechanical parameters (B) ultimate force and (C) yield force (ns, p=0.0727). (D) Yield 
stress was calculated to normalize for differences in cortical bone morphology (WT 
n=5; TSP1-/- n=4). Reference point indentation was completed to evaluate local 
material properties: (E) initial indentation distance, (F) indentation distance increase. 
(n=3 tests/femur; WT n=5 femurs; TSP1-/- n = 3 femurs)  
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Figure 2.4. 
TSP1-/- mice had normal bone formation parameters. 
(A) Pro-collagen type I (P1NP) was measured in the serum of fasted WT and TSP1-/- 
mice (8-week WT n=6, TSP1-/- n=5; 16- and 32-week n=5/group). (B) Double calcein 
labeling of 16-week old WT and TSP1-/- mice.  (C)  WT and TSP1-/- bone marrow 
stromal cells were differenitated into OB in osteogenic media and stained for alkaline 
phosphatase (ALP) and alizarin red on day 14.  (D) ALP and (E) alizarin red were 
quantitated on day 3 and day 7.    
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Figure 2.5. 
TSP1 deficiency resulted in decreased osteoclast function in vivo and reduced 
osteoclast formation in vitro.  
(A) Collagen breakdown products (CTX) was measured in the serum of fasted WT and 
TSP1-/- mice (8-week n=5/group; 16-week n=4/group; 32-week n=7/group). (B) WT 
bone marrow macrophages differentiated into OC in the presence of anti-TSP1 A4.1 
antibody or IgM isotype control antibody at indicated days. TRAP staining for 
multinucleated OC at day 5 shown (representative images of n>3 biological replicates, 
scale bar = 0.25 mm). (C) qRT-PCR analysis for day 3 OC cultured with anti-TSP1 
A4.1 or IgM control (n=3 biological replicates).  
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Figure 2.6. 
TSP1-/- mice did not have significantly reduced osteoclast numbers in vivo. 
(A) 8-week old (left panels) and 32-week old (right panels) WT and TSP1-/- tibiae 
were sectioned and stained for TRAP (scale bar = 2 mm; representative images of n > 
3). (B) OC per bone surface and (C) OC surface per bone surface of 8- and 32-week 
WT and TSP1-/- mice.   
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Figure 2.7. 
Neutralization of exogenous TSP1 prevents OC formation in wild type and TSP1-/- cells. 
TRAP stain of WT or TSP1-/- bone marrow macrophages differentiated into OC in IgM 
isotype control of TSP1 neutralizing antibody (clone A4.1). TRAP staining for multinucleated 
OC at day 5 shown. (scale bar = 0.25 mm; representative images of n>3 biological replicates) 
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Figure 2.8. 
TSP1 regulates osteoclasts through inhibition of iNOS.  
(A) qRT-PCR of iNOS from WT OC cultures in the presence of TSP1 neutralizing 
antibody (A4.1) or istoype control (IgM). (n=3 biological replicates). (B) WT and 
TSP1-/- mice were administered pan-NOS inhibitor L-NAME, 40 mg/kg/day for 6 
weeks, and fasted serum CTX was measured (WT n=7/group; TSP1-/- n=8/vehicle, 
n=10/L-NAME).  
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Figure 2.9. 
Bone-derived TSP1 is sufficient to inhibit iNOS in osteoclasts.  
(A) qRT-PCR of early OC marker NFATc1 and iNOS from WT OC cultured on WT or 
TSP1-/- bone powder (n=2 biological replicates) for 24 hours. (B) Model of the role of 
TSP1 in bone biology.  
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Table 2.1. Mechanical properties of WT and TSP1-/- femurs 
Property WT (n=5) TSP1-/- (n=4) p-value 
Stiffness (N/mm) 58.71 ± 14.34 70.41 ± 7.961 0.5294 
Yield displacement (mm) 0.1180 ± 0.02089 0.1190 ± 0.01096 0.9699 
Post-yield displacement (mm) 0.2248 ± 0.01568 0.3100 ± 0.02640 0.0225 
Energy to fracture (N*mm) 2.806 ± 0.2241 3.940 ± 0.4317 0.0419 
Data are expressed as mean ± SEM !
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Chapter 3 
 
Samsn1 deletion contributes to monoclonal gammopathy of undetermined significance and 
multiple myeloma susceptibility through effects on multiple cell types
75
Abstract 
Multiple myeloma (MM) is a malignancy of plasma B-cells that is invariably preceded by 
monoclonal gammopathy of undetermined significance (MGUS), a pre-neoplastic plasma cell 
proliferative disorder.   Epidemiologic and population association studies demonstrated that 
inherited susceptibility to MM is due to an increased risk of MGUS, rather than an increased rate 
of transformation to overt malignancy.  Therefore, prevalence of MM is likely mediated by 
germline MGUS risk alleles.  C57Bl/KaLwRij (KaLwRij) is a spontaneous mutant mouse strain 
predisposed to benign idiopathic paraproteinemia (BIP), analogous to human MGUS. Using a 
integrative approach, we combined KaLwRij x B6 SNP analysis (418 genes) and a MM patient 
association study (180 genes) to identify five candidate genes likely to contribute to both murine 
BIP-susceptibility and human MM risk.  Surprisingly, we found KaLwRij mice had complete 
germline deletion of one of the five candidate genes, Samsn1, a negative regulator of B-cell 
activation.  Samsn1 is expressed in hematopoietic cells, including B-cells and macrophages.  
Consistent with the reported inhibitory function of SAMSN1 in B-cells, KaLwRij mice had 
enhanced B-cell responses in vitro and in vivo.  We also found that SAMSN1 re-expression 
decreases proliferation in myeloma cells, demonstrating its inhibitory function in malignant B-
cells.  Moreover, we found KaLwRij macrophages to have increased proliferation and markedly 
elevated expression of pro-tumorigenic M2 macrophage markers in vitro, and increased tumor-
promoting activity in vivo, suggesting that Samsn1 regulates macrophage activation.  Thus, we 
identified Samsn1 as a gene contributing to BIP-susceptibility in KaLwRij mice through 
mutually exclusive function in multiple cell types. It is likely that SAMSN1 and its pathway 
members contribute to human MM progression, and may represent a point for preventative 
therapeutic intervention.   
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Introduction 
 
Monoclonal gammopathy of undetermined significance (MGUS) is a hematological 
disorder characterized by an expansion of one or more antibody-producing plasma cells in the 
bone marrow, diagnosed by the presence of constant serum level of monoclonal paraprotein (<3 
g/dL, “M-spike”).  MGUS is a common syndrome of aging, with a prevalence of >3-5% in 50-70 
year olds (Kyle et al., 2006; Landgren et al., 2009).  While MGUS does not present with severe 
clinical features, the disorder is not wholly benign, and is associated with increased fracture risk 
and osteoporosis (Melton et al., 2005).  Most significant, MGUS is the requisite precursor to 
multiple myeloma (MM), and MGUS patients progress to overt malignancy at an annual rate of 
1%.  MM is the second most common hematological malignancy and is invariably fatal with a 
~6 year median survival (Kumar et al., 2013).  MM is characterized by an M-spike of >3 g/dL 
and is clinically diagnosed by the presence of CRAB symptoms: hypercalcemia, renal 
insufficiency, anemia, and lytic bone lesions.  Because of the low rate of transformation to 
myeloma (lifetime risk of 10-30% (Kyle et al., 2010; Sirohi and Powles, 2006; Zingone and 
Kuehl, 2011)), however, MGUS is not clinically treated, and, due to lack of symptoms, most 
cases remain undiagnosed until the patient presents with MM. 
Epidemiologic and association studies indicate germline risk alleles contribute to MM 
and MGUS susceptibility.  Interestingly, the majority of plasma-cell intrinsic genetic events in 
MM cells are present in MGUS-affected B-cells (Davies 2003). There is a higher incidence for 
MM in African Americans that is the result of elevated risk to MGUS, rather than an increased 
rate of conversion from MGUS to MM (Kyle et al., 2010; Kyle et al., 2006; Landgren et al., 
2006).  In addition, there is a higher risk of MM in individuals with an MGUS-affected first 
degree relative (Jain et al., 2009; Kyle et al., 2004; Vachon et al., 2009).  Seven common variants 
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were identified to confer a significant increase in MM risk in patients (Broderick et al., 2012; 
Chubb et al., 2013).  Interestingly, these SNPs also confer increased risk to MGUS, (Weinhold et 
al., 2014), providing further evidence that MM risk is a consequence of increased risk to MGUS.  
These studies highlight the necessity for a better understanding of the genetic predisposition to 
MGUS. 
A common spontaneous model for MGUS and MM is the C57Bl/KaLwRij mouse 
(KaLwRij).  KaLwRij has been inbred separate from the other C57Bl strains, including the 
common wild-type C57Bl/6 (B6) strain, since approximately 1978. KaLwRij mice develop 
benign idiopathic paraproteineima (BIP), analogous to human MGUS, with a penetrance of 
~45% by 12 months of age (Radl and Hollander, 1974; Radl et al., 1978).  Affected mice may 
also progress to overt malignancy (~1%) with similar clinical features as MM, including severe 
bone pathology (Alici et al., 2004; Asosingh et al., 2000; Vanderkerken et al., 2003).  The 5T 
myeloma cell lines were subcloned from these spontaneous myelomas, and may be transplanted 
into KaLwRij mice to propagate the myeloma (Radl et al., 1979). Importantly, the 5TMM cell 
lines will not engraft in closely related C57Bl/6 (B6) mice (Asosingh et al., 2000).  Notably, 
while KaLwRij is a model that recapitulates many features of human disease, the genetic basis of 
BIP susceptibility in these mice remains unknown.   
In this study, we identify Samsn1 as a candidate gene contributing to inherited risk of 
KaLwRij mice to BIP, analogous to human MGUS.  We used KaLwRij x B6 mouse SNP 
analysis and a human MM population association study to identify a candidate gene list.  We 
found that KaLwRij mice were null for Samsn1, a negative regulator of B-cell activation, and 
show that Samsn1 plays a role in B-cells, myeloma cells, and macrophages.  We sequenced 
Samsn1 in unaffected tissue from MM patients and found genetic variability that suggests that 
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the SAMSN1 pathway may be relevant to human disease.  Together, these data suggest that 
Samsn1 underlies predisposition to BIP in KaLwRij mice and that the SAMSN1 pathway may be 
involved in human MGUS and MM. 
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Materials and Methods 
 
Mice 
129S1/SvImJ, A/J, AKR/J, BALB/cByJ, CBA/J, C3H/HeJ, C57BL/6J, DBA/2J, FVB/NJ, 
NOD/ShiLtJ, SJL/J, and NOD-scid –IL2Rγ mice were purchased from Jackson Laboratory (Bar 
Harbor, ME). C57Bl/KaLwRij mice were originally obtained from Dr. Gregory Mundy at 
Vanderbilt University.  Mice were housed in shared pathogen-free conditions according the 
guidelines of the Division of Comparative Medicine, Washington University School of 
Medicine. The animal ethics committee approved all experiments. 
Immunization 
Mice were immunized with 50 µg chicken gamma globulin (Biosearch Technologies, Novato, 
CA) in complete or incomplete Freund’s adjuvant (Sigma-Aldrich, St. Louis, MO) by 
intraperitoneal injection at 6 (primary immunization) and 7.5 (boosting immunization) months of 
age. Blood samples were collected serially as indicated and stored frozen. 
Immunoglobulin ELISA  
Serum levels of immunoglobulins were monitored by ELISA for IgG and IgG2b according to 
manufacture’s instructions (Bethyl Laboratories, Montgomery, TX).   
Serum protein electrophoresis (SPEP) 
SPEP test was performed with the SPIFE 3000 analyzer according to the manufacturer’s 
instructions, using SPIFE SPE gel (Helena Laboratories, Beaumont, TX). The protein fractions 
were quantified by densitometer (QuickScan 2000, Helena Laboratories, Beaumont, TX). 
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Mouse phylogenetic analysis  
KaLwRij genomic DNA was isolated from kidney using DNeasy blood & tissue kit as described 
by the manufacturer (QIAGEN, Valencia, CA). SNP array analysis was performed using the 
Affymetrix mouse diversity genotyping array.  Sample preparation, hybridization and scanning 
were performed by Jackson Laboratory according to the standard Affymetrix genotyping 
protocol. The PHYLIP package (University of Washington, Seattle, WA) was used for the 
phylogenetic analysis. A distance matrix was created by the Neighbor program based on the 
KaLwRij and the published SNP data of other 11 strains (Didion et al., 2012; Yang et al., 2009). 
The neighbor-joining algorithm was used to calculate a phylogenetic tree followed by the 
Drawtree program for drawing the tree. 
B6xKaLwRij mouse strain SNP analysis 
SNP analysis was completed as previously described (Burgess-Herbert et al., 2008).   KaLwRij 
SNPs identified from the Affymetrix mouse diversity genotyping array were compared the 
published SNP data of B6 mice (Yang et al., 2009).  All genes annotated in Ensembl mouse 
genome build 37 with ≥ 5 variants were included as candidate genes for further analysis.  
Human subjects 
DNA for WGAA and sequencing analysis was extracted from skin cells. The study cohort 
consisting of 183 MM patients and 105 unaffected controls was approved by the Human 
Research Protection Office at Washington University School of Medicine and at the Mayo 
Clinic. Informed consent from the patients was obtained in accordance with the Declaration of 
Helsinki. 
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Whole-genome association analysis (WGAA) 
305 MM patients and 353 unaffected volunteers were genotyped using Affymetrix 6.0 platform.  
Data was analyzed by logistic regression analysis, adjusted for sex and group using PLINK 
software (http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell et al., 2007).  SNPs in the 99th 
significance percentile were included in further analysis.  Genes containing these SNPs were 
included as human candidate genes. 
Sequencing of SAMSN1 in MM patients 
Coding exons and adjacent intronic regions of SAMSN1 were sequenced in non-affected tissue 
from 183 MM patients and 105 unaffected volunteers by the Genome Technology Access Center 
at Washington University School of Medicine.  PCR amplicons were constructed using the 
Fluidigm Access Array (Fluidigm, San Francisco, CA).  Samples were harvested and indexed 
using the BioMark HD system (Fluidigm, San Francisco, CA).  Samples were pooled into 
sample libraries and sequenced on a MiSeq sequencer (Illumina, San Diego, CA).  Following 
annotation, variants in the case and control population were analyzed using logistic regression of 
reference allele dosage in cases and controls.   
Immunoblotting 
Western blot was performed as previously described(Chu et al., 2012).  Antibodies:  SAMSN1 
(Sigma-Aldrich, St. Louis, MO), actin (Sigma), and GFP (Santa Cruz Biotechnology, Dallas, 
TX). Blots were incubated with horseradish conjugated secondary antibodies (GE Healthcare, 
Fairfield, CT) and visualized by chemiluminescence (Pierce Biotechnology, Rockford, IL).  
Primary cell culture 
Splenic B-cells were negatively selected via MACS with anti-CD43 beads (Miltenyi Biotec, 
Cologne, Germany).  Cells were cultured in RPMI1650 media, 10% FBS, BME, 1% penicillin-
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streptomycin and stimulated with 10 ng/ml LPS and 20 ng/ml IL-4 for 72 hours.  To generate 
macrophages, whole bone marrow or peritoneal fluid was cultured in αMEM, 10% FBS, 1% 
penicillin-streptomycin, 50 ng/ml MCSF for 3 days (bone marrow macrophages) or 12 hours 
(peritoneal macrophages).  Proliferation was measured by standard MTT assay (Sigma-Aldrich, 
St Louis, MO).  M2 polarized macrophages were generated by stimulating day 3 bone marrow 
macrophages with 5 ng/ml IL-4 for 24 hours.  Osteoclasts were generated by culturing bone 
marrow macrophages in 50 ng/ml MCSF and 50 ng/ml RANKL for 3 days.  Bone marrow 
macrophages were generated by plating whole bone marrow cells in ascorbic acid-free αMEM, 
10% FBS, 1% penicillin-streptomycin for 7 days in 5% oxygen followed by negative selection 
via MACS with anti-CD45 beads (Miltenyi Biotec, Cologne, Germany).   
5TGM1 cell culture 
The 5TGM1 murine myeloma line was originally obtained from Dr. Gregory Mundy at 
Vanderbilt University. 5TGM1 stably overexpressing Samsn1 were generated using lentivirus 
transduction.  Briefly, full-length mouse Samsn1 cDNA was subconed into an MSCV-PGK-Puro 
plasmid (MPP).  To generate lentivirus, SAMSN1-MPP or MPP control and lentiviral vectors 
pCMVΔ8.9 and pM2G were transfected into HEK293T cells. Cell supernatant containing 
lentivirus was then plated on 5TGM1 cells and selected with puromycin for 72 hours.  Samsn1 
expression was assayed by Western Blot.  Cells were maintained in DMEM, 10% FBS, 1% 
penicillin-streptomycin.  Proliferation was measured by BrdU ELISA according to the 
manufacture’s instructions (Roche Diagnostics, Indianapolis, IN).   
M2-macrophage injection into 5TGM1 subcutaneous tumors 
1x106 5TGM1 cells were injected subcutaneously in the right flank of NOD-scid –IL2Rγ female 
mice.  14 days following tumor inoculation, 3x106 in vitro M2 polarized macrophages from B6 
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or KaLwRij mice were injected directly into the tumor.  Tumor burden was monitored by serum 
murine IgG2b ELISA (Bethyl Laboratories, Montgomery, TX).   
Macrophage comparison by microarray 
Bone marrow macrophages were isolated from B6 and KaLwRij mice (n = 3 biologic replicates) 
and RNA extracted using RNeasy Mini kit (Qiagen, Venlo, Netherlands).  RNA samples were 
submitted to the Genome Technology Access Center at Washington University School of 
Medicine for hybridization using the GeneChip Mouse Gene 1.0 ST array (Affymetrix, Santa 
Clara, CA).  Data was analyzed using Partek Genomics Suite (Partek Inc., St. Louis, MO).  
Differentially expressed genes were based on changes of 1.5 fold or more between B6 and 
KaLwRij.   
Quantitative reverse-transcription PCR 
RNA was extracted using RNeasy Mini kit (Qiagen, Venlo, Netherlands) and cDNA generated 
using iScript (Bio-Rad, Hercules, CA). Quantitative PCR was completed using SsoFast EVA 
Green Supermix (Bio-Rad, Hercules, CA). All samples run with biological replicates of ≥ 2. 
Primer sequences (forward/reverse): 
Cyclophilin:  AGCATACAGGTCCTGGCATC / TTCACCTTCCCAAAGACCAC 
Samsn1:  TTCACGCCAAGTCCCTATGAC / TTCCCATTGGTGTTTTGCACATA 
FIZZ1:  GCTGATGGTCCCAGTGAATA / CGTTACAGTGGAGGGATAGTTAG 
YM1:  GGGCATACCTTTATCCTGAG / CCACTGAAGTCATCCATGTC 
VEGF:  GGAGAGCAGAAGTCCCATGA / AGATCTCCACCAGGGTCTCA 
DNA amplification 
Genomic DNA was extracted from tail tissue or 5TGM1 culture using DNeasy blood & tissue kit 
as described by the manufacturer (QIAGEN, Valencia, CA).  DNA was amplified using standard 
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PCR and amplified products were visualized on an agarose gel stained with ethidium bromide 
under UV light.   
Primer sequences (forward/reverse):  
Gapdh:  ACTTTGTCAAGCTCATTTCC / TGCAGCGAACTTTATTGATG 
Samsn1 exons: 
exon 1:  TCACCAAGTGCTTTCCTTCC / AAGGCAGCAACGTGACATAA 
exon 2:  AGTCTTCATCATGCCCTTGG / GTTGCTTGGCAGATGGAGTT 
exon 3:  AACACACACACCGCCAAAGT / CCAAACCTCTTTCCAAACACA 
exon 4:  TCCCTTTTCAGGTTTCATGG / CTGGGACTAAACCCCCAATC 
exon 5:  CATCCGAGGACCACTGTTTT / TTTGCCTTTTCCTTCACCTG 
exon 6:  GGGTTCATCCCATTTTGTTG / TCTCACCTGCTTCCTGGACT 
exon 7:  TTCCTGGCTTATCCTGTGCT / GGAGCATCTCTGATCTTTGGA 
exon 8:  TAATGGGGGAAGGGATTAGG / AATGTCCTTACCTAACTCAGAAAAAT 
exon 9:  AGGCAGCCTGTTGAACAAT / TGTCCCAACTTAAACAATGCAC 
exon 10:  AATTGCAGTTGAATTCCACAAT / CATTGCACCAGATCCCTGTA 
exon 11:  ATGCCCTTTAAGGCAGATCA / TGCTAACAGCCACAGTCGAT 
exon 12:  CCCAGCACATATGAGTGAGTACTAT / GAACTGTTCTAGGAAATCAGGTTTA 
Statistics 
Data are shown as mean +/- SEM.  Unless otherwise indicated, experiments were analyzed using 
Student’s t-test or 1-way ANOVA as appropriate.   Sequencing results were considered to reach 
significance at p<0.05. *p<0.05; **p<0.01; ***p<0.001.  
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Results 
 
KaLwRij mice are an inbred strain susceptible to BIP 
The KaLwRij mouse strain is reported to have a high frequency of BIP (Radl et al., 
1978).  KaLwRij has been inbred separately from the other C57Bl strains, including B6, for over 
30 years.   To evaluate the relatedness of KaLwRij to B6 and other common lab strains, we 
performed high-density mouse SNP array analysis using KaLwRij genomic DNA.  The genetic 
distance values were estimated based on the comparison between the KaLwRij SNP data and the 
published single nucleotide polymorphism (SNP) data of 11 mouse strains (Yang et al., 2009), 
selected for relative genetic diversity.  These data demonstrated that, while closely related to B6, 
KaLwRij is a unique inbred strain (Figure 3.1a).    
 We hypothesized that the predisposition of KaLwRij mice to BIP and myeloma would be 
reflected in a unique antibody response to immune challenge. We evaluated immune response in 
KaLwRij and the other 11 strains of mice.  We treated mice with a primary and boosting 
immunization, collected serial serum samples, and performed immunoglobulin ELISA and serum 
protein electrophoresis (SPEP) (Figure 3.1b).  We quantitated immunoglobulin isotypes IgG 
(Figure 3.1c), IgM, and IgA.  Differences in antibody isotype response among strains were 
highly significant, indicating that immunoglobulin response was influenced by genetic 
background.    
 In patients, SPEP is used to screen for the presence of clonal serum immunoglobulin 
(Figure 1.4a).  In mice, an abnormal peak in the gamma fraction suggests an accumulation of 
monoclonal protein (M-spike) and indicates BIP, analogous to human MGUS.  Most strains 
presented with an M-spike post-primary or post-boosting immunization, indicating a normal 
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immune response.  By 18 months, however, the highest frequency of sustained M-spike was 
found in KaLwRij (Table 1.1).  Notably, the M-spike incidence in its closest related mouse 
strain, B6, had resolved.    
Our initial intention to map quantitative trait loci underlying murine BIP was confounded 
by the fact that the ELISA profiles we obtained appeared to reflect heterogeneity of normal 
immune responses rather than BIP development, and the SPEP signal took 18 months to 
manifest, making repeated crosses impractical. 
 
SNP analysis identified 418 genes divergent between B6 and KaLwRij haplotypes 
To identify candidate loci underlying susceptibility to BIP, we compared B6 and 
KaLwRij genotypes using high-density genome-wide SNP data.  Of the 562,061 SNPs queried 
across the 19 mouse autosomes, 21,133 SNPs varied between KaLwRij and B6. 11,323 were 
single nucleotide variation (53.6% of variation observed), while the remaining 9,810 SNPs 
grouped into 3,468 blocks of two or more consecutive non-identical SNPs.  Included in the 
observed SNP variation between B6 and KaLwRij, SNP no-calls in KaLwRij were also 
identified. While most of these were solitary, there were 48 groups of two or greater consecutive 
SNP no-calls, suggesting possible deletions affecting the locus.  The largest blocks of no-calls 
(two instances of 6 SNPs) fall in the Samsn1 locus that contains a total of 22 no-calls, the highest 
number of observed in a single gene locus.   
SNP blocks of two or greater fell within a total of 1,519 gene loci, with the highest 
number of variants in Ptprt, containing 128 polymorphic SNPs between B6 and KaLwRij.  For 
subsequent analysis, we used an arbitrary cut-off off blocks of five or greater consecutive SNPs, 
representing 56.1% of all SNPs that group in blocks of two or greater (Figure 3.2a).  This 
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defined a ranked candidate gene list of 418 genes that many contribute to BIP susceptibility in 
KaLwRij mice (Table 3.2). !
 
Association analysis of MM patients identified common variants in 180 genes  
 Inherited genetic susceptibility to MM is likely due to increased risk of MGUS, rather 
than increased risk of MGUS-to-MM transformation. We next sought to identify genetic loci 
contributing to increased risk of human MGUS and MM.  We performed whole-genome 
association analysis (WGAA) in a Caucasian population of MM patients (n=305) and healthy 
controls (n=353) to identify common genetic variation associated with MM and its requisite 
precursor MGUS (Figure 3.2b).  Relatively low sample size resulted in overall decreased 
significance of SNPs, and only one SNP (rs1029654 in an intergenic region) reached genome-
wide significance (p<5×10-8).  Therefore, to encompass all possible genetic variation 
contributing to MGUS and MM risk, we queried SNPs in the 99th significance percentile as 
differentially represented in MM patients versus controls (343 SNPs).  This identified a 
candidate gene list of 180 genes that may contribute to MM risk in humans (Table 3.3).  
 
Integrating murine BIP and human MM genetic analyses identified 5 shared genes 
 To further narrow our gene list and ensure that we pursued loci of clinical relevancy, we 
employed an integrative cross-species approach.  Combining the murine KaLwRij x B6 SNP 
analysis (418 genes) and human MM patient WGAA analysis (180 genes) yielded five shared 
genes (Figure 3.3a).  These genes are likely to contribute to inherited susceptibility to both 
human MGUS/MM and murine BIP/myeloma:  Fstl14, Samsn1, Ccm2, Tenm2, and Csmd1 
(Figure 3.3b).   
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KaLwRij mice have a germline homozygous deletion of Samsn1 
MGUS is a syndrome characterized by a clonal expansion of plasma B-cells and 
increased monoclonal immunoglobulin production; therefore, Samsn1, a negative regulator of B-
cell function, drew particular interest.  In activated B-cells, SAMSN1 is an adaptor protein in a 
B-cell signaling inhibitory complex, binding SHP-1/2 and the ITIM domain of PIR-B (Wang et 
al., 2010; Zhu et al., 2004).  We hypothesized that inactivating SNPs in the Samsn1 locus of 
KaLwRij would lead dysregulation of B-cells, increased B-cell activation, and subsequent BIP 
development. 
Close inspection of the KaLwRij SNP array data at the gene locus (Chromosome 16: 
75,858,793-76,022,270; SNPs encompassing Chromosome 16: 75,815,371-75,999,906) revealed 
that 29 no-calls in KaLwRij, suggesting a gene deletion (Figure 3.4a).  We amplified the coding 
regions of Samsn1 from DNA of KaLwRij and B6 by PCR.  Surprisingly, all protein-coding 
exons 1-12 of Samsn1 failed to amplify from KaLwRij germline DNA, further implying deletion 
of the locus (Figure 3.4b).  To confirm loss of protein expression anticipated by gene deletion, 
we probed for SAMSN1 in splenic B-cells treated with IL-4 and LPS.  Following treatment, 
SAMSN1 was strongly expressed in B6 B-cells, but not in KaLwRij B-cells (Figure 3.4c).  
Together, these data indicate a homozygous germline deletion of the Samsn1 gene in KaLwRij 
mice. 
 
KaLwRij mice have enhanced B-cell function 
 SAMSN1 has been shown to regulate B-cell activity, likely through its interactions with 
the B-cell inhibitory protein PIR-B (Zhu et al., 2004).  Samsn1-/- mice have enhanced B-cell 
function compared to wild type, with increased proliferation in purified splenic B-cell culture 
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and increased immunoglobulin response following immunization in vivo (Wang et al., 2010).  To 
evaluate whether KaLwRij mice showed similar increased B-cell activity, we cultured purified 
CD43- splenic B-cells from KaLwRij and B6 mice. Importantly, we demonstrated loss of 
SAMSN1 in KaLwRij cells, while purified splenic B-cells from B6 mice showed increased 
levels of SAMSN1 protein following stimulation with IL-4 and LPS (Figure 3.4c).  Next, we 
measured proliferation of cultured primary B-cells in response to IL-4 and LPS stimulation by 
MTT assay. KaLwRij B-cells displaced enhanced proliferative response to B-cell activation 
compared to B6 (Figure 3.5a).   
 To test whether KaLwRij mice also had increased B-cell activity in vivo, we immunized 
6 month old KaLwRij and B6 mice (Figure 3.1b) and monitored immunoglobulin response until 
the mice reached 24 months of age.  KaLwRij mice had a significant and progressive elevation in 
IgG2b levels, first evident after primary immunization and continuing throughout the entirety of 
the experiment, more than a year following immunization (Figure 3.5b). Therefore, we 
demonstrated that KaLwRij mice showed considerable B-cell phenotypic overlap with Samsn1-/- 
mice, both in vitro and in vivo.   
 
Samsn1 decreases KaLwRij MM cell line 5TGM1 proliferation  
The murine 5T myeloma cell lines were originally isolated from a myeloma-bearing 
KaLwRij mouse (Asosingh et al., 2000; Radl et al., 1979), and subsequent subclones were 
isolated, including 5TGM1. We confirmed Samsn1 deletion in 5TGM1 by PCR and RT-qPCR 
(Figure 4.6a-b).  Because SAMSN1 is down regulated in many human MM cell lines (Claudio et 
al., 2001), and because of Samsn1’s role in regulating murine B-cell activation, we hypothesized 
that Samsn1 was a myeloma-cell intrinsic tumor suppressor.  5TGM1 cells with stable 
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overexpression of Samsn1 had decreased proliferation compared to control under both basal and 
IL-6 stimulated conditions (Figure 3.6b-c).  These data suggest that Samsn1 contributes in part 
to myeloma tumor growth through a cell-intrinsic mechanism, consistent with its published anti-
proliferative role (Wang et al., 2010; Zhu et al., 2004).   
 
KaLwRij mice have an altered MGUS- and MM-supportive bone microenvironment 
Germline risk alleles to MGUS and MM may also influence cell types beyond pre-
malignant plasma B-cells.  MGUS and MM are both characterized by bone microenvironment 
contributions from host cells including macrophages, bone marrow stromal cells, and osteoclasts 
(reviewed in (Kuehl and Bergsagel, 2002)).  Differential gene expression in whole bone marrow 
of KaLwRij and B6 mice has been previously demonstrated (Fowler et al., 2011), but individual 
cell-type gene expression variation has not been evaluated. 
To query specific components of the BIP- and myeloma-supportive bone 
microenvironment we cultured primary macrophages and CD45- bone marrow stromal cells 
from whole bone marrow of B6 and KaLwRij mice.  Microarray analysis identified 31 
differentially expressed genes, including Samsn1, in bone marrow macrophages (Figure 3.7a, 
Table 3.4) and eight differentially expressed genes in bone marrow stromal cells (Figure 3.7b, 
Table 3.5).  Notably, six genes from the macrophage analysis (Tnfrsf26, Samsn1, Lyrm7, Sparc, 
Lrrc27, and Qpct) and three genes from the stromal cell analysis (Tnfrsf26, Tnfrsf23, and Lyrm7) 
are included in the list of candidate genes underlying genetic susceptibility to BIP in KaLwRij 
mice (Table 3.2).   
We verified the Samsn1 expression observed in the bone marrow macrophage and bone 
marrow stromal cell microarrays, and confirmed that bone marrow macrophages express Samsn1 
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while bone marrow stromal cells are non-expressors (Figure 3.7c).  To further evaluate the role 
of Samsn1 in other BIP- and myeloma-supportive host microenvironment cells, we cultured 
primary peritoneal macrophages and differentiated osteoclasts from bone marrow macrophages.  
Osteoclasts expressed low but detectable levels of Samsn1.  Peritoneal macrophages were high 
Samsn1 expressors, with 70-fold higher levels than bone marrow macrophages (Figure 3.7c).  
As a population, peritoneal macrophages are more mature and have increased activation 
compared to bone marrow macrophages, likely due to recruitment to the peritoneal cavity in 
response to infection (Wang et al., 2013). These data suggest that Samsn1 may play a role in 
macrophage activation. 
 
Enhanced macrophage function in KaLwRij mice  
Gene expression data from bone marrow macrophages and peritoneal macrophages 
suggest that Samsn1 may contribute to macrophage function, similar to its role in B-cells.  
Notably, SAMSN1 binding partners (PIR-B and SHP-1/2) and pathway members (Syk, PI3K, 
among others) in B-cells, also participate in macrophage biology (Brenner et al., 2004; Munitz et 
al., 2010; Xie et al., 2014).  To assess macrophage activity in Samsn1-null KaLwRij mice, we 
cultured bone marrow macrophages from whole bone marrow and measured proliferation by 
MTT assay.  We found that KaLwRij macrophages had increased proliferation compared to B6 
(Figure 3.8a).   
Tumor associated macrophages (TAMs) are established host microenvironment 
contributors to myeloma pathogenesis (reviewed in (Asimakopoulos et al., 2013; Berardi et al., 
2013; Ribatti et al., 2013)).  TAMs are broadly classified as anti-tumor M1 macrophages and 
pro-tumor M2 macrophages.  In vitro, macrophage polarization to M1 requires stimulation with 
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interferon-gamma, while polarization to M2 is induced upon addition of IL-4.  Under basal 
conditions, that is, without the addition of any stimulatory cytokines, we found that KaLwRij had 
significant and dramatic elevation of M2-macropahge markers FIZZ1 and YM1 in both bone 
marrow macrophages (Figure 3.8b) and peritoneal macrophages (Figure 3.8c).  TAMs from 
MM patients promote tumor growth through vasculomimicry, including increased expression of 
pro-angiogenic VEGF.  We found that KaLwRij had increased levels of VEGF transcription 
compared to B6 in both bone marrow (Figure 3.8b) and peritoneal (Figure 3.8c) macrophage 
cultures.  These data suggest that under homeostatic conditions, KaLwRij macrophages are 
skewed towards a pro-tumor M2 polarization phenotype. 
To evaluate the ability of KaLwRij M2 macrophages to promote tumor growth in vivo, 
we inoculated 5TGM1 myeloma cells subcutaneously in NOD-scid –IL2Rγ mice.  Once tumors 
were established (day 14), we injected B6 or KaLwRij ex vivo M2-polarized macrophages 
directly into the tumor and monitored tumor growth by IgG2b, the 5TGM1 Ig clonotype (Figure 
3.8d).  Tumors injected with KaLwRij M2 macrophages had significantly increased tumor 
growth as measured by serum IgG2b compared to tumors injected with B6 M2 macrophages 
(Figure 3.8e; representative tumors Figure 3.8f).  Together, these findings indicate that 
KaLwRij macrophages have enhanced activation and contribute to myeloma pathogenesis. 
 
SAMSN1 genetic variation in unaffected tissue of MM  
To directly investigate the impact of SAMSN1 to confer risk in patients, SAMSN1 exome 
sequencing was performed on non-affected tissue from MM patients (n=183) and healthy 
controls (n=105).  In total, we identified 38 SNPs contained in the protein coding regions, 5’ and 
3’ untranslated regions (UTR), and exon/intron boundaries (Table 3.6).  Of these, 15 SNPs only 
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occurred in one individual.  While the majority of variants were previously known and annotated 
in the dbSNP database, we identified six novel SNPs, all private variants.  Of the annotated 
SNPs, six fell in the 3’UTR, three in the 5’UTR, and two SNPs were located in exon/intron 
splice regions.  In addition, we observed seven annotated missense variants.  The remainder 20 
SNPs were silent mutations or fell in intronic regions or were unannotated.  Two variants 
reached statistical significance, rs2822790 (OR = 0.5098, p = 0.0472) and rs2822792 (OR = 
0.5098, p = 0.0472). Both variants were present at lower frequency in MM cases (4.12%) than 
controls (8.09%), suggesting that the alternate allele may be protective.  While few SNPs 
reached statistical significance, the variability observed in MM patients suggests that the 
SAMSN1 pathway may play a role in human MGUS and MM pathogenesis. 
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Discussion 
 
Using a combinatorial genetics approach, we identified genes underlying inherited 
susceptibility to MGUS and MM in humans and in mice.  Specifically, this study identifies 
Samsn1 as a novel MGUS/MM susceptibility gene, likely conferring risk via effects in both pre-
neoplastic B-cells as well as host supportive macrophages. We found that KaLwRij mice are null 
for Samsn1, reported to have decreased expression in human MM cell lines (Claudio et al., 
2001), thus providing compelling evidence that Samsn1 is a permissive allele in both mouse and 
human pathogenesis.  KaLwRij mice phenocopied the published enhanced B-cell response in 
Samsn1-/- mice (Zhu et al., 2004).  We further found a cell-intrinsic role for Samsn1 as a tumor 
suppressor in malignant myeloma cells.  We identified a novel putative role for Samsn1 in 
macrophages, with KaLwRij macrophages exhibiting enhanced macrophage activation under 
basal conditions and increased ability to enhance myeloma growth in mice.  Finally, we found 
two SNPs at reduced frequency in a MM patient population, providing further evidence that 
germline variants SAMSN1 may confer increased risk to MGUS and MM in humans.  Together, 
these data indicate that Samsn1 confers risk to murine BIP and human MGUS with roles both in 
the pre-neoplastic B-cell and in the host macrophages.   
While KaLwRij mice are a widely used spontaneous model of MGUS and MM, the 
genetic basis for its susceptibility to BIP remains largely unknown.  SNP analysis of KaLwRij x 
B6 revealed more than 1000 genes containing multiple variants, including several deletions, in 
the KaLwRij strain.  We generated a candidate gene list underlying inherited susceptibility to 
BIP in KaLwRij of 418 genes.  Importantly, it is likely that multiple genes contribute to the 
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complex trait of BIP, and investigation of additional candidate genes in KaLwRij mice is 
underway. 
To query genetic loci conferring risk to human MGUS and MM and ensure that we were 
pursuing genes with clinical relevancy in the KaLwRij mouse model, we completed a WGAA of 
human MM patients and healthy controls.  Typically, sample sizes of greater than 2000 cases and 
controls are necessary to identify causal variants in WGAA; published MM WGAA analyzed 
1675-4692 cases and 5903-10990 controls to identify risk loci with genome-wide significance 
(Jain et al., 2009; Kyle et al., 2004; Vachon et al., 2009).  In the study described here, low 
sample size (205 cases, 353 controls) resulted in overall decreased significance of SNPs. To 
ensure inclusion of all biologically significant genetic variation, therefore, we queried SNPs in 
the 99th significance percentile that fell in 180 gene loci.  Importantly, we identified SNPs in 
three of the seven previously published genetic loci associated with MGUS and MM risk 
(2p23.3, 3p22.1, and 7p15.3), validating our approach.   
Finally, in order to identify candidate genes for biologic validation in the KaLwRij mouse 
model, we combined the mouse and human gene sets.  This approach ensures clinical relevancy 
of further work in gene variant validation and investigation of biologic function.  Moreover, 
combining the mouse and human datasets also guarantees that the human variants of interest 
have a murine counterpart, providing a practical, relevant, and immediate mouse model.   Using 
this integrative approach, we identified five genes that may underlie susceptibly murine BIP and 
also contribute to MGUS and MM risk in patients.  
 Because it has been implicated in human MM cell lines and has an established role in 
regulating B-cell activation, we investigated the Samsn1 locus in the KaLwRij mouse strain.  
Surprisingly, we found that KaLwRij had homozygous germline deletion for the coding regions 
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of Samsn1.  Moreover, KaLwRij mice have a similar phenotype as the the published enhanced 
B-cell response of Samsn1-/- mice with increased B-cell proliferation in vitro and enhanced and 
sustained antibody response in vivo (Wang et al., 2010).  These data strongly indicate that loss of 
Samsn1 in pre-malignant plasma B-cells confers increased risk of developing BIP in mice.   
 Next, we evaluated the role of Samsn1 in myeloma cells.  In human MM cell lines, 
Samsn1 expression is dramatically reduced (Claudio et al., 2001), suggesting a role as a tumor 
suppressor in myeloma.  Like the KaLwRij mouse, the KaLwRij-derived myeloma cell line 
5TGM1 is null for Samsn1.  Overexpression of Samsn1 in 5TGM1 reduces in vitro proliferation 
under both basal and pro-tumorigenic conditions.  These data provide compelling evidence that 
Samsn1 is a myeloma-autonomous intrinsic negative regulator of tumor growth. 
While it is well established that genetic risk factors contribute to susceptibility to MM, 
the majority of genetic alterations in MM cells are already present in MGUS plasma cells 
(Davies et al., 2003).  These data suggest that plasma-cell extrinsic factors contribute to the 
conversion of MGUS to MM.  Rather than being confined to the affected plasma cell, it is likely 
that genetic susceptibility alleles are expressed in both the pre-malignant B-cell and in supportive 
host microenvironment cells.   
To investigate specific cell types of the bone microenvironment in BIP-susceptible 
KaLwRij mice, we completed gene expression analysis of B6 and KaLwRij bone marrow 
macrophages and bone marrow stromal cells.  31 genes were differentially expressed in B6 and 
KaLwRij bone marrow macrophages, and eight genes were differentially expressed in bone 
marrow stromal cells.  Interestingly, six of the 31 differentially expressed macrophage genes 
(including Samsn1) and three of the eight differentially expressed stromal cell genes contain 
germline variants in KaLwRij mice as identified in the B6xKaLwRij SNP analysis.  This 
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suggests that genetic variation likely influences these genes’ macrophage expression and 
provides further evidence of B-cell extrinsic activity of BIP susceptibility alleles. 
Samsn1 is expressed in many cells of the hematopoietic lineage, and we found that 
Samsn1 is expressed by bone marrow macrophages and, to a greater extent, peritoneal 
macrophages from B6 mice.  Increased expression in the more mature peritoneal macrophages 
compared to bone marrow macrophages led us to hypothesize that Samsn1 may participate in 
macrophage activation via similar mechanisms as its role in B-cells.  
Host tumor-associated macrophages (TAMs) have been implicated in promoting MM 
progression.  Macrophages from MM patient bone marrow are functionally distinct from bone 
marrow macrophages from MGUS patients (Scavelli et al., 2008).  MM tumor-associated 
macrophages (TAMs) support MM progression directly through elevated secretion of pro-
tumorigenic factors such as IL-6 (Kim et al., 2012; Zheng et al., 2009) and by promoting 
angiogenesis through elevated expression of VEGF (Ribatti et al., 2006; Scavelli et al., 2008; 
Vacca and Ribatti, 2011). 
We investigated KaLwRij macrophages to determine whether they had increased capacity 
to support BIP- and myeloma cells.  Non-stimulated KaLwRij bone marrow macrophages and 
peritoneal macrophages had significantly increased macrophage activation, with elevated pro-
tumorigenic M2 macrophage markers.  These data suggest that, similar to its role in B-cells, 
Samsn1 negatively regulates macrophage activation.  Importantly, we further demonstrated that 
KaLwRij M2-polarized macrophages potently increased myeloma tumor growth in vivo.  
Together, these data indicate that KaLwRij Samsn1-null macrophages have enhanced 
macrophage response and a greater capacity to support tumor growth in vivo. 
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Finally, we sought to identify whether SAMSN1 germline variants confer risk to MM in a 
patients.  We sequenced SAMSN1 in 183 MM patients and 105 controls.  We observed 38 SNPs 
and identified six rare variants that are not annotated in the dbSNP database.  Two SNPs had 
greater frequency in the control population, suggesting that they may confer MM or MGUS 
resistance.  Further GWAS studies and sequencing of normal tissue from MM patients in 
necessary to validate and expand upon these findings. SAMSN1 does not represent the only 
possible locus for genetic lesions; variation in other members of the SAMSN1 signaling pathway 
likely also contribute to MM susceptibility.  Further work is necessary to elucidate binding 
partners and downstream effects of SAMSN1 in human cells, and in different cell types 
including macrophages.   
Described here is a novel integrative approach to identify candidate genes contributing to 
risk of murine BIP and human MGUS and MM.  Combining mouse and human datasets was 
successful in identifying genes relevant to human disease, including Samsn1.  BIP-prone 
KaLwRij mice harbor a homozygous deletion of Samsn1, the first germline mutation identified 
in the KaLwRij strain.  We demonstrate that Samsn1 plays functionally important and cell-
autonomous roles in multiple cell types involved in MM pathogenesis, including B-cells (as 
previously published), in myeloma cells, and in host supportive macrophages.  Importantly, 
while our work focused on the role of Samsn1, other identified genes listed are also promising 
candidates to influence MM risk in multiple cell types, and work is ongoing to investigate these 
candidates.  In particular, candidate gene Fstl4 is especially intriguing with possible downstream 
effects on B-cell immunoglobulin production and M2 macrophage activation (Ogawa et al., 
2008; Sierra-Filardi et al., 2011).  In conclusion, this work informs and prioritizes ongoing and 
future human genetics studies and mechanistic studies in mice.  It is highly likely that SAMSN1 
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and other members of its pathway play important roles in MGUS and MM pathogenesis in 
humans, and future work will further define the effects of Samsn1 in myeloma progression as 
well as explore other risk loci contributing to MGUS and MM susceptibility.   
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Figure 3.1.  
Immunoglobulin responses are significantly different between mouse strains. 
(a) Phylogenetic tree demonstrating genetic distances of 12 strains of mice by whole 
genome SNP array. (b) Schema for immunization and serial serum sample protocol. 
Serum was collected at baseline (T0), post-primary immunization (T1), post-boosting 
immunization (T2), 12 months (T3), and 18 months (T4). (c) Serum IgG analysis of 
serial serum samples by ELISA. 
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Figure 3.4.   
The Samsn1 locus is deleted in KaLwRij mice. 
(a) Mouse chromosome 16 map.  Red regions are non-shared polymorphic alleles 
between KaLwRij and B6 mice; green arrowhead indicates MM WGAA SNP 
rs12626593.  Closer analysis of the region of Samsn1 covered by the high-density 
genotyping SNP array (Chr16: 75,815,371–75,999,906).  Boxes represent SNP calls 
(red = no-call; pink = heterozygous; white = reference allele (B6); blue = alternate 
allele).  (b) PCR amplification of exons 1-12 of Samsn1 and Gapdh control from B6 
and KaLwRij tail DNA.  (c) Western blot analysis of SAMSN1 in CD43- splenic B-
cells from B6 or KaLwRij mice stimulated with IL-4 and LPS for 72 hours. 
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Figure 3.5.   
Enhanced B-cell response in KaLwRij mice.  
(a) CD43- splenic B-cells were stimulated with IL-4 and LPS for 72 hours.  Cell 
proliferation was measured by MTT.  (b) Mice were immunized (arrowheads indicate 
primary and secondary immunization) and serial serum samples collected.  Levels of 
IgG2b were determined by ELISA. 
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Figure 3.6.   
Samsn1 inhibits proliferation in KaLwRij myeloma cell line 5TGM1.  
(a)  PCR amplification of exons 1-12 of Samsn1 and Gapdh control from the 
KaLwRij-derived 5TGM1 cell line DNA.  (b) RT-qPCR for Samsn1 in parental 
5TGM1 cells, control vector cells (5TGM1-MPP), and cells overexpressing Samsn1 
(5TGM1-SAMSN1).  (c) 5TGM1-MPP and 5TGM1-SAMSN1 cells were stimulated 
with IL-6 for 24 hours.  Cell proliferation was measured by BrdU incorporation.   
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Figure 3.7.   
Differential gene expression in B6 and KaLwRij bone marrow macrophages and 
bone marrow stromal cells. 
Microarray analysis of gene expression in B6 and KaLwRij (a) bone marrow 
macrophages and (b) bone marrow stromal cells..  (c) Samsn1 expression in B6 
peritoneal macrophages (PM) bone marrow macrophages (BMM), osteoclasts (OC), 
and bone marrow stromal cells (BMSC).  
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Figure 3.8.   
KaLwRij mice have enhanced pro-tumorigenic macrophage activation  
Proliferation of B6 and KaLwRij macrophages was measured by MTT assay.  (b) M2 
macrophage polarization markers (FIZZ1, YM1) and VEGF in (b) bone marrow 
macrophages and (c) periotoneal macrophages by qPT-PCR.  (d) B6 or KaLwRij in 
vitro M2-polarized macrophages were injected directly into 5TGM1 tumors 14 days 
after tumor innoculation.  Mice were sacrificed at day 21 (representative tumors (f)).  
(g)  Tumor burden was monitored by serum levels of IgG2b (clonotype of 5TGM1 
cells).  
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Table 3.1.  Mice with positive M-spike on SPEP
Strain Baseline Post-PI Post-BI 12 mo 18 mo
KaLwRij 0/12 (0) 1/12 (8) 2/11 (18) 8/11 (73) 5/9 (56)
C57BL/6J 0/10 (0) 0/10 (0) 4/10 (40) 3/9 (33) 0/7 (0)
129S1/SvlmJ 0/10 (0) 2/9 (22) 6/9 (67) 2/8 (25) 0/8 (0)
A/J 0/10 (0) 7/7 (100) 4/7 (57) 0/4 (0) 0/2 (0)
AKR/J 0/10 (0) 4/7 (57) 5/6 (83) 1/2 (50) --
BALB/cByJ 0/10 (0) 3/10 (30) 3/9 (33) 4/9 (44) 0/7 (0)
C3H/HeJ 0/10 (0) 3/8 (38) 5/8 (63) 4/8 (50) 0/2 (0)
CBA/J 0/10 (0) 3/30 (30) 1/10 (10) 6/7 (86) 0/1 (0)
DBA/2J 0/10 (0) 1/9 (11) 1/9 (11) 0/5 (0) 0/2 (0)
FVB/NJ 0/10 (0) 1/10 (10) 6/10 (60) 4/9 (44) 0/6 (0)
NOD/ShiLtJ 2/10 (20) 7/3 (43) 4/5 (80) 0/5 (0) 0/4 (0)
SJL/J 0/10 (0) 0/9 (0) 4/5 (80) 1/5 (20) 1/3 (33)
M-spike positive mice / total mice (percentage)
No strain AKR/J mice survived to 18 months. 
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Table 3.2.  Candidate genes underlying genetic susceptibility to BIP in KaLwRij mice
Gene SNP score Ensembl gene ID Chr Strand Start (bp) End (bp) Band
Ptprt 128 ENSMUSG00000053141 2 - 161521990 162661147 H2
Thsd4 109 ENSMUSG00000032289 9 - 59966931 60522046 B
Arfip1 102 ENSMUSG00000074513 3 - 84496093 85887516 F1
Dab1 95 ENSMUSG00000028519 4 + 103619359 104744844 C6
5033411D12Rik 95 ENSMUSG00000055137 13 - 16857855 17694732 A2
Shank2 92 ENSMUSG00000037541 7 + 144001928 144424494 F5
Rora 85 ENSMUSG00000032238 9 + 68653786 69388246 C
Cdh4 75 ENSMUSG00000000305 2 + 179442431 179899373 H4
Elmo1 74 ENSMUSG00000041112 13 + 20090507 20608353 A2
Ush2a 68 ENSMUSG00000026609 1 + 188262023 188965041 H6
Esrrg 63 ENSMUSG00000026610 1 + 187608791 188214885 H5
Fgfr2 62 ENSMUSG00000030849 7 - 130162451 133123350 F3
Dock1 62 ENSMUSG00000058325 7 + 134670687 135173639 F3
Sgcd 61 ENSMUSG00000020354 11 - 46896253 47988969 B1.1
Fstl5 58 ENSMUSG00000034098 3 + 76074270 76710019 E3
Fstl4 54 ENSMUSG00000036264 11 + 52764634 53188538 B1.3
Gm12132 52 ENSMUSG00000085301 11 + 40008194 40337831 A5
Pou6f2 44 ENSMUSG00000009734 13 - 18121101 18382041 A2
Kcnq1 43 ENSMUSG00000009545 7 + 143107254 143427042 F5
Kcnq5 42 ENSMUSG00000028033 1 - 21398403 21961942 A4
Gm12239 41 ENSMUSG00000086020 11 + 55772088 56070848 B1.3
Adamtsl1 38 ENSMUSG00000066113 4 + 86053915 86428385 C4
Map2k5 37 ENSMUSG00000058444 9 - 63163769 63377902 C
A230004M16Rik 34 ENSMUSG00000087306 11 + 41710342 41973117 A5
Samsn1 33 ENSMUSG00000022876 16 - 75858793 76022270 C3.1
Stpg2 33 ENSMUSG00000047940 3 + 139205694 139710299 H1
Slc24a2 32 ENSMUSG00000037996 4 - 86983124 87230477 C4
C1qtnf7 32 ENSMUSG00000061535 5 + 43515569 43618817 B3
Ptprd 31 ENSMUSG00000028399 4 - 75941238 78211961 C3
Wdr17 30 ENSMUSG00000039375 8 - 54629055 54887184 B1.3
Col23a1 29 ENSMUSG00000063564 11 + 51289920 51583918 B1.3
Arid5b 27 ENSMUSG00000019947 10 - 68095593 68278726 B5.2
Vps41 27 ENSMUSG00000041236 13 + 18717292 18866809 A2
Ano1 26 ENSMUSG00000031075 7 - 144588549 144751974 F5
Tln2 26 ENSMUSG00000052698 9 - 67217087 67559703 C
Aoah 25 ENSMUSG00000021322 13 + 20794119 21024252 A2
Mark1 25 ENSMUSG00000026620 1 - 184896443 184999549 H5
Nxph1 25 ENSMUSG00000046178 6 + 8948431 9249032 A1
Unc5c 25 ENSMUSG00000059921 3 + 141465564 141834924 H1
Iqsec1 24 ENSMUSG00000034312 6 - 90659598 90810123 D1
Vps13c 24 ENSMUSG00000035284 9 + 67840396 67995634 C
Znrf3 24 ENSMUSG00000041961 11 - 5276324 5444847 A1
Dhx35 23 ENSMUSG00000027655 2 + 158794807 158858214 H1
D7Ertd443e 23 ENSMUSG00000030994 7 - 134266262 134385661 F3
Neo1 23 ENSMUSG00000032340 9 - 58874679 59036441 B
Focad 23 ENSMUSG00000038368 4 + 88094629 88411011 C4
Tcerg1l 22 ENSMUSG00000091002 7 - 138208974 138397730 F4
Adcy1 21 ENSMUSG00000020431 11 + 7063489 7178506 A1
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Gene SNP score Ensembl gene ID Chr Strand Start (bp) End (bp) Band
Tspan5 21 ENSMUSG00000028152 3 + 138742195 138904433 H1
Ldb2 21 ENSMUSG00000039706 5 - 44472133 44799707 B3
Ebf1 21 ENSMUSG00000057098 11 + 44617317 45008091 B1.1
Stk32c 20 ENSMUSG00000015981 7 - 139103638 139213307 F4
Tns3 20 ENSMUSG00000020422 11 - 8431652 8664535 A1
Spata17 20 ENSMUSG00000026611 1 - 187044648 187215465 H5
Prom1 20 ENSMUSG00000029086 5 - 43993625 44102032 B3
Itga11 20 ENSMUSG00000032243 9 + 62677826 62783982 B
Atg2b 20 ENSMUSG00000041341 12 - 105613539 105685241 E
Bmpr1b 20 ENSMUSG00000052430 3 - 141837136 142169425 H1
4933427D06Rik 20 ENSMUSG00000055403 6 + 88950683 89110030 D1
Kcnn3 19 ENSMUSG00000000794 3 + 89520164 89667761 F1
Rab28 19 ENSMUSG00000029128 5 - 41624976 41708155 B3
Coro2b 19 ENSMUSG00000041729 9 - 62419492 62537044 B
Tnip1 18 ENSMUSG00000020400 11 - 54910785 54962917 B1.3
Trim2 18 ENSMUSG00000027993 3 - 84160439 84305446 F1
Foxp2 18 ENSMUSG00000029563 6 + 14901349 15441977 A1
Fam196a 18 ENSMUSG00000073805 7 - 134881926 134938430 F3
Nf2 17 ENSMUSG00000009073 11 - 4765845 4849536 A1
Osbp2 17 ENSMUSG00000020435 11 - 3703731 3863903 A1
Phf14 17 ENSMUSG00000029629 6 + 11907809 12081197 A1
Etl4 17 ENSMUSG00000036617 2 + 19909780 20810713 A3
Rtel1 17 ENSMUSG00000038685 2 + 181319739 181356616 H4
Akap9 17 ENSMUSG00000040407 5 + 3928054 4080209 A1
Dscam 17 ENSMUSG00000050272 16 - 96592079 97170752 C4
Gm20388 17 ENSMUSG00000092329 8 + 119910841 124345722 E1
Lrba 16 ENSMUSG00000028080 3 + 86224690 86782693 F1
Rap1gds1 16 ENSMUSG00000028149 3 - 138925906 139075199 H1
Car12 16 ENSMUSG00000032373 9 + 66713686 66766845 C
Adamts2 16 ENSMUSG00000036545 11 + 50602084 50807573 B1.3
Ppp1r16b 16 ENSMUSG00000037754 2 + 158665398 158766334 H1
Arhgef11 16 ENSMUSG00000041977 3 + 87617559 87738034 F1
Mgmt 16 ENSMUSG00000054612 7 + 136894611 137128187 F3
Map2k1 15 ENSMUSG00000004936 9 - 64185770 64253631 C
Ankrd36 15 ENSMUSG00000020481 11 + 5569684 5689337 A1
Pdgfc 15 ENSMUSG00000028019 3 + 81036416 81214040 E3
Gpm6a 15 ENSMUSG00000031517 8 + 54954728 55060877 B1.3
Lyplal1 15 ENSMUSG00000039246 1 - 186087731 186117310 H5
Ak7 15 ENSMUSG00000041323 12 + 105705982 105782447 E
2410076I21Rik 15 ENSMUSG00000074269 9 - 58652856 58741559 B
Glra1 14 ENSMUSG00000000263 11 - 55514238 55608198 B1.3
Prdm15 14 ENSMUSG00000014039 16 - 97791467 97851850 C4
Slc22a4 14 ENSMUSG00000020334 11 - 53983123 54028090 B1.3
Vit 14 ENSMUSG00000024076 17 + 78508063 78627409 E3
Strn 14 ENSMUSG00000024077 17 - 78649913 78737196 E3
Fam83d 14 ENSMUSG00000027654 2 + 158768093 158786637 H1
Sepsecs 14 ENSMUSG00000029173 5 - 52640087 52669729 C1
Vegfc 14 ENSMUSG00000031520 8 + 54077532 54186454 B1.3
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Gene SNP score Ensembl gene ID Chr Strand Start (bp) End (bp) Band
Zfyve9 14 ENSMUSG00000034557 4 - 108637466 108780798 C7
Iqch 14 ENSMUSG00000037801 9 - 63421455 63602493 C
Gpatch2 14 ENSMUSG00000039210 1 + 187215508 187351704 H5
Myo9a 14 ENSMUSG00000039585 9 + 59750896 59928866 B
Adam12 14 ENSMUSG00000054555 7 - 133883199 134232146 F3
Atp10b 14 ENSMUSG00000055415 11 + 43149877 43262285 A5
Ppapdc1a 14 ENSMUSG00000070366 7 + 129257094 129391307 F3
Lrig3 13 ENSMUSG00000020105 10 + 125966219 126015359 D3
Ascc2 13 ENSMUSG00000020412 11 + 4637747 4685699 A1
Nup210l 13 ENSMUSG00000027939 3 + 90104132 90212017 F1
Ddah1 13 ENSMUSG00000028194 3 + 145758675 145894277 H2
Pias1 13 ENSMUSG00000032405 9 - 62880077 62980879 B
Eri3 13 ENSMUSG00000033423 4 + 117550365 117674297 D1
Mtmr3 13 ENSMUSG00000034354 11 - 4480868 4594863 A1
Rtkn2 13 ENSMUSG00000037846 10 + 67979570 68059740 B5.1
Heatr5b 13 ENSMUSG00000039414 17 - 78752906 78835381 E3
Pnldc1 13 ENSMUSG00000073460 17 - 12888902 12910000 A1
Gm12160 13 ENSMUSG00000087089 11 + 45160943 45213656 B1.1
Gm11376 13 ENSMUSG00000087140 13 + 31299628 31396579 A3.2
Igsf5 12 ENSMUSG00000000159 16 + 96361668 96525580 C4
Stard3nl 12 ENSMUSG00000003062 13 - 19357677 19395752 A2
Sh3gl2 12 ENSMUSG00000028488 4 + 85205126 85639195 C4
Fam154a 12 ENSMUSG00000028492 4 - 86444641 86558328 C4
Mllt3 12 ENSMUSG00000028496 4 - 87769925 88033364 C4
Podn 12 ENSMUSG00000028600 4 - 108014791 108096445 C7
Stra6 12 ENSMUSG00000032327 9 + 58063788 58153996 B
Nptn 12 ENSMUSG00000032336 9 + 58582240 58657955 B
Map9 12 ENSMUSG00000033900 3 + 82358072 82395268 E3
Acot11 12 ENSMUSG00000034853 4 - 106744555 106804998 C7
Nudcd3 12 ENSMUSG00000053838 11 - 6105691 6200415 A1
Fat2 12 ENSMUSG00000055333 11 - 55250609 55336564 B1.3
Tox2 12 ENSMUSG00000074607 2 + 163203125 163324170 H2
Ccm2 11 ENSMUSG00000000378 11 + 6546887 6596744 A1
Tmprss2 11 ENSMUSG00000000385 16 - 97564684 97611195 C4
Csf2 11 ENSMUSG00000018916 11 - 54247271 54249667 B1.3
Gabrg2 11 ENSMUSG00000020436 11 - 41910195 42000857 A5
Prkd3 11 ENSMUSG00000024070 17 - 78949405 79020816 E3
Eif2ak2 11 ENSMUSG00000024079 17 - 78852564 78882573 E3
Pja2 11 ENSMUSG00000024083 17 - 64281005 64331916 E1.1
4930555F03Rik 11 ENSMUSG00000031559 8 + 49370886 49521095 B1.2
Scaper 11 ENSMUSG00000034007 9 - 55549883 55919605 B
Rxfp1 11 ENSMUSG00000034009 3 - 79641611 79737880 E3
Megf11 11 ENSMUSG00000036466 9 + 64385626 64709205 C
Ppfia1 11 ENSMUSG00000037519 7 - 144476758 144553729 F5
Rapgef6 11 ENSMUSG00000037533 11 + 54522847 54699285 B1.3
Osbpl2 11 ENSMUSG00000039050 2 + 180119306 180162680 H4
Olfr56 11 ENSMUSG00000040328 11 + 48978889 49135387 B1.2
Gal3st1 11 ENSMUSG00000049721 11 + 3983636 3999326 A1
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Dlgap4 11 ENSMUSG00000061689 2 + 156613705 156764363 H1
Gm16223 11 ENSMUSG00000067285 5 + 42067960 42216798 B3
D430019H16Rik 11 ENSMUSG00000094910 12 + 105453856 105493095 E
Galntl6 11 ENSMUSG00000096914 8 - 57776225 57962564 B2
Pkn2 10 ENSMUSG00000004591 3 - 142790902 142882004 H1
Ebf3 10 ENSMUSG00000010476 7 - 137193673 137314445 F3
Mcoln2 10 ENSMUSG00000011008 3 + 146149833 146195513 H2
Kcnq2 10 ENSMUSG00000016346 2 - 181075579 181135291 H4
Sparc 10 ENSMUSG00000018593 11 - 55394500 55420080 B1.3
Lyrm7 10 ENSMUSG00000020268 11 - 54826866 54860916 B1.3
Hormad2 10 ENSMUSG00000020419 11 - 4345814 4441105 A1
Papola 10 ENSMUSG00000021111 12 + 105784694 105838944 E
Sfrp4 10 ENSMUSG00000021319 13 + 19623175 19632821 A2
Arih1 10 ENSMUSG00000025234 9 - 59388258 59486618 B
Anxa2 10 ENSMUSG00000032231 9 + 69453620 69491795 C
Ptpn9 10 ENSMUSG00000032290 9 + 56994968 57062805 B
Thsd7a 10 ENSMUSG00000032625 6 - 12311610 12749410 A1
Szt2 10 ENSMUSG00000033253 4 - 118362743 118409273 D2.1
Mnd1 10 ENSMUSG00000033752 3 - 84087934 84155786 F1
Osbpl5 10 ENSMUSG00000037606 7 - 143688762 143756985 F5
D630003M21Rik 10 ENSMUSG00000037813 2 - 158182533 158229222 H1
Lgi2 10 ENSMUSG00000039252 5 - 52537864 52566303 C1
Ccbl2 10 ENSMUSG00000040213 3 + 142701051 142744910 H1
Fez2 10 ENSMUSG00000056121 17 - 78377885 78418131 E2
Ica1 10 ENSMUSG00000062995 6 - 8630527 8778488 A1
B3galt5 10 ENSMUSG00000074892 16 + 96235801 96319859 C4
Gm16759 10 ENSMUSG00000086539 9 + 63399381 63568691 C
Gm12153 10 ENSMUSG00000087172 11 + 43959089 44134987 B1.1
Gm17231 10 ENSMUSG00000091908 9 + 57777865 57834295 B
Zfp804b 10 ENSMUSG00000092094 5 - 6769030 6876523 A1
Th 9 ENSMUSG00000000214 7 - 142892752 142931128 F5
Rmnd5b 9 ENSMUSG00000001054 11 - 51623671 51635896 B1.3
Arid3b 9 ENSMUSG00000004661 9 - 57790353 57836793 B
Lbp 9 ENSMUSG00000016024 2 + 158306493 158332852 H1
Kremen1 9 ENSMUSG00000020393 11 - 5191552 5261558 A1
Qpct 9 ENSMUSG00000024084 17 + 79051906 79090243 E3
Inpp5a 9 ENSMUSG00000025477 7 + 139389109 139579652 F4
Fbxw7 9 ENSMUSG00000028086 3 + 84815268 84979198 F1
Slc6a9 9 ENSMUSG00000028542 4 + 117834506 117875198 D2.1
Scp2 9 ENSMUSG00000028603 4 - 108043839 108144998 C7
Glcci1 9 ENSMUSG00000029638 6 + 8509600 8597548 A1
Plxna1 9 ENSMUSG00000030084 6 - 89316316 89362613 D1
Gm498 9 ENSMUSG00000031085 7 + 143866871 143897506 F5
Aga 9 ENSMUSG00000031521 8 + 53511702 53523421 B1.3
Uaca 9 ENSMUSG00000034485 9 + 60794548 60880370 B
Zfp365 9 ENSMUSG00000037855 10 - 67886103 67912662 B5.1
Pogz 9 ENSMUSG00000038902 3 + 94837567 94882326 F2.1
Gm12169 9 ENSMUSG00000078924 11 + 46524212 46538156 B1.1
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Gm15866 9 ENSMUSG00000087290 5 - 43557285 43601730 B3
Gm12130 9 ENSMUSG00000087296 11 - 38493330 38520013 A5
Gm12680 9 ENSMUSG00000087349 4 + 85514327 85783127 C4
Pcp4 9 ENSMUSG00000090223 16 + 96467606 96525793 C4
Gm17114 9 ENSMUSG00000091237 4 - 117835299 117868558 D2.1
Xpo6 8 ENSMUSG00000000131 7 - 126101715 126200501 F3
Sod2 8 ENSMUSG00000006818 17 + 13007839 13018119 A1
Lrrc27 8 ENSMUSG00000015980 7 + 139212988 139242979 F4
Anxa6 8 ENSMUSG00000018340 11 - 54979108 55033445 B1.3
Slc36a2 8 ENSMUSG00000020264 11 - 55158470 55185077 B1.3
Cyfip2 8 ENSMUSG00000020340 11 - 46193850 46312859 B1.1
Zfp354a 8 ENSMUSG00000020364 11 + 51059257 51072799 B1.3
Ralgapb 8 ENSMUSG00000027652 2 + 158409848 158499253 H1
Ash1l 8 ENSMUSG00000028053 3 + 88965812 89079373 F1
Sh3d19 8 ENSMUSG00000028082 3 + 85971109 86130526 F1
Dnajc6 8 ENSMUSG00000028528 4 + 101496648 101642799 C6
Rnf220 8 ENSMUSG00000028677 4 - 117271463 117497052 D1
Sesn2 8 ENSMUSG00000028893 4 - 132492032 132510501 D2.3
Ctbp2 8 ENSMUSG00000030970 7 - 132987563 133124354 F3
Pstpip1 8 ENSMUSG00000032322 9 + 56089962 56128888 B
Tesk2 8 ENSMUSG00000033985 4 + 116720948 116805956 D1
Golim4 8 ENSMUSG00000034109 3 - 75876183 75956949 E3
Chst11 8 ENSMUSG00000034612 10 + 82985498 83195900 C1
Cdc42ep3 8 ENSMUSG00000036533 17 - 79334025 79355091 E3
Ccdc33 8 ENSMUSG00000037716 9 - 58028677 58118823 B
Sox5 8 ENSMUSG00000041540 6 - 143828425 144781977 G3
Rims1 8 ENSMUSG00000041670 1 - 22286251 22805994 A5
Tenm2 8 ENSMUSG00000049336 11 - 36006656 37235964 A5
Cdc42se2 8 ENSMUSG00000052298 11 - 54717456 54787675 B1.3
5830411N06Rik 8 ENSMUSG00000054672 7 + 140247301 140299791 F4
Alk 8 ENSMUSG00000055471 17 - 71869442 72603709 E1.3
Lepr 8 ENSMUSG00000057722 4 + 101717404 101815352 C6
Acat3 8 ENSMUSG00000062480 17 - 12923833 12940402 A1
Arhgap40 8 ENSMUSG00000074625 2 + 158512796 158550762 H1
Gm12147 8 ENSMUSG00000086791 11 - 43259791 43311088 A5
4930401O12Rik 8 ENSMUSG00000087460 13 - 31213410 31222096 A3.2
Gm16039 8 ENSMUSG00000089862 6 + 8259288 8597480 A1
Olfr1328 8 ENSMUSG00000096368 4 - 118933897 118934840 D2.1
1110019D14Rik 8 ENSMUSG00000097616 6 + 13871526 14044373 A1
Celf2 7 ENSMUSG00000002107 2 - 6539694 7509563 A1
Tpra1 7 ENSMUSG00000002871 6 + 88902251 88912238 D1
Pabpc4 7 ENSMUSG00000011257 4 + 123262351 123298925 D2.2
P4ha2 7 ENSMUSG00000018906 11 + 54100095 54131665 B1.3
Vdac1 7 ENSMUSG00000020402 11 + 52360860 52389397 B1.3
Eif4enif1 7 ENSMUSG00000020454 11 + 3202392 3244588 A1
Lrrc71 7 ENSMUSG00000023084 3 - 87736923 87748625 F1
Tubgcp2 7 ENSMUSG00000025474 7 - 139995955 140036350 F4
Serpini1 7 ENSMUSG00000027834 3 + 75557547 75643495 E3
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Glrb 7 ENSMUSG00000028020 3 - 80843599 80913660 E3
Dclk2 7 ENSMUSG00000028078 3 - 86786150 86920884 F1
Snx27 7 ENSMUSG00000028136 3 - 94497544 94582716 F2.1
Gtf2b 7 ENSMUSG00000028271 3 + 142765226 142783603 H1
Ndc1 7 ENSMUSG00000028614 4 + 107367784 107416346 C7
Ermap 7 ENSMUSG00000028644 4 - 119175457 119190011 D2.1
Ppt1 7 ENSMUSG00000028657 4 + 122836242 122859175 D2.2
Pik3r3 7 ENSMUSG00000028698 4 + 116221618 116303056 D1
Pi4k2b 7 ENSMUSG00000029186 5 + 52741587 52769344 C1
Zranb1 7 ENSMUSG00000030967 7 + 132931142 132986391 F3
Hcn4 7 ENSMUSG00000032338 9 + 58823512 58860955 B
Mgll 7 ENSMUSG00000033174 6 + 88724412 88828360 D1
Tie1 7 ENSMUSG00000033191 4 - 118471191 118490061 D2.1
Fgb 7 ENSMUSG00000033831 3 - 83042247 83049803 E3
Zbbx 7 ENSMUSG00000034151 3 - 75037907 75165034 E3
Glis1 7 ENSMUSG00000034762 4 + 107434591 107635061 C7
Ttc22 7 ENSMUSG00000034919 4 + 106622432 106640189 C7
Smad6 7 ENSMUSG00000036867 9 - 63953076 64022059 C
Btnl9 7 ENSMUSG00000040283 11 - 49165585 49187159 B1.2
Gsg1l 7 ENSMUSG00000046182 7 - 125878419 126082411 F3
Lrp1b 7 ENSMUSG00000049252 2 - 40595248 42653598 B
Aff4 7 ENSMUSG00000049470 11 + 53350833 53421830 B1.3
8030423F21Rik 7 ENSMUSG00000052295 5 - 52607550 52619011 C1
Fut9 7 ENSMUSG00000055373 4 - 25609332 25800244 A3
Dhcr7 7 ENSMUSG00000058454 7 + 143823145 143848410 F5
Slc22a21 7 ENSMUSG00000063652 11 - 53949965 53980332 B1.3
Cntnap5a 7 ENSMUSG00000070695 1 + 115684756 116582026 E2.3
Gm12649 7 ENSMUSG00000084833 4 - 93453258 93671070 C5
Gm12223 7 ENSMUSG00000085585 11 + 54247600 54254495 B1.3
4930564K09Rik 7 ENSMUSG00000086273 3 + 82876705 82943638 E3
3110021N24Rik 7 ENSMUSG00000094958 4 + 108719649 108781904 C7
Gm26551 7 ENSMUSG00000097219 11 - 51949882 52269514 B1.3
Wwox 6 ENSMUSG00000004637 8 + 114439655 115352708 E1
Ripk4 6 ENSMUSG00000005251 16 - 97741933 97763737 C4
Gabrb2 6 ENSMUSG00000007653 11 + 42419757 42629028 A5
Vps72 6 ENSMUSG00000008958 3 + 95111022 95123051 F2.1
Camta1 6 ENSMUSG00000014592 4 - 150917322 151861876 E2
Fcrls 6 ENSMUSG00000015852 3 - 87250758 87263738 F1
G3bp1 6 ENSMUSG00000018583 11 + 55469685 55504838 B1.3
Canx 6 ENSMUSG00000020368 11 - 50293961 50325673 B1.3
Drg1 6 ENSMUSG00000020457 11 - 3187360 3266415 A1
Bdkrb2 6 ENSMUSG00000021070 12 + 105563172 105593071 E
Plce1 6 ENSMUSG00000024998 19 + 38481109 38785030 C3
Paox 6 ENSMUSG00000025464 7 + 140125657 140134334 F4
Stmn3 6 ENSMUSG00000027581 2 - 181306459 181314500 H4
Lce1m 6 ENSMUSG00000027912 3 - 93017807 93019060 F1
Asic5 6 ENSMUSG00000028008 3 + 81982290 82021233 E3
Arhgef2 6 ENSMUSG00000028059 3 + 88607454 88648052 F1
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Caap1 6 ENSMUSG00000028578 4 - 94500081 94556796 C5
Cap1 6 ENSMUSG00000028656 4 - 122859047 122886056 D2.2
Dmbx1 6 ENSMUSG00000028707 4 - 115914544 115939926 D1
Chchd6 6 ENSMUSG00000030086 6 - 89383146 89595652 D1
Tenm3 6 ENSMUSG00000031561 8 - 48227682 48674690 B1.2
Hpgd 6 ENSMUSG00000031613 8 + 56294552 56321046 B2
Thoc5 6 ENSMUSG00000034274 11 + 4895320 4928867 A1
Uroc1 6 ENSMUSG00000034456 6 + 90333289 90364551 D1
Zcchc11 6 ENSMUSG00000034610 4 + 108459426 108559421 C7
Rims4 6 ENSMUSG00000035226 2 - 163859751 163918683 H3
Pml 6 ENSMUSG00000036986 9 - 58218076 58249786 B
Aff3 6 ENSMUSG00000037138 1 - 38177326 38664955 B
Acer2 6 ENSMUSG00000038007 4 + 86874396 86934822 C4
Sult6b1 6 ENSMUSG00000038045 17 - 78883938 78906992 E3
Neil3 6 ENSMUSG00000039396 8 - 53586867 53639065 B1.3
Cc2d2a 6 ENSMUSG00000039765 5 + 43662379 43740972 B3
Bace2 6 ENSMUSG00000040605 16 + 97356728 97439012 C4
Nme8 6 ENSMUSG00000041138 13 - 19645078 19697794 A2
Kirrel 6 ENSMUSG00000041734 3 - 87078593 87174747 F1
Mat2b 6 ENSMUSG00000042032 11 - 40679314 40695203 A5
Inpp5f 6 ENSMUSG00000042105 7 + 128611328 128696425 F3
Zfp536 6 ENSMUSG00000043456 7 - 37472135 37773641 B3
Tnfrsf26 6 ENSMUSG00000045362 7 - 143607685 143627845 F5
Spesp1 6 ENSMUSG00000046846 9 - 62270729 62282179 B
Urgcp 6 ENSMUSG00000049680 11 - 5713417 5762376 A1
Lrrc4c 6 ENSMUSG00000050587 2 + 96318169 97631666 E1
Gpatch11 6 ENSMUSG00000050668 17 + 78835516 78848299 E3
Camk2b 6 ENSMUSG00000057897 11 - 5969644 6066362 A1
R74862 6 ENSMUSG00000059277 7 - 143021784 143053686 F5
Olfr530 6 ENSMUSG00000060974 7 - 140372587 140373666 F4
Rapgef2 6 ENSMUSG00000062232 3 - 79062516 79181340 E3
Nlgn1 6 ENSMUSG00000063887 3 - 25431811 26133734 A3
Kndc1 6 ENSMUSG00000066129 7 + 139894696 139941537 F4
Gramd2 6 ENSMUSG00000074259 9 + 59680144 59718874 B
C230081A13Rik 6 ENSMUSG00000074305 9 - 56201131 56418050 B
Gm12856 6 ENSMUSG00000084133 4 - 118942060 118943352 D2.1
Gm14372 6 ENSMUSG00000085745 7 - 144368048 144406933 F5
Gm14342 6 ENSMUSG00000086166 2 - 180829490 180889660 H4
Gm26547 6 ENSMUSG00000097095 17 + 55557166 55563507 C
2510016G02Rik 6 ENSMUSG00000097595 7 - 132889489 132931375 F3
Tcf7 5 ENSMUSG00000000782 11 - 52252371 52283014 B1.3
Rrp15 5 ENSMUSG00000001305 1 - 186720978 186749358 H5
Mcm2 5 ENSMUSG00000002870 6 - 88883475 88898780 D1
Gpx5 5 ENSMUSG00000004344 13 - 21286429 21292731 A3.1
Mpl 5 ENSMUSG00000006389 4 - 118442415 118457513 D2.1
Zmat5 5 ENSMUSG00000009076 11 + 4704678 4737669 A1
Trpm5 5 ENSMUSG00000009246 7 - 143069153 143094642 F5
Cars 5 ENSMUSG00000010755 7 - 143557230 143600090 F5
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Kif3a 5 ENSMUSG00000018395 11 + 53567379 53601967 B1.3
Hcfc2 5 ENSMUSG00000020246 10 + 82696160 82742428 C1
Mgat1 5 ENSMUSG00000020346 11 + 49244191 49263030 B1.2
3010026O09Rik 5 ENSMUSG00000020381 11 + 50174444 50200115 B1.3
Itk 5 ENSMUSG00000020395 11 - 46325150 46389515 B1.1
Myo1g 5 ENSMUSG00000020437 11 - 6506548 6520965 A1
Polm 5 ENSMUSG00000020474 11 - 5827860 5838016 A1
Amph 5 ENSMUSG00000021314 13 + 18948371 19150913 A2
Zkscan3 5 ENSMUSG00000021327 13 - 21387013 21402755 A3.1
Exoc2 5 ENSMUSG00000021357 13 - 30813919 30974047 A3.2
Dapk1 5 ENSMUSG00000021559 13 + 60601947 60763185 B2
Marc1 5 ENSMUSG00000026621 1 - 184786776 184811313 H5
Fam198b 5 ENSMUSG00000027955 3 + 79884533 79946280 E3
Tmem144 5 ENSMUSG00000027956 3 - 79813148 79842662 E3
Npy2r 5 ENSMUSG00000028004 3 - 82538383 82548084 E3
Gucy1b3 5 ENSMUSG00000028005 3 - 82032004 82074711 E3
Sh2d2a 5 ENSMUSG00000028071 3 + 87846755 87855722 F1
Pdlim5 5 ENSMUSG00000028273 3 - 142239586 142395696 H1
Ptplad2 5 ENSMUSG00000028497 4 - 88396144 88438928 C4
B4galt2 5 ENSMUSG00000028541 4 - 117869260 117883487 D2.1
Col9a2 5 ENSMUSG00000028626 4 + 121039385 121055322 D2.2
Wdr65 5 ENSMUSG00000028730 4 - 118554551 118620777 D2.1
Rcc1 5 ENSMUSG00000028896 4 - 132331919 132353605 D2.3
Auts2 5 ENSMUSG00000029673 5 - 131437333 132543344 G2
Asb5 5 ENSMUSG00000031519 8 + 54550331 54587836 B1.3
Kirrel3 5 ENSMUSG00000032036 9 + 34486126 35036716 A4
Anp32a 5 ENSMUSG00000032249 9 + 62341293 62378812 B
1700017B05Rik 5 ENSMUSG00000032300 9 - 57252322 57262599 B
Dis3l 5 ENSMUSG00000032396 9 - 64306756 64341288 C
Smad3 5 ENSMUSG00000032402 9 - 63646767 63757994 C
Cspg4 5 ENSMUSG00000032911 9 + 56865104 56899870 B
Kbtbd12 5 ENSMUSG00000033182 6 - 88547340 88637950 D1
Gpbp1l1 5 ENSMUSG00000034042 4 + 116557658 116593882 D1
Tmem132d 5 ENSMUSG00000034310 5 - 127783491 128433077 G1.3
Morc2a 5 ENSMUSG00000034543 11 + 3649494 3690477 A1
Arhgap10 5 ENSMUSG00000037148 8 - 77250366 77517907 C1
Nmur2 5 ENSMUSG00000037393 11 - 56024987 56041010 B1.3
Dennd4c 5 ENSMUSG00000038024 4 + 86748555 86850603 C4
Slco4a1 5 ENSMUSG00000038963 2 + 180456245 180474867 H4
Cdk13 5 ENSMUSG00000041297 13 - 17715962 17805097 A2
Slc39a11 5 ENSMUSG00000041654 11 - 113244853 113650079 E2
Zfp62 5 ENSMUSG00000046311 11 + 49203292 49218816 B1.2
C1qtnf2 5 ENSMUSG00000046491 11 + 43474276 43491525 B1.1
Dlgap2 5 ENSMUSG00000047495 8 + 14095865 14847680 A1.1
Mroh7 5 ENSMUSG00000047502 4 - 106680417 106730925 C7
Olfr1396 5 ENSMUSG00000047511 11 - 49112777 49114874 B1.2
Dmbt1 5 ENSMUSG00000047517 7 + 131032076 131121626 F3
Lrrc49 5 ENSMUSG00000047766 9 - 60568859 60688158 B
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Fcrl5 5 ENSMUSG00000048031 3 + 87435885 87457836 F1
Tenm4 5 ENSMUSG00000048078 7 + 96171244 96911093 E1
Olfr1394 5 ENSMUSG00000048378 11 + 49160016 49160954 B1.2
Trpm3 5 ENSMUSG00000052387 19 + 22139119 22989884 B
Bpi 5 ENSMUSG00000052922 2 + 158258094 158284531 H1
Dnajc8 5 ENSMUSG00000054405 4 + 132535550 132553742 D2.3
Sec14l3 5 ENSMUSG00000054986 11 + 4064841 4077736 A1
Ubl7 5 ENSMUSG00000055720 9 + 57910986 57929968 B
Slit3 5 ENSMUSG00000056427 11 + 35121224 35708507 A4
Ptprn2 5 ENSMUSG00000056553 12 + 116485720 117278167 F2
Wtap 5 ENSMUSG00000060475 17 - 12966796 12992546 A1
Dcc 5 ENSMUSG00000060534 18 - 71258738 72351069 E2
Csmd1 5 ENSMUSG00000060924 8 - 15892537 17535586 A1.3
Agbl4 5 ENSMUSG00000061298 4 + 110397661 111664324 C7
Dpp6 5 ENSMUSG00000061576 5 + 26817203 27727505 B1
Tmem117 5 ENSMUSG00000063296 15 + 94629185 95096097 E3
Phactr4 5 ENSMUSG00000066043 4 - 132355923 132422489 D2.3
Mas1 5 ENSMUSG00000068037 17 - 12841079 12868143 A1
Trcg1 5 ENSMUSG00000070298 9 + 57236556 57249863 B
Ccdc24 5 ENSMUSG00000078588 4 - 117866524 117872557 D2.1
AY761185 5 ENSMUSG00000079120 8 - 20943693 20944748 A2
Gm14278 5 ENSMUSG00000080880 2 - 156888854 156915383 H1
Gm11980 5 ENSMUSG00000083075 11 + 6685824 6686809 A1
Gm12131 5 ENSMUSG00000083806 11 - 39727070 39727712 A5
4933416E03Rik 5 ENSMUSG00000085198 2 + 159947341 159981288 H2
Gm11958 5 ENSMUSG00000085512 11 + 4285460 4286939 A1
Gm12648 5 ENSMUSG00000085931 4 - 94089576 94425588 C5
Gm16144 5 ENSMUSG00000086399 9 - 69477029 69479598 C
Gm14204 5 ENSMUSG00000086496 2 - 158595472 158610723 H1
5133400J02Rik 5 ENSMUSG00000086646 11 - 51189833 51220418 B1.3
0610043K17Rik 5 ENSMUSG00000087361 4 + 101353783 101399181 C6
Gm17359 5 ENSMUSG00000091685 3 + 79345376 79464129 E3
Gm26561 5 ENSMUSG00000097625 17 + 70878078 71393284 E1.3
9530052C20Rik 5 ENSMUSG00000097858 3 + 142882495 142894644 H1
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Chr Gene Ensembl gene ID Strand Start (bp) End (bp) Band SNP P-value Position (bp)
1 SSBP3 ENSG00000157216 - 54691105 54879152 p32.3 rs3753405 0.0004368 54745708
HSP90B3P ENSG00000203914 + 92100568 92109639 p22.1 rs1887055 0.0002949 92113813
RP11-433J22.3 ENSG00000234190 + 147249700 147261065 q21.2 rs1908628 0.0001312 147260568
HMCN1 ENSG00000143341 + 185703683 186160085 q25.3 rs10911784 0.00005891 185915391
rs7550425 0.0003429 186045280
CSRP1 ENSG00000159176 - 201452658 201478584 q32.1 rs645390 0.0004114 201454923
GPR37L1 ENSG00000170075 + 202091986 202102720 q32.1 rs11588918 0.0001055 202095560
rs12737525 0.00006792 202095852
RP11-400N13.1 ENSG00000236230 - 222262511 222560776 q41 rs4511115 0.0002854 222513180
DNAH14 ENSG00000185842 + 225083964 225586996 q42.12 rs13376645 0.0004052 225551281
EDARADD ENSG00000186197 + 236511562 236648214 q42.3 rs16833652 0.0004461 236577350
SMYD3 ENSG00000185420 - 245912642 246670614 q44 rs10924674 0.00006615 246452817
rs12037567 0.00002431 246458746
rs10802383 0.00008869 246459480
2 SH3YL1 ENSG00000035115 - 217730 266398 p25.3 rs6742278 0.00002812 226999
AC012445.1 ENSG00000229550 - 4184234 4188321 p25.3 rs10178086 0.00001205 4187138
LPIN1 ENSG00000134324 + 11817721 11967535 p25.1 rs7569901 0.0004234 11897225
rs6726960 0.0003213 11898931
rs6744695 0.000358 11899088
ADCY3 ENSG00000138031 - 25042038 25142708 p23.3 rs17799872 0.0002614 25044957
CENPO ENSG00000138092 + 25016005 25045245 p23.3 rs17799872 0.0002614 25044957
RP11-443B20.1 ENSG00000271936 + 25048479 25049586 p23.3 rs17799872 0.0002614 25044957
CTNNA2 ENSG00000066032 + 79412357 80875905 p12 rs17017514 0.0004403 79903804
KIAA1211L ENSG00000196872 - 99410309 99552722 q11.2 rs13005148 0.0003975 99467538
rs6757098 0.0001547 99471399
rs11123756 0.0001437 99508012
rs12464134 0.00004374 99540101
CACNB4 ENSG00000182389 - 152689290 152955593 q23.3 rs13416880 0.0001254 152868683
rs13421383 0.00009218 152879348
rs7591461 0.0003871 152882123
rs6722774 0.00005946 152916802
rs12693235 0.0000739 152924481
rs1806702 0.0004061 152930124
UPP2 ENSG00000007001 + 158733214 158992666 q24.1 rs6731028 0.0004357 158890762
AC104820.2 ENSG00000234663 + 181966659 182264286 q31.3 rs877226 0.0003604 182117625
PTH2R ENSG00000144407 + 209224438 209719227 q34 rs1598140 0.0003792 209471702
SPAG16 ENSG00000144451 + 214149113 215275225 q34 rs1876837 0.0003171 215077766
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2 AC064853.2 ENSG00000236116 - 228481714 228482506 q36.3 rs16823719 0.00004776 228481316
C2orf83 ENSG00000042304 - 228474806 228498036 q36.3 rs16823719 0.00004776 228481316
AC009410.1 ENSG00000232023 - 229347977 229476111 q36.3 rs16825085 0.0001298 229390795
3 CCDC174 ENSG00000154781 + 14693271 14714166 p25.1 rs2276754 0.00001082 14702982
AC133680.1 ENSG00000237838 + 24729410 25215796 p24.2 rs17576864 0.0002854 25192389
rs17517875 0.0002831 25208270
rs17577191 0.0002344 25208341
rs12152294 0.0002837 25215670
RARB ENSG00000077092 + 25215823 25639423 p24.2 rs12152294 0.0002837 25215670
rs17518622 0.0002824 25227079
SLC4A7 ENSG00000033867 - 27414214 27525911 p24.1 rs3755652 0.0003041 27472936
CMTM8 ENSG00000170293 + 32280171 32411817 p22.3 rs3853711 0.0003912 32395577
CCDC13 ENSG00000244607 - 42734155 42814745 p22.1 rs9836162 0.0002569 42747548
HHATL ENSG00000010282 - 42734155 42744319 p22.1 rs9836162 0.0002569 42747548
HHATL-AS1 ENSG00000230970 + 42744145 42748154 p22.1 rs9836162 0.0002569 42747548
ENSG00000244607 - 42734155 42814745 p22.1 rs2240861 0.0003139 42750324
ENSG00000230970 + 42744145 42748154 p22.1 rs2240861 0.0003139 42750324
ENSG00000244607 - 42734155 42814745 p22.1 rs17238798 0.0003606 42799765
HIGD1A ENSG00000181061 - 42798669 42846023 p22.1 rs17238798 0.0003606 42799765
ENSG00000244607 - 42734155 42814745 p22.1 rs11915803 0.0003606 42800291
ENSG00000181061 - 42798669 42846023 p22.1 rs11915803 0.0003606 42800291
LINC00971 ENSG00000242641 - 84687557 84930830 p12.1 rs2326227 0.0003381 84755963
CLDND1 ENSG00000080822 - 98216756 98241910 q11.2 rs9819403 0.0003452 98245718
CPOX ENSG00000080819 - 98239976 98312567 q12.1 rs9819403 0.0003452 98245718
RP11-227H4.5 ENSG00000248839 + 98241414 98244178 q11.2 rs9819403 0.0003452 98245718
RPL38P4 ENSG00000250562 - 98243905 98244118 q11.2 rs9819403 0.0003452 98245718
TMCC1 ENSG00000172765 - 129366635 129612419 q22.1 rs4306849 0.0004246 129384180
RP11-23D24.2 ENSG00000238755 - 153102723 153697975 q25.2 rs17745929 0.000283 153506050
KCNAB1 ENSG00000169282 + 155755490 156256545 q25.31 rs1474024 0.0000279 155775874
RP11-85M11.2 ENSG00000244128 + 164924748 165373211 q26.1 rs9839370 0.00007675 165200881
rs3106448 0.0003237 165343107
B3GNT5 ENSG00000176597 + 182971032 183016292 q27.1 rs6803209 0.0000113 182968709
MCF2L2 ENSG00000053524 - 182895831 183146566 q27.1 rs6803209 0.0000113 182968709
RP11-430L16.1 ENSG00000234238 + 187824884 187864808 q27.3 rs9852144 0.0004035 187842721
RP11-513G11.4 ENSG00000225742 - 193920805 193967942 q29 rs6800138 0.0003418 193937606
4 STK32B ENSG00000152953 + 5053169 5502725 p16.2 rs1838973 0.0004397 5157262
MUC7 ENSG00000171195 + 71296209 71348714 q13.3 rs11249502 0.0001027 71341161
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4 AC107072.2 ENSG00000231335 + 77558776 77565521 q21.1 rs1986966 0.0003857 77558777
SHROOM3 ENSG00000138771 + 77356253 77704406 q21.1 rs1986966 0.0003857 77558777
rs17002148 0.0001498 77580240
rs6817407 0.0003579 77616338
CCNG2 ENSG00000138764 + 78078304 78354542 q21.1 rs12649862 0.000331 78343820
RP11-625I7.1 ENSG00000249036 - 78315645 78415440 q21.1 rs12649862 0.000331 78343820
ENSG00000138764 + 78078304 78354542 q21.1 rs41476645 0.0001599 78344385
ENSG00000249036 - 78315645 78415440 q21.1 rs41476645 0.0001599 78344385
ENSG00000138764 + 78078304 78354542 q21.1 rs12644936 0.0001599 78345120
ENSG00000249036 - 78315645 78415440 q21.1 rs12644936 0.0001599 78345120
rs12501028 0.0001656 78391533
rs7689830 0.00003848 78416791
RASGEF1B ENSG00000138670 - 82347547 82965397 q21.22 rs17005163 0.00006777 82483468
PLAC8 ENSG00000145287 - 84011201 84058228 q21.22 rs17006484 0.00006746 84035969
CCSER1 ENSG00000184305 + 91048686 92523064 q22.1 rs1849809 0.0002955 91596240
RP11-255I10.2 ENSG00000248656 + 112561651 112569964 q25 rs17043540 0.000003519 112558571
ZNF827 ENSG00000151612 - 146678779 146859787 q31.22 rs6814298 0.0000153 146780732
AC108142.1 ENSG00000177822 - 182795591 183066402 q34.3 rs10009617 0.0004117 182874271
MIR1305 ENSG00000221227 + 183090446 183090531 q34.3 rs12504374 0.000003003 183086701
RP11-402C9.1 ENSG00000248266 + 183066005 183111535 q34.3 rs12504374 0.000003003 183086701
TENM3 ENSG00000218336 + 183065140 183724177 q34.3 rs12504374 0.000003003 183086701
5 FSTL4 ENSG00000053108 - 132532147 132948255 q31.1 rs11242158 0.0004328 132835992
ARHGAP26 ENSG00000145819 + 142149949 142608576 q31.3 rs10875602 0.0001677 142599713
CTD-2270F17.1 ENSG00000253647 + 169816497 169849848 q35.1 rs314120 0.00006844 169823196
KCNIP1 ENSG00000182132 + 169780491 170163636 q35.1 rs314120 0.00006844 169823196
RNA5SP200 ENSG00000252169 - 172719520 172719622 q35.1 rs7714152 0.00005878 172715409
rs10061599 0.00004471 172723332
rs17675787 0.00002048 172724246
6 GMDS ENSG00000112699 - 1624041 2245926 p25.3 rs3800125 0.00001667 1906861
B3GALT4 ENSG00000226936 + 33166523 33168208 p21.32 rs458679 0.0001654 33164098
RPS18 ENSG00000235650 + 33161393 33165893 p21.32 rs458679 0.0001654 33164098
VPS52 ENSG00000225590 - 33139671 33161430 p21.32 rs458679 0.0001654 33164098
WDR46 ENSG00000204221 - 33168491 33178914 p21.32 rs458679 0.0001654 33164098
ENSG00000206285 + 33173759 33175444 p21.32 33171335
ENSG00000096150 + 33168626 33173129 p21.32 33171335
ENSG00000206286 - 33146871 33168663 p21.32 rs458679 0.0001654 33171335
ENSG00000206284 - 33175727 33186150 p21.32 33171335
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6 ENSG00000235155 + 33222842 33224527 p21.32 33220417
ENSG00000223367 + 33217712 33222212 p21.32 33220417
ENSG00000228425 - 33195972 33217749 p21.32 rs458679 0.0001654 33220417
ENSG00000226916 - 33224810 33235233 p21.32 33220417
ENSG00000235863 + 33244917 33252609 p21.32 33242492
ENSG00000231500 + 33239787 33244287 p21.32 33242492
ENSG00000223501 - 33218049 33239824 p21.32 rs458679 0.0001654 33242492
ENSG00000227057 - 33246885 33257304 p21.32 33242492
ENSG00000227794 + 33379131 33382651 p21.32 33381840
ENSG00000236014 - 33357416 33379168 p21.32 rs458679 0.0001654 33381840
ENSG00000236802 + 33415294 33416979 p21.32 33412869
ENSG00000226225 + 33410160 33414664 p21.32 33412869
ENSG00000224455 - 33388442 33410197 p21.32 rs458679 0.0001654 33412869
ENSG00000236222 - 33417262 33427651 p21.32 33412869
KLHL31 ENSG00000124743 - 53512699 53530506 p12.1 rs6942249 0.0003955 53515483
rs2478352 0.0003203 53533265
RP11-304C16.3 ENSG00000217331 - 97120005 97120845 q16.1 rs17797978 0.0003369 97115085
ADGB ENSG00000118492 + 146920101 147136598 q24.3 rs1572902 0.0004276 146979589
rs1340996 0.0004072 146988978
RP1-125N5.2 ENSG00000235815 + 169116745 169123604 q27 rs196469 0.0000181 169123297
rs196479 0.00004366 169127361
7 ITGB8 ENSG00000105855 + 20370325 20455377 p21.1 rs6461490 0.000337 20381806
rs7793190 0.00006727 20407356
RAPGEF5 ENSG00000136237 - 22157856 22396763 p15.3 rs17507 0.0003288 22175235
rs3901281 0.0001779 22175472
rs3807531 0.0003865 22187744
STEAP1B ENSG00000105889 - 22459063 22672544 p15.3 rs740295 0.0002376 22473288
rs10250954 0.0002395 22474949
rs4318962 0.00009263 22475742
GLI3 ENSG00000106571 - 42000548 42277469 p14.1 rs846394 0.0001328 42162825
rs846393 0.0001339 42163860
rs846385 0.0001009 42168935
CCM2 ENSG00000136280 + 45039074 45116068 p13 rs10951785 0.0002309 45047791
CCDC146 ENSG00000135205 + 76751751 76958850 q11.23 rs3108440 0.0003706 76896701
rs3108442 0.0003706 76901907
rs7780929 0.0001147 76914712
rs7786334 0.0001152 76915253
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Chr Gene Ensembl gene ID Strand Start (bp) End (bp) Band SNP P-value Position (bp)
7 rs17151066 0.0001152 76917303
rs17151097 0.0001152 76918307
rs17151110 0.00006989 76918782
DBF4 ENSG00000006634 + 87505531 87538856 q21.12 rs11982729 0.0003455 87516527
8 CSMD1 ENSG00000183117 - 2792875 4852494 p23.2 rs17414486 0.0004013 4283673
RP11-1080G15.1 ENSG00000253557 - 18942502 19116979 p21.3 rs2672282 0.0002106 19055204
RP11-624C23.1 ENSG00000253535 - 24153327 24769586 p21.2 rs17052236 0.0002338 24462582
AC012215.1 ENSG00000233863 + 35649365 35653384 p12 rs16884444 0.0001357 35648980
UNC5D ENSG00000156687 + 35092975 35654068 p12 rs16884444 0.0001357 35648980
ASPH ENSG00000198363 - 62413116 62627155 q12.3 rs16927431 0.00009409 62424008
RP11-6I2.3 ENSG00000254288 + 74964575 75012088 q21.11 rs6988353 0.0003492 74997242
KB-1184D12.1 ENSG00000253585 - 95109992 95116550 q22.1 rs2446833 0.000418 95111326
FSBP ENSG00000265817 - 95390605 95449180 q22.1 rs2470737 0.0002017 95407427
RAD54B ENSG00000197275 - 95384188 95487337 q22.1 rs2470737 0.0002017 95407427
AF216667.1 ENSG00000222570 - 133693146 133693248 q24.22 rs7827081 0.0002315 133696552
TMEM71 ENSG00000165071 - 133697253 133772958 q24.22 rs7827081 0.0002315 133696552
rs10956677 0.000438 133708897
9 HAUS6 ENSG00000147874 - 19053141 19103117 p22.1 rs7869414 0.0003545 19082832
NOL8 ENSG00000198000 - 95059640 95087918 q22.31 rs16908281 0.0002286 95072094
CDC26 ENSG00000176386 - 116018115 116037869 q32 rs17831256 0.0001976 116042867
PRPF4 ENSG00000136875 + 116037623 116055185 q32 rs17831256 0.0001976 116042867
rs12352784 0.0001976 116045074
GSN ENSG00000148180 + 123970072 124095121 q33.2 rs4837817 0.0004299 123995163
10 CACNB2 ENSG00000165995 + 18429606 18830798 p12.33 rs2482100 0.00009705 18481080
rs1277768 0.0003153 18499676
VSTM4 ENSG00000165633 - 50222290 50323554 q11.23 rs4488117 0.0002074 50309905
TSPAN15 ENSG00000099282 + 71211229 71267425 q22.1 rs7078095 0.00001963 71263424
SEC23IP ENSG00000107651 + 121652223 121702014 q26.11 rs2279939 0.0001692 121693020
RPS27P18 ENSG00000233135 - 127162255 127162501 q26.13 rs3813859 0.000005007 127166793
11 SCUBE2 ENSG00000175356 - 9041071 9159661 p15.4 rs2647537 0.0001835 9125301
rs7931872 0.0001388 9142062
rs10840175 0.0002378 9143548
DENND5A ENSG00000184014 - 9160372 9286937 p15.4 rs10840176 0.0001697 9155570
ENSG00000175356 - 9041071 9159661 p15.4 rs10840176 0.0001697 9155570
ENSG00000184014 - 9160372 9286937 p15.4 rs2133217 0.0003779 9177012
rs7394878 0.0003604 9198276
NELL1 ENSG00000165973 + 20691117 21597227 p15.1 rs12791900 0.0002738 21022007
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Chr Gene Ensembl gene ID Strand Start (bp) End (bp) Band SNP P-value Position (bp)
11 RNA5SP336 ENSG00000201059 - 21022427 21022543 p15.1 rs12791900 0.0002738 21022007
ENSG00000165973 + 20691117 21597227 p15.1 rs7122556 0.0004212 21045022
SLC1A2 ENSG00000110436 - 35272753 35441610 p13 rs3847613 0.000157 35338345
rs11033071 0.00032 35347685
rs7114383 0.0003204 35356793
rs11033080 0.0003811 35362357
rs7934047 0.0004051 35367925
rs4756221 0.0001532 35378069
INCENP ENSG00000149503 + 61891445 61920635 q12.3 rs1675126 0.000403 61906374
RP11-691L4.2 ENSG00000236607 + 61936765 61937300 q12.3 rs1792908 0.0001881 61941265
rs11230950 0.000106 61941816
ACY3 ENSG00000132744 - 67410026 67418130 q13.2 rs12288023 0.0003361 67421341
AP003385.2 ENSG00000227834 - 67419047 67420875 q13.2 rs12288023 0.0003361 67421341
MAML2 ENSG00000184384 - 95709762 96076344 q21 rs12286219 0.0001786 95770904
CNTN5 ENSG00000149972 + 98891683 100229616 q22.1 rs614096 0.0003917 99577390
rs2010803 0.00009028 99600358
RP11-94P11.4 ENSG00000254998 - 105028654 105402424 q22.3 rs7947277 0.0002016 105301479
USP2-AS1 ENSG00000245248 + 119252488 119397374 q23.3 rs7949052 0.0001409 119400127
12 PTPRB ENSG00000127329 - 70910630 71031220 q15 rs17108396 0.00008915 71009354
LGR5 ENSG00000139292 + 71833550 71980090 q21.1 rs4486718 0.00006204 71899966
13 HNF4GP1 ENSG00000228611 - 56573334 56574582 q21.1 rs9316831 0.0002368 56574936
MYO16 ENSG00000041515 + 109248500 109860355 q33.3 rs651270 0.0002752 109629324
14 OR4U1P ENSG00000258899 + 20512075 20512986 q11.2 rs1952805 0.0001053 20516355
RP11-116N8.1 ENSG00000258342 + 36367188 36532949 q13.2 rs7401172 0.0003348 36451285
SEC23A ENSG00000100934 - 39501123 39578850 q21.1 rs4902308 0.0003054 39499158
FRMD6 ENSG00000139926 + 51955818 52197445 q22.1 rs4898705 0.0003329 52109999
rs8019441 0.0002757 52110329
BMP4 ENSG00000125378 - 54416454 54425479 q22.2 rs12434228 0.0001107 54427602
15 FAM189A1 ENSG00000104059 - 29412457 29862927 q13.1 rs511092 0.0004207 29733674
AGBL1 ENSG00000166748 + 86685227 87572283 q25.3 rs11073666 0.00008602 87299209
RP11-266O8.1 ENSG00000257060 + 93855786 94112712 q26.1 rs8037879 0.0001737 93900397
rs735912 0.00008711 93900938
CERS3 ENSG00000154227 - 100940600 101085200 q26.3 rs4965668 0.0003708 101077349
16 CASC16 ENSG00000249231 - 52586002 52686017 q12.2 rs4784227 0.0003197 52599188
CDH11 ENSG00000140937 - 64977656 65160015 q21 rs7203623 0.0002642 65138590
RP11-95H3.1 ENSG00000259847 - 65175659 65210616 q21 rs7206260 0.0003446 65211408
C16orf95 ENSG00000260456 - 87117168 87351022 q24.2 rs7498934 0.0003701 87313604
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Chr Gene Ensembl gene ID Strand Start (bp) End (bp) Band SNP P-value Position (bp)
16 RP11-178L8.5 ENSG00000261697 - 87296365 87326044 q24.2 rs7498934 0.0003701 87313604
17 WDR16 ENSG00000166596 + 9479944 9546776 p13.1 rs6503235 0.000431 9515777
AC005772.2 ENSG00000232058 + 14918122 14955593 p12 rs2323554 0.00002671 14927112
IGF2BP1 ENSG00000159217 + 47074774 47133012 q21.32 rs1495274 0.000006974 47077648
RP11-501C14.5 ENSG00000250838 - 47072628 47074854 q21.32 rs1495274 0.000006974 47077648
RP11-501C14.6 ENSG00000251461 - 47082093 47091087 q21.32 rs1495274 0.000006974 47077648
RP11-120M18.2 ENSG00000267009 + 66409764 66521090 q24.2 rs6501468 0.00005995 66427696
WIPI1 ENSG00000070540 - 66417089 66453654 q24.2 rs6501468 0.00005995 66427696
ENSG00000267009 + 66409764 66521090 q24.2 rs2909207 0.00007614 66439605
ENSG00000070540 - 66417089 66453654 q24.2 rs2909207 0.00007614 66439605
ENSG00000267009 + 66409764 66521090 q24.2 rs883541 0.00008579 66449122
ENSG00000070540 - 66417089 66453654 q24.2 rs883541 0.00008579 66449122
RBFOX3 ENSG00000167281 - 77085427 77613550 q25.3 rs8073623 0.0001163 77209928
ENSG00000267483 - 77085427 77512230 q25.3 rs8073623 0.0001163 77209928
CARD14 ENSG00000141527 + 78143791 78183130 q25.3 rs3829611 0.0003766 78161815
18 CABLES1 ENSG00000134508 + 20714528 20840431 q11.2 rs4800149 0.00007593 20744254
rs8094261 0.0001353 20746728
rs7244739 0.00004108 20747874
RNF125 ENSG00000101695 + 29598335 29653176 q12.1 rs17718931 0.000376 29595943
RP11-53I6.2 ENSG00000263917 + 29598792 29691742 q12.1 rs17718931 0.000376 29595943
LINC00907 ENSG00000267586 + 39739247 40271387 q12.3 rs7233167 0.0004234 39905099
RNF165 ENSG00000141622 + 43906772 44043103 q21.1 rs4890643 0.00005549 43913125
rs9958625 0.00005135 43914787
RP11-146N18.1 ENSG00000267134 + 61771325 62090836 q22.1 rs11877311 0.00008493 62032809
19 TJP3 ENSG00000105289 + 3708107 3750811 p13.3 rs475112 0.0001404 3745546
MRPL54 ENSG00000183617 + 3762662 3768573 p13.3 rs917546 0.000003929 3769834
RAX2 ENSG00000173976 - 3769087 3772233 p13.3 rs917546 0.000003929 3769834
AC005307.3 ENSG00000267243 - 28926295 29218684 q12 rs1476739 0.000003327 29083380
AC005616.1 ENSG00000266893 - 28982771 29123635 q12 rs1476739 0.000003327 29083380
ENSG00000267243 - 28926295 29218684 q12 rs9653109 0.000228 29090291
AC005394.1 ENSG00000267537 - 29093286 29139210 q12 rs9653109 0.000228 29090291
ENSG00000266893 - 28982771 29123635 q12 rs9653109 0.000228 29090291
CD22 ENSG00000012124 + 35810164 35838258 q13.12 rs11673522 0.00009619 35807727
MAG ENSG00000105695 + 35783028 35804707 q13.12 rs11673522 0.00009619 35807727
ZNF321P ENSG00000221874 - 53431728 53466076 q13.41 rs8110394 0.0003313 53439481
ZNF816 ENSG00000180257 - 53430388 53466164 q13.41 rs8110394 0.0003313 53439481
ZNF816-ZNF321P ENSG00000213801 - 53430388 53445854 q13.41 rs8110394 0.0003313 53439481
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20 MACROD2 ENSG00000172264 + 13976015 16033842 p12.1 rs6131652 0.0003937 15211513
rs1304179 0.0004005 15296031
RPL7AL3 ENSG00000235208 - 16664753 16665049 p12.1 rs6044230 0.0001602 16665232
EYA2 ENSG00000064655 + 45523263 45817492 q13.12 rs1541256 0.00001494 45784212
GNAS-AS1 ENSG00000235590 - 57393974 57425958 q13.32 rs6128441 0.0003562 57402992
GNAS ENSG00000087460 + 57414773 57486247 q13.32 rs35113254 0.000007265 57435532
RP1-309F20.3 ENSG00000225806 - 57438583 57463864 q13.32 rs35113254 0.000007265 57435532
21 SAMSN1 ENSG00000155307 - 15857549 15955723 q11.2 rs12626593 0.0004051 15857846
ABCG1 ENSG00000160179 + 43619799 43717354 q22.3 rs225401 0.0003771 43693693
UBASH3A ENSG00000160185 + 43824008 43867791 q22.3 rs884339 0.0003464 43866505
PCBP3 ENSG00000183570 + 47063608 47362368 q22.3 rs17004793 0.0002008 47119273
22 LL22NC03-30E12.13 ENSG00000227710 + 22522682 22523027 q11.22 rs5995601 0.00006649 22524871
SOCS2P2 ENSG00000224465 - 22525369 22525942 q11.22 rs5995601 0.00006649 22524871
LARGE ENSG00000133424 - 33558212 34318829 q12.3 rs16992029 0.0002015 33668879
RP1-41P2.7 ENSG00000228587 + 36081987 36085420 q12.3 rs16995953 0.00007196 36084258
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Table 3.4.  Differentially expressed genes in KaLwRij bone marrow macrophages
Gene Fold change P-value
* Tnfrsf26 -29.9811 2.65E-09
Tnfrsf23 -14.6596 1.89E-07
* Samsn1 -14.4329 1.14E-07
2210012G02Rik -9.58558 4.43E-07
Mpo 6.93897 1.54E-06
Ctsg 5.64399 2.33E-05
Pdlim4 -5.33088 3.23E-05
Tspan32 -5.15177 6.34E-07
Ms4a3 4.77849 2.22E-05
Elane 4.51361 1.21E-07
2210012G02Rik -4.36785 2.98E-05
Timp3 4.17675 4.94E-07
Ly6g 4.09308 3.00E-05
Ada 3.75752 5.59E-05
Bgn 3.33172 1.19E-07
Igfbp7 2.95073 3.30E-06
* Qpct -2.89029 5.46E-05
Chi3l1 2.8762 8.41E-06
* Lrrc27 -2.87336 1.43E-05
* Lyrm7 2.82725 1.19E-06
Ceacam10 2.76395 3.59E-05
Cd81 -2.62216 8.44E-06
Wdfy1 2.60413 3.57E-06
* Sparc 2.52091 1.38E-06
Cd276 2.23131 1.09E-05
Fcnb 2.00202 6.59E-06
Scnm1 -1.6946 7.08E-07
Mtg1 1.67805 4.04E-05
ND3 -1.64285 1.77E-05
Alad 1.60752 4.37E-05
Dmwd 1.53818 1.33E-05
2410091C18Rik -1.5002 3.72E-05
Fold change is expression in KaLwRij bone marrow macropchages compared to B6
* gene is present on KaLwRij BIP susceptibility candidate gene list
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Table 3.5.  Differentially expressed genes in KaLwRij bone marrow stromal cells
Gene Fold change P-value
* Tnfrsf26 "11.3288 3.81E"08
* Tnfrsf23 "21.709 6.49E"08
Wdfy1 3.27725 6.87E"07
Tceanc2 "6.67305 1.05E"05
* Lyrm7 2.21795 8.92E"06
Mtg1 1.90874 7.88E"06
ND3 "1.75834 6.83E"06
5830417I10Rik "6.2556 1.73E"05
Fold change is expression in KaLwRij compared to B6
* gene is present on KaLwRij BIP susceptibility candidate gene list
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Table 3.6.  SAMSN1 variant frequencies in MM patients 
N
variant 
alleles % N
variant 
alleles %
15830578 rs2822669 C/T 366 44 12.02 210 38 18.10 0.6421 0.0593
15857533 A/G 366 1 0.27 210 0 0
15857592 rs76251857 G/A 3' UTR variant 366 3 0.82 210 2 0.95 0.8583 0.8683
15857846 rs12626593 C/G 3' UTR variant 366 34 9.29 210 19 9.05 1.0276 0.9245
15858171 rs28470776 G/A 3' UTR variant 366 1 0.27 210 0 0
15858207 rs80062901 G/A 3' UTR variant 366 3 0.82 210 4 1.90 0.4209 0.2634
15858228 rs373757186 C/T 3' UTR variant 366 1 0.27 210 0 0
15858229 rs149543089 G/A 3' UTR variant 366 1 0.27 210 0 0
15858302 T/C 366 1 0.27 210 0 0
15872961 C/T 366 1 0.27 210 0 0
15873026 rs62227165 T/C missense variant 366 8 2.19 210 3 1.43 1.5540 0.5217
15882622 rs118173592 T/C 366 0 0 210 1 0.48
15884758 s376866016 G/A 366 0 0 210 1 0.48
15884899 rs73344160 A/G splice region variant 366 4 1.09 210 3 1.43 0.8090 0.7533
15889304 rs34607574 C/G missense variant 366 6 1.64 210 3 1.43 1.1525 0.8432
15889359 rs368475908 G/A missense variant 366 0 0.00 210 1 0.48
15893545 rs150644782 A/T 366 1 0.27 210 0 0
15893567 rs760344 A/T 366 54 14.75 210 28 13.33 1.1323 0.6360
15893594 rs760345 T/C 366 165 45.08 210 87 41.43 1.1476 0.4214
15893619 rs139733326 A/G 366 1 0.27 210 0 0
15918508 T/C 366 1 0.27 210 0 0
15918577 rs7281104 G/C 366 88 24.04 210 57 27.14 0.8651 0.4360
15918601 rs118133999 C/T 366 10 2.73 210 5 2.38 1.1359 0.8017
15918714 rs12329657 A/G 364 169 46.43 210 107 50.95 0.8571 0.3396
15954440 G/A 366 1 0.27 210 0 0
15954528 rs2822785 G/A missense variant 352 145 41.19 210 87 41.43 0.9902 0.9564
odds ratio
private variant
private variant
private variant
private variant
private variant
private variant
private variant
P-value
Position 
Chr21
MM patients ControlsAllele 
(Ref/Alt) SNP Consequence
private variant
private variant
private variant
private variant
private variant
private variant
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variant 
alleles %
15954593 rs2822786 G/A missense variant 366 104 28.42 210 50 23.81 1.3256 0.1707
15954601 rs139465416 G/T missense variant 366 2 0.55 210 1 0.48 1.1492 0.9101
15954660 rs2822787 T/C missense variant 366 301 82.24 210 163 77.62 1.3270 0.1834
15954748 C/A 366 0 0 210 1 0.48
15954849 rs2822788 T/C 366 17 4.64 210 17 8.10 0.5710 0.0921
15954862 rs34228133 G/A 366 5 1.37 210 4 1.90 0.7093 0.6146
15955575 rs2822790 C/T 364 15 4.12 210 17 8.10 0.5098 0.0472
15955633 rs2822791 G/A splice region variant 364 15 4.12 210 17 8.10 0.5098 0.0472
15955648 rs2822792 T/C 5' UTR variant 350 273 78.00 210 156 74.29 1.2195 0.3184
15955691 rs144975197 A/T 5' UTR variant 366 1 0.27 210 1 0.48 0.5714 0.6934
15955693 rs17240787 G/A 5' UTR variant 366 0 0 210 1 0.48
15955779 rs9980152 G/A 366 17 4.64 210 17 8.10 0.5710 0.0921
Odds ratio and P-value were calculated by logistic regression analysis.
Allele 
(Ref/Alt) SNPPosition
ControlsMM patients
Consequence
private variant
private variant
P-valueodds ratio
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Chapter 4 
 
Summary of work, future directions, and clinical relevancy 
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Part I:  Summary of work 
 
Contributions to the understanding of Paget’s “congenial soil” 
 
 The “seed and soil” hypothesis has been accepted as a model for cancer cell metastasis 
for decades, but, despite advances in the field’s knowledge of cancer cell biology and the bone 
microenvironment, the definition of a “congenial soil” remains incomplete.  This dissertation is 
focused on elucidation of this question, addressing both the composition of the bone 
microenvironment “soil” and whole-host “congeniality” to disease progression. 
 We demonstrated a novel role for anti-angiogenic and therapeutic target TSP1 in bone 
homeostasis in Chapter 2.  We found that TSP1 played important roles in maintaining bone 
matrix integrity through effects on materials properties and overall morphology.  Further, we 
identified TSP1 as a necessary ligand in OC formation, inhibiting iNOS and thus permitting 
osteoclastogenesis.  Finally, we demonstrated that TSP1-deficient bone failed to inhibit iNOS in 
OC, leading to a model of TSP1 as a paracrine signaling molecule, coupling OB activity to OC 
formation.  These findings have implications for TSP1-pathway directed therapeutics in trial and 
in clinical use to have effects on bone that will be discussed in Part II. 
 
 In Chapter 3, we focused on identifying genetic risk loci contributing to bone marrow-
dependent MGUS and MM susceptibility.  Using a non-biased approach, we identified large 
candidate gene lists that may underlie susceptibility to MGUS and/or MM in humans and BIP, 
the analogous disorder in mice.  Combining these two datasets, we identified a candidate gene 
list of five genes that may contribute to both murine BIP and human MGUS.  One of these genes, 
Samsn1, drew our particular attention because it is a negative regulator of B-cell activation (Zhu 
136
et al., 2004).  Importantly, we found that BIP-prone KaLwRij mice have complete germline 
deletion of Samsn1, the first germline lesion identified in these mice.  KaLwRij mouse plasma B-
cells had enhanced activity in vitro and vivo, consistent with the published role for Samsn1 as a 
negative regulator in B-cells. KaLwRij mice have increased pro-tumorigenic M2-macrophage 
activation under basal conditions, and macrophages polarized to M2 have increased ability to 
promote tumor growth in vivo.  These findings suggest a novel role for Samsn1 in macrophages, 
fulfilling a similar inhibitory role as in B-cells.  Finally, we demonstrated that restoration of 
Samsn1 expression in KaLwRij-derived 5TGM1 myeloma cells reduced proliferation, indicating 
that Samsn1 also contributes to cell-autonomous myeloma cell regulation.  Thus, we 
demonstrated a single risk allele that participates in the negative regulation of both pre-malignant 
plasma B-cells and host MGUS- and MM-supportive macrophages.   
 While our studies focused on the role of Samsn1 in conferring risk to murine BIP, it is 
likely not the only susceptibility gene contributing to the KaLwRij BIP phenotype.  We will 
discuss the utility of further characterization of the KaLwRij mouse strain in Part III. 
 
 Collectively, the data presented in Chapter 2 and Chapter 3 contribute to our 
understanding of Paget’s “congenial soil,” providing important rationale for studying genes and 
proteins with pleiotropic roles in multiple cell types, locations, and pathologic states. 
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Part II:  Future directions and clinical significance of Chapter 2 
 
The work described in Chapter 2 more fully characterized the role of TSP1 in bone 
homeostasis, but several questions regarding TSP1 function remain.  As in other cell types and 
processes, it is likely that TSP1 plays pleiotropic, and perhaps contradictory, roles in bone. 
 
What are the effects of bone-resident TSP1 on matrix composition and osteoclast activity? 
We found that TSP1 contributes to bone quality, in part through maintenance of bone 
material properties.  It is unclear, however, whether this phenotype is due to presence of the 
TSP1 ligand itself or TSP1 regulation of the stoichiometry and physical organization of other 
components of the bone matrix.  TSP1 binds many proteins essential for bone quality, including 
hydroxyapatite, collagen, and numerous non-collagenous proteins including osteonectin, 
fibronectin, osteopontin, and proteoglycans.  To determine whether presence of TSP1 influences 
the protein stoichiometry of bone, it would be useful to perform mass spectroscopy on 
devitalized bone from wild type and TSP1-/- mice. Unfortunately, the technology to perform 
mass spectroscopy in rigid calcified bone tissue is currently unavailable.  As part of an effort to 
map the proteins of the extracellular matrisome, however, methods are being developed to digest 
bone lysate while maintaining protein structure with promising preliminary results (Alexandra 
Naba, 2013; Hynes and Naba, 2012).  As these technologies become available, it will be 
important to evaluate mice deficient for TSP1 and other non-collagenous proteins to determine 
how they influence each other and, in turn, the bone extra cellular matrix to effect bone strength 
and osteoclast function. 
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A conditional TSP1 knock out in OBs would be a useful model to further evaluate the 
role of OB-deposited TSP1 in bone strength and quality.  These mice presumably would not 
express TSP1 in the bone matrix or in OBs, but would have active TSP1 signaling elsewhere.  
While it has been shown that OBs secrete TSP1 during bone formation (Clezardin et al., 1989; 
Robey et al., 1989), it is possible that other cell types also produce TSP1 for deposition in the 
bone matrix. If we observed TSP1 in the bone of OB-conditional TSP1-/- mice, we could use the 
floxed TSP1 mouse crossed to cell-specific cre mice to isolate the secretory cells contributing 
bone matrix TSP1. To achieve a similar mouse model, we would typically create bone marrow 
chimeras by lethally irradiating TSP1-/- mice and transplanting wild type bone marrow to 
measure normal osteoclast resorption of TSP1-/- bone.  TSP1-/- mice, however, are protected 
from sub-lethal irradiation (Isenberg et al., 2008) and partially protected from lethal irradiation.  
Attempts to engraft wild type donor bone marrow have failed, resulting in a chimeric 
hematopoietic compartment containing both wild type and TSP1-/- cells. 
In Chapter 2, we identify that loss of TSP1 influences both bone morphology and bone 
matrix materials properties, and it is likely that OB expression and secretion of TSP1 plays a role 
in these phenotypes.  While it has been established that OB secrete TSP1, it is unclear at what 
maturation stage OB contribute to TSP1 deposition in bone.  It may be interesting to use multiple 
OB-lineage cre mice (osterix-cre to target early OBs, osteocalcin-cre to target mature OB, and 
DMP1-cre to target osteocytes) to identify the temporal requirement of TSP1 expression and 
secretion for matrix deposition during OB maturation.  Using this OB-conditional TSP1-/- 
model, we could evaluate bone morphology, bone strength parameters, and bone material 
properties as in Chapter 2 to determine if bone strength phenotype in TSP1-/- is solely 
contributed to osteoblastic secretion of TSP1.  Moreover, beyond the scope of our work 
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described here, further work is necessary to understand the role of TSP1 in bone strength and 
fracture healing, especially given established roles for TSP1 in wound healing and angiogenesis.  
In addition to its role in promoting bone quality, we hypothesize in Chapter 2 that TSP1 
deposited in the bone matrix by OB is responsible for inhibiting iNOS transcription in OC 
progenitors.   If OB-deposited TSP1 is necessary for OC formation, we would observe a similar 
OC phenotype in conditional TSP1-/- in OB mice as in the global TSP1-/- mouse:  decreased 
serum CTX that is rescued upon inhibition of nitric oxide synthase.  These experiments would 
also further elucidate the role of TSP1 as a paracrine signaling molecule, coupling OB activity to 
OC formation via the bone matrix.   
 
What receptors does TSP1 bind to modulate OC activity? 
While we demonstrated that TSP1 is a negative regulator of iNOS in pre-OC, it remains 
unclear what receptor(s) it binds to exert this effect.  In other cell types, both CD47 and CD36 
have been implicated in TSP1-mediated inhibition of NO signaling (Isenberg et al., 2006; 
Isenberg et al., 2005).  Importantly, TSP1 has not previously been described to modulate iNOS, 
though effects on eNOS and downstream molecules have been reported.  Our lab previously 
demonstrated that CD47 negatively regulates iNOS in OC (Uluckan et al., 2009), leading us to 
hypothesize that it is likely a requisite receptor for TSP1-mediated NO effects.  TSP1-/- mice had 
a more severe OC phenotype in vivo than any TSP1-receptor knock out mouse models, including 
CD47-/- and CD36-/-, suggesting that TSP1 exerts its effects on OC via multiple different 
receptors. To test whether TSP1 binds both CD47 and CD36 to inhibit NO signaling in early OC, 
we could evaluate iNOS in OC from double knock-out CD47-/-, CD36-/- mice.  If both receptors 
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contribute to TSP1-mediated NOS inhibition, treating OC with TSP1 neutralizing antibody 
should have no additional effect beyond the null phenotype. 
 
 
Does TSP1 promote or inhibit metastatic tumor growth in bone? 
In addition to understanding its role in homeostasis, it is important to investigate the role 
of TSP1 in bone during pathologic states such as bone metastasis.  TSP1 was the first identified 
endogenous anti-angiogenic, and TSP1-/- mice have increased primary tumor burden and tumor-
associated vasculature (Rodriguez-Manzaneque et al., 2001).  In some bone metastatic prostate 
cancer models however, increased TSP1 promotes tumor progression through effects on cancer 
cell migration (Dias et al., 2012; Firlej et al., 2011; John et al., 2010; Tuszynski et al., 1987).  
Interestingly, high tumor-derived TSP1 levels are a prognostic marker for cancer progression and 
relapse (Firlej et al., 2011). We found that the bone metastatic C42b prostate cancer cell line 
expressed significantly higher levels of TSP1 compared to its parental non-metastatic LnCaP cell 
line by RNA-seq (Li Jia, unpublished data).  Similarly, but to a lesser magnitude, TSP1 
expression is also elevated in bone metastatic melanoma cell line subclone B16-F10 compared to 
its parental non-metastatic cell line, B16-F0.  We would hypothesize that high TSP1-expressing 
bone metastatic tumors overcome TSP1’s anti-angiogenic functions and take advantage of other 
TSP1 functions such as mediating migration and adhesion.  Once in the bone microenvironment, 
tumoral secretion of TSP1 will stimulate OC and initiate the vicious cycle of bone metastasis, 
leading to increased tumor growth.  We would anticipate, therefore, that injection of TSP1-low 
primary tumor cell line and TSP1-high bone metastatic subclone into the mammary fat pad of 
mice would show similar primary tumor growth, but that the TSP1-high tumor would have 
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increased bone metastasis.  In an intratibial model, we would anticipate that TSP1-high 
expressing tumors would have increased bone lesions and increased tumor burden.  Subsequent 
overexpression and knock-down experiments in these cell lines would demonstrate sufficiency 
and necessity of tumor-derived TSP1 in mediating migration to and growth in bone.   
While the experiments outlined address the role of tumor-derived TSP1 in tumor growth 
in bone, it is still unclear what role bone microenvironment TSP1 plays in bone metastasis.  We 
hypothesized that TSP1 would promote tumor growth in bone by promoting OC activity and 
stimulating the vicious cycle.  Our studies of bone metastasis in TSP1-/- mice, however, have 
been largely inconclusive with TSP1-/- mice having modest but non-statistically significant 
increases in tumor burden in aggressive intratibial models (B16-F10 melanoma and PyMMT-
LV1) and an intracardiac model (B16-F10) of bone metastases, but no increases in tumor-
associated osteolysis.  Though we are unable to make any definitive conclusions, these data are 
consistent with the hypothesis that host-derived TSP1 may play different roles in tumor 
progression based on location and severity of malignancy.  To investigate the role of TSP1 in 
bone metastasis, it will be necessary to use a less aggressive model, such as a orthotopic injection 
of PyMMT cells into the mammary fat pad of TSP1-/- mice, performing tumor resection, and 
monitoring bone metastasis. A slower-growing tumor may allow the time necessary to uncover 
subtle effects of TSP1 on metastatic bone tumor burden. 
Subtle effects of host TSP1 on bone metastasis may be due in part to the role of TSP1 in 
angiogenesis.  TSP1 is largely recognized an anti-angiogenic through its interactions with CD47 
and αvβ3, but there are also reports that TSP1 interacts with α6 to promote angiogenesis.  
Moreover, TSP1’s angiogenic properties have not been evaluated in the sinusoidal blood vessels 
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of the bone microenvironment.  It would be useful to evaluate the effects of tumor- and host-
TSP1 on angiogenesis in the experiments described above.  
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Clinical significance 
Will pharmacologic modulation of the TSP1 pathway have effects on bone? 
 
It will be interesting to evaluate the bone effects of TSP1-pathway directed therapeutics 
under development and in clinical use as anti-cancer therapeutics (TSP1 mimetics and CD47 
antibodies) and to modulate blood pressure (NO donors and NOS inhibitors).  We anticipate that 
agents that mimic TSP1 signaling (TSP1 mimetics, CD47 antagonists, and NOS inhibitors such 
as L-NAME used in our study) will stimulate osteoclastic bone resorption.  While this increase in 
bone remodeling may be of minimal concern in the general population, it will be important to 
monitor patients at increased risk of skeletal related events such as cardiovascular disease 
patients presenting with osteoporosis and cancer patients at risk for bone metastasis. Our data 
provide rationale for TSP1-pathway inhibitory therapeutics (NO donors such as Isordil and 
TSP1-blocking CD47 antibodies) to reduce OC activity, especially in comorbidities such as 
osteoporosis and bone metastasis.  As these TSP1-pathway directed therapeutics become 
standard-of-care, it will be important to identify and monitor both harmful and positive bone 
effects, including effects on bone mineral density as well as bone quality. 
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Part III:  Future directions and clinical significance of Chapter 3 
 
 The major finding presented in Chapter 3 is that Samsn1 is deleted in the germline of 
BIP-resistant KaLwRij mice.  KaLwRij have enhanced B-cell and macrophage activation, and 
re-expression of Samsn1 in myeloma cells reduces proliferation.  Therefore, we hypothesize that 
Samsn1 contributes to genetic susceptibility of murine BIP through independent effects on 
multiple cell types, and that the SAMSN1 pathway likely participates in human genetic risk to 
MGUS and MM. 
 
Is Samsn1 deficiency sufficient to confer increased risk of BIP in mice?  
To determine whether Samsn1 deletion is sufficient to confer BIP-susceptibility in mice, 
we could use a targeted Samsn1-/- mouse model (Wang et al., 2010).  To determine effects on 
BIP-susceptibility, we could immunize Samsn1-/- mice and monitor SPEP response as in Figure 
3.1b.  In addition, to determine whether loss of Samsn1 creates a myeloma-permissive 
microenvironment, we could inoculate Samsn1-/- mice with 5TGM1 myeloma cells and monitor 
tumor growth.  If Samsn1 contributes to host BIP susceptibility and microenvironment support of 
myeloma, we would predict that SPEP response and tumor burden in Samsn1-/- mice would be 
similar to KaLwRij. 
 
What role do Samsn1-null macrophages play in BIP and myeloma? 
 The only published role for Samsn1 is in B-cell activation ((Wang et al., 2010; Zhu et al., 
2004)), but many cells of the hematopoietic lineage, including macrophages, are Samsn1 
expressors (BioGPS, (Claudio et al., 2001)).  In B-cells, SAMSN1 is a proposed adaptor protein 
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that interacts with the ITIM domain of PIR-B and phosphorylated SHP-1/2 to inhibit B-cell 
activation, likely through modulation of Lyn phosphorylation and subsequent effects on B-cell 
receptor (BCR) and its binding partners, including Syk, PI3 kinase, and PLCγ ((Wang et al., 
2010; Zhu et al., 2004)) (Figure 4.1).  Notably, many of these proteins participate in regulation 
of other hematopoietic cells, with reports of BCR complex proteins to promote and PIR-B 
complex proteins to inhibit macrophage activation and function (Brenner et al., 2004; Munitz et 
al., 2010; Xie et al., 2014).  We found that KaLwRij mice have increased macrophage activation 
in vitro and increased pro-tumor effects in vivo, and we hypothesize that these effects are due to 
Samsn1 deletion. Repeating these macrophage experiments in Samsn1-/- mice would determine 
whether Samsn1 deletion is the causal variant of the KaLwRij macrophage phenotype.  
Furthermore, it will also important to identify the macrophage-autonomous role of Samsn1, 
including regulatory factors, binding partners, and downstream effects, to identify manipulatable 
pathways for modulating MGUS and myeloma microenvironment in a preventative setting.  
 Increased macrophage activation has been implicated in human MM pathogenesis 
(Asimakopoulos et al., 2013; Berardi et al., 2013; Ribatti et al., 2013).  We found that KaLwRij 
mice have macrophage activation that precedes the onset of detectable BIP.  We hypothesize that 
the increased KaLwRij macrophage activation increases BIP development, and subsequently 
contributes to transformation to overt myeloma.  Notably, however, it is unclear both in mice and 
in humans whether the microenvironment promotes MGUS and myeloma development or 
whether microenvironment changes are a result of increased B-cell activation, representing “low-
level” MGUS undetectable by current methods.  It will be difficult to answer this question using 
current mouse models of MGUS, with the KaLwRij mouse only presenting with BIP at 2 years 
of age.  Vitamin D deficiency and irradiation can accelerate BIP development in KaLwRij mice 
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(Michael Tomasson, unpublished data).  We predict that chronic activation of macrophages by 
LPS treatment or transplant of in vitro activated macrophages may also accelerate BIP 
development via increased support of pre-malignant plasma B-cells.  In addition, as the field 
identifies susceptibility loci contributing to MGUS and MM susceptibility in humans and in 
mice, more precise genetic models can be developed to study the pre-malignant 
microenvironment and evaluate the contribution of individual microenvironment cell types to 
disease progression, including macrophages as well as osteoclasts and bone marrow stromal 
cells. 
 
What genetic variation contributes to stepwise progression of myeloma in KaLwRij mice? 
 We found that KaLwRij mice have homozygous germline deletion of Samsn1, but, while 
Samsn1 likely contributes to the increased penetrance of BIP in KaLwRij, it is unlikely to be the 
only participating locus.  Our SNP analysis identified several thousand variants between BIP-
resistant B6 mice and BIP-susceptible KaLwRij mice, providing a wealth of information of 
genes that may contribute to BIP in mice.  Particularly compelling are genes with dramatically 
high variation between B6 and KaLwRij, in some cases with more than 100 variant SNPs.  In 
addition to the germline variants, we also identified differential gene expression between B6 and 
KaLwRij in macrophages and bone marrow stromal cells, both known to support MGUS and 
MM cells.  Interestingly, several differentially expressed genes have genetic variation between 
B6 and KaLwRij, suggesting that those alleles confer risk via impacts on the microenvironment.  
Importantly, however, we did not identify germline genetic variation in many of the 
differentially expressed genes, indicating that their gene expression is dependent on non-cell 
autonomous effects or due to downstream effects of KaLwRij genetic variants.  It is likely that 
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causal gene variants lie in shared or cooperative pathways to modulate B-cells and 
microenvironment cells to confer increased BIP risk.  Bioinformatics pathway analysis of all 
candidate genes would be useful to identify pathways of interest for further investigation. 
 
What role do the other candidate genes (Fstl4, Ccm2, Tenm3, and Csmd1) play in BIP risk? 
 In addition to whole gene-set analysis, focused examination and verification of the other 
four candidate genes identified in the mouse and human integrative analysis would be useful to 
further characterize the genetic contributions to BIP-risk in KaLwRij mice and MM-risk in 
humans.  None of the remaining four candidate genes have been reported to play roles in plasma 
B-cells, myeloma cells, or host supportive cells.  Based on the success of Samsn1, however, we 
anticipate that further investigation of Fstl4, Ccm2, Tenm3, and Csmd1 will identify new roles 
for the genes in cells contributing to MM progression. 
 While most of the research of Ccm2 has focused on its effects in cerebral cavernous 
malformations, there is evidence that it is involved in p38 MAP kinase signaling (Zawistowski et 
al., 2005), known to promote MM growth and a target for therapeutic intervention (Campbell et 
al., 2014).  Csmd may also be a good candidate as it exerts anti-tumor effects in solid tumors, 
and loss of Csmd1 is associated with poor prognosis in colorectal cancer patients (Tang et al., 
2012; Zhang and Song, 2014). Relatively little is known about the function of Tenm3, with most 
of the published research focused on its role in vision.  It is possible that Tenm3 underlies a trait 
other than BIP-susceptibility present in KaLwRij that has not yet been characterized. 
 The most intriguing gene for subsequent follow-up studies is Fstl4.  While there are no 
reports of Fstl4 directly influencing cells contributing to myeloma pathogenesis, there is 
evidence for a downstream molecule, activin A, in multiple cell types participating in MM 
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progression.  Follistatin inhibits the activity of activin A to promote B-cell immunoglobulin 
secretion (Ogawa et al., 2008), MM bone disease (Vallet et al., 2010), and pro-tumor M2 
macrophage polarization (Sierra-Filardi et al., 2011).  Further, the actvin A pathway has direct 
clinical implications with increased circulating activin A correlated with increased bone disease 
and decreased survival in MM patients (Terpos et al., 2012).  With potential roles in multiple cell 
types, it will be interesting to characterize the role of Fstl4 in mediating the activin A pathway in 
BIP-prone mice and in MGUS patients.   
 
Sequencing of KaLwRij to identify genetic events during myeloma progression 
While SNP mapping was successful in our approach described in Chapter 3, the 
approach has substantial shortcomings.  SNP mapping takes advantage of “marker” SNPs that 
are likely in linkage with causal variants, but are not necessarily causal themselves.  Moreover, 
SNP mapping will not identify small but biologically significant genetic lesions that may 
contribute to disease, especially when used to compare two closely related strains.  To fully 
characterize the KaLwRij mouse strain, whole genome sequencing is necessary to identify all 
variants, including protein coding genes, non-coding RNAs, and regulatory regions.  Logistically 
important, the closely related but BIP-resistant B6 strain is the mouse reference genome and is 
complete, well annotated, and publically available.  
It is likely that much of the variation between B6 and KaLwRij is unrelated to inherited 
BIP risk. To reduce follow-up studies of non-BIP related variation, we could compare the 
sequence of the locus of interest from our KaLwRij colony to other isolated BIP-susceptible 
KaLwRij colonies.  Because of the limited commercial availability, individual laboratories 
maintain independent KaLwRij colonies, all of which have been inbred independently for more 
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than 20 generations, the requisite for defining a substrain (2013).  Comparing our KaLwRij sub-
strain sequence to the sequences of other sub-strains (e.g. Croucher colony and Zannettino 
colony at the Garvan Institute, Mundy colony at Vanderbilt University, etc.) will help to filter 
variation due to genetic drift. We anticipate that all BIP-susceptible KaLwRij colonies would 
share alleles contributing to increased BIP risk. 
While the work presented in Chapter 3 explored the transition from a normal state to 
BIP, it does not address the transition to overt myeloma.  The KaLwRij 5T myeloma model is 
the ideal system to identify plasma-cell intrinsic genetic changes between BIP and myeloma.  
The 5T myeloma cell lines were isolated from spontaneous myelomas arising in KaLwRij mice, 
and can be transplanted into syngeneic KaLwRij mice to propagate the myeloma (Alici et al., 
2004; Asosingh et al., 2000; Vanderkerken et al., 2003).  In this work, we utilized 5TGM1 
myeloma cells to determine the role of Samsn1 in myeloma cell proliferation.  Whole genome 
sequencing of the 5TGM1 cell line and comparing the variation to the KaLwRij sequence would 
identify genes that are mutated during the BIP-to-myeloma transition in mice.  Similar to 
comparing our KaLwRij colony sequence to other KaLwRij substrains, it would be useful to 
compare the 5TGM1 sequence to other available 5T cell lines (e.g. 5T33vv, 5T33vt, etc.) to filter 
any variation due to genetic drift.  At the conclusion of these sequencing efforts, therefore, we 
would have a genetic model for the plasma-cell intrinsic variation that participates in the step-
wise progression of myeloma:  normal (B6), “MGUS” (BIP – KaLwRij), and myeloma (5T cell 
line). 
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Clinical significance: 
Genetic screening and treatment strategies for high-risk MGUS patients 
 
 Despite advances in treatment, including chemotherapy, proteasome inhibitors, and 
bisphosphonates, that target both the malignant plasma cell as well as host supportive cells, MM 
remains an invariably fatal disease with a short median survival of only 6 years.  MM has a 
requisite precursor, MGUS, that represents a unique opportunity for preventative treatment of 
malignancy.  Despite the rapid progression of MM, however, MGUS remains non-malignant for 
decades, and often never transforms to overt myeloma.  Because of low rates of progression, 
MGUS patients are not clinically treated.   
 Inherited risk of MM is due to increased risk of MGUS, not increased rate of 
transformation from MGUS to myeloma.  Notably, plasma-cell autonomous genetic changes 
occur during the transition from normal to MGUS, with few variations between MGUS and MM 
affected cells (Davies et al., 2003), implicating B-cell extrinsic events in promoting malignancy.  
Identifying susceptibility loci to MGUS, specifically in genes that participate in 
microenvironment cells, will provide important data for the development of screening strategies 
to identify high-risk MGUS patients.  Moreover, understanding malignant-cell extrinsic 
mechanisms that promote the progression of MGUS to MM will help to identify preventative 
strategies to prevent or delay onset of MM. 
 In our work presented here, we used a strategy to identify inherited genetic variation in 
MM patients compared to controls.  Our analysis yielded gene candidates that act in multiple cell 
types, both B-cells, the current focus of the myeloma field, and in host supportive 
microenvironment cells.  We focused our efforts on the candidate gene Samsn1 and evaluated its 
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biologic function in murine myeloma cells, BIP-susceptible B-cells, and supportive 
macrophages.  Importantly, we identified two SNPs in Samsn1 that are underrepresented in a 
MM patient population.  These data provide important rationale for pursuing Samsn1 pathway 
genes for both screening of MGUS patients and development of preventative strategies targeted 
to both B-cells and macrophages.   
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Figure 4.1.   
SAMSN1 is member of the PIR-B / SHP-1/2 B-cell inhibitory complex 
Following activation of the B-cell receptor (BCR), Lyn phosphorylates the ITAM for 
recruitment of the positive regulatory signaling complex.  Lyn also phosphorylates the 
ITIM domain of PIR-B for recruitment of SHP-1/2 for negative regulation of B-cells.  
SAMSN1  is likely a component of this inhibitory complex, with interactions with the 
PIR-B ITIM domains and SHP-1/2. 
Modified from (Wang et al., 2010). 
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Integrins on both tumor cells and the supporting host stromal cells in bone (osteoclasts, new blood vessels,
inflammatory cells, platelets and bone marrow stromal cells) play key roles in enhancing bone metastasis.
Tumor cells localize to specific tissues through integrin-mediated contacts with extracellular matrix and
stromal cells. Integrin expression and signaling are perturbed in cancer cells, allowing them to “escape” from
cell–cell and cell–matrix tethers, invade, migrate and colonize within new tissues and matrices. Integrin
signaling through αvβ3 and VLA-4 on tumor cells can promote tumor metastasis to and proliferation in the
bonemicroenvironment. Osteoclast (OC) mediated bone resorption is a critical component of bonemetastasis
and can promote tumor growth in bone and αvβ3 integrins are critical to OC function and development.
Tumors in the bone microenvironment can recruit new blood vessel formation, platelets, pro-tumor immune
cells and bone marrow stromal cells that promote tumor growth and invasion in bone. Integrins and their
ligands play critical roles in platelet aggregation (αvβ3 and αIIbβ3), hematopoietic cell mobilization (VLA-4
and osteopontin), neoangiogenesis (αvβ3, αvβ5, α6β4, and β1 integrin) and stromal function (osteopontin
and VLA-4). Integrins are involved in the pathogenesis of bone metastasis at many levels and further study to
define integrin dysregulation by cancer will yield new therapeutic targets for the prevention and treatment of
bone metastasis.
© 2010 Elsevier Inc. All rights reserved.
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Introduction
The development of bone metastasis is common in many cancers,
occurring in virtually all patients with multiple myeloma, in 65%–75%
of patients with advanced breast and prostate cancers, and in 30%–
40% of patients with lung cancer [1–3]. The consequences of bone
metastases are often devastating and can cause pain, pathologic
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fractures, spinal cord and other nerve-compression syndromes and
life-threatening hypercalcemia [4]. Both osteolytic lesions and
osteoblastic bonemetastases are associatedwith increased OC activity
and disrupted bone micro-architecture [5,6]. In the bone microenvi-
ronment, tumor cells secrete soluble factors that promote bone
remodeling resulting in the release of additional bone matrix-bound
growth factors which further activate OCs and osteoblasts (OB) and
promote tumor growth [3,4,7–16]. Anti-resorptive therapy, e.g. with
bisphosphonates or denosumab, significantly decreases skeletal
complications of cancer and is a standard of care for patients with
bone metastases [4,8,17–19]. In addition to their effects on bone,
tumors in the bone microenvironment recruit blood vessel formation,
platelets, immune cells and stromal cells that promote tumor growth
and invasion in bone. Integrin-mediated cell signaling plays a critical
role in many of these processes during bone metastasis, including
platelet aggregation (αIIbβ3), hematopoietic/immune cell mobiliza-
tion (VLA-4 and osteopontin), neoangiogenesis (αvβ3, αvβ5, α6β4,
and β1 integrin) and stromal function (osteopontin and VLA-4) (see
Fig. 1). For these reasons, the mechanisms by which integrin signaling
mediates the pathogenesis of bone metastasis have been an area of
active research.
Integrin structure, activation and signaling
Integrins are heterodimeric transmembrane glycoproteins that
facilitate cell–cell and cell–extracellular matrix (ECM) adhesion and
cell migration [20]. Integrins recruit many intracellular signaling
molecules and can activate survival, proliferation, andmotility signaling
pathways [21]. There are 8 beta and 18 alpha integrin subunits that
assemble into 24 unique known combinations in different cell types,
each characterized by distinct ligand binding specificities (including
collagen, osteopontin, fibronectin, laminin, and others, depending on
the integrin family), signaling abilities, and regulatorymechanisms [22].
Integrins are activated by conformational changes in the integrin
extracellular domains. When the integrin α and β subunit cytoplasmic
and transmembrane domains remain closely juxtaposed, the extracel-
lular domains are held in a closed conformation. Activation by
intracellular signals to the cytoplasmic tails results in separation of the
α and β cytoplasmic and transmembrane domains and exposure of the
extracellular ligand binding domain [23] (inside-out signaling). The
open conformation, facilitates high affinity ligand binding and triggers
integrin-mediated cell signaling cascades (outside-in signaling) [24,25].
Many proteins play critical roles in the activation of specific
integrins, but two cytoplasmic proteins, talin and kindlin, are
necessary for inside-out signaling required for the activation of all
integrin subtypes [23,26–29]. Talin binds to the proximal end of the
beta cytoplasmic tail via a phosphotyrosine-binding (PTB) domain
within its FERM domain [27] and links the integrin to the actin
cytoskeleton [23]. Kindlin 1, 2, or 3, is necessary for talin-induced
integrin activation [26,30,31]. Kindlin, like talin, also interacts with
intracellular proteins resulting in cytoskeleton reorganization and
adhesion [32]. G-protein coupled receptors such as the ADP receptor
P2Y12, also play critical roles in the inside-out signaling required for
integrin activation [25,33,34]. Structure–function analyses on β3
integrins have shown that a membrane-proximal region is important
for inside-out signaling [28,35–40].
In addition to activation by inside-out signaling, ligand binding
and integrin clustering can be significantly modulated by growth
factor receptor interactions and other integrin interacting proteins, as
reviewed in [22,23,41]. For example, integrin associated protein,
CD47, augments integrin activation and affects the ability of αvβ3
integrin to cluster upon ligand binding [42]. Ligation of the integrin
then stimulates outside-in signaling that leads to the activation of
numerous signals critical for growth, migration, survival and other
functions, including FAK phosphorylation, ERK signaling, and NF-κB
activation. Thus, integrin signaling in cancer cells and in associated
stromal, endothelial and hematopoietic cells can be influenced by
intracellular signaling proteins, growth factors, chemokines and other
receptors that participate in regulating integrin function through
effects on integrin activation, ligand binding, ligand affinity and
integrin clustering.
Maintaining adhesion to the ECM, in part through integrin
signaling, is critical to cell survival [43]. Altered cell–cell or cell–
ECM interactions results in disruption of downstream survival
signaling and anchorage-dependent non-transformed cells undergo
anoikis [43]. Under normal conditions, because each cell type
expresses a unique set of integrins that recognize underlying ECM
ligands, this form of apoptosis ensures that detached cells do not
colonize inappropriate locations [43]. Cells that resist anoikis, such as
metastatic cells, take advantage of several different mechanisms so
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Fig. 1. Integrin Expression During Bone Metastasis: Numerous host stromal cells types interact with tumor cells to facilitate tumor cell homing, colonization and invasion in bone.
Preclinical and clinical evidence demonstrate that specific integrin expression and signaling on both tumor cells and host cells are central to facilitating bone metastasis.
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that the cell can adhere to a novel ECM, including aberrant integrin
expression [44], constitutive activation of molecules usually activated
via integrin signaling including FAK [45], EGFR [46] and SRC [47], and
lack of activation of pro-apoptotic pathways [48], among others.
The integrin family of adhesion receptors links ECM to the
cytoskeleton through a complex and regulated network of activation,
interaction with numerous growth factor, GPCR, chemokine and
cytokine receptors and induction of complex signaling cascades.
Integrin expression and signaling on tumor cells that metastasize
to bone
Tumor progression, invasion and eventual metastasis require the
activity of many adhesion proteins, including the integrin superfam-
ily. At each stage of cancer progression, subsets of integrin hetero-
dimers are activated, providing the necessary signaling pathways for
adhesion, migration and cell survival. Metastatic tumor cells show
differential integrin heterodimerization and activation compared to
non-metastatic tumor cells that enable the cell to home to and
colonize in a metastatic site, such as the bone marrow cavity [49,50].
In order for primary epithelial cancers to metastasize, the tumor cells
must become resistant to anoikis and detach from the primary tumor
site ECM, enter the vasculature, and eventually colonize a distant site.
Upon reaching a successful metastatic site, however, tumor cells use
both anoikis and anoikis-resistance to their advantage, in some cases
forming micro-metastases that are resistant to cancer treatment via
integrin binding to the underlying bone ECM as reviewed in [51].
Tumor cells must also form interactions between the tumor cell and
bone stroma to establish and maintain skeletal metastasis. Many
integrins have been implicated in tumor cell–host bone stroma
interactions during bonemetastasis and tumor growth in bone (Fig. 1,
Table 1), including the β1 and β3 integrin family members.
avβ3 is a receptor for osteopontin, fibronectin, and vitronectin,
ECM proteins that are important bone matrix proteins, and αvβ3 has
been identified as a critical integrin in breast cancer and prostate
cancer skeletal metastasis [50,52–56]. Interestingly, although αvβ3
has been shown to bind to fibronectin in other locations with high
affinity, tumorαvβ3 integrins do not bind fibronectin in bonemarrow
stroma, indicating that αvβ3-expressing tumor cells bind to the bone
stromal ligands vitronectin and osteopontin [57]. In breast cancer,
αvβ3 binding of host osteopontin is necessary for tumor cell
colonization to bone [58]. Bone metastatic cells have a higher
expression of αvβ3 than the primary tumor [53], promoting
adherence to the bone matrix by binding osteopontin expressed by
bone stromal cells [58]. Breast cancer cells that overexpress αvβ3
have increased levels of bonemetastasis and associated tumor burden
and osteolysis [52,59–62]. This overexpression of αvβ3 in the tumor
cells leads to increased tumor cell adhesion, migration and invasion to
bone as well as enhanced OC recruitment within the bone microen-
vironment [60,61], implicating a role of tumor-specific αvβ3
expression in breast cancer metastasis to bone as well as tumor-
associated osteolysis. Likewise, in prostate cancer cells, active αvβ3 is
necessary for the adherence and migration to bone matrix proteins at
early stages of skeletal metastasis. This tumor cell αvβ3 integrin
expression allows cancer cells to adhere to the bone matrix and
interact directly with the native bone cells, OBs and OCs, as well as
with the bone matrix itself [59].
The β1 family member, α5β1, has been identified as the primary
integrin receptor for fibronectin on human bone marrow stroma [57].
α5β1 expression on leukemia, prostate and breast cancer cells
facilitates interaction with bone stroma [57,63–65]. Antibody inhibi-
tion of α5, β1 or fibronectin blocks prostate cancer tumor cell binding
to bone stroma, indicating necessary roles for both integrin α5β1 on
tumor cells and fibronectin on bone marrow stromal cells [57]. In
breast cancer skeletal metastasis, the interaction between malignant
cell α5β1 and host stromal cell fibronectin contributes to the survival
of growth-arrested tumor cells, a potential mechanism throughwhich
tumor cells can become sequestered and “dormant” within the bone
marrow cavity andmay later begin to proliferate to establish a skeletal
metastasis [64]. Upon FGF-2 growth factor stimulation, breast cancer
cells undergo growth arrest and up-regulateα5β1 expression. Inmost
cases, these cells die, but cells that bind fibronectin via α5β1 and
initiate cell survival signaling cascades survive [64].
Another β1 family member, α2β1, a collagen type I receptor, is
expressed by prostate tumor cells, and its activity promotes invasion
and adherence to the bone stroma. The presence of collagen I, the
most abundant protein in bone, significantly increases prostate
epithelial cell adhesion in culture, and antibody inhibition of integrin
subunits α2 and β1 significantly inhibits tumor cell binding to stroma
[66]. Hall et al. showed that a skeletal metastatic prostate cancer cell
line, but not cell lines that are metastatic to other organs, binds to
collagen I and that this collagen I binding is α2β1 dependent in vivo
[67]. Interestingly, stromal expression of collagen I does not increase
tumor growth, but instead promotes tumor cell migration [67]. Tumor
cell α2β1 binding of host bone marrow stromal collagen I activates
RhoC GTPase which instigates a signaling cascade responsible for
cytoskeleton reorganization, migration, and, eventually, collagen-
stimulated invasion and preferential skeletal metastasis [68].
α4β1/vascular cell adhesion molecule-1 (VCAM-1) binding has
been identified as important for cell–cell contact between α4β1
expressing myeloma cells and VCAM-1 expressing bone marrow
stroma [69]. This interaction contributes to bone tumor growth, OC
stimulation and resultant osteolysis [69,70]. Likewise, epithelial
tumor cells (CHO) that overexpress α4β1 developed significantly
more bone metastases than mice inoculated with CHO cells alone
[71]. Bone metastases, but not other metastases, were inhibited by
antibodies against α4 and/or VCAM-1, suggesting a role for α4β1/
VCAM-1 binding in the skeletal metastases of solid tumors [71].
The role of integrins and chemokine cross talk in tumor cell
homing to bone will be discussed later. While many aspects of
tumor–bone stromal interactions remain unknown, it is clear that
specific interactions between tumor cell integrins and bone stromal
cell ligands are essential for successful homing and metastasis to
bone.
Integrin expression and signaling in osteoclast function and bone
metastasis
Bone invading metastatic tumor cells co-opt integrin signaling
pathways that enhance OC function and recruitment. As part of
bone remodeling, OCs bind to the bone matrix, form an actin ring
mediated sealing zone, secrete enzymes and acid to degrade bone,
and then migrate to a new site. Each of these functions is regulated
in part by integrins located on the membrane surface of the OC,
interacting with neighboring cells and with the ECM [72].
Table 1
Extracellular matrix proteins and the main integrins that participate in bone metastasis
and tumor growth in bone.
Integrin ECM ligands
αvβ3 Vitronectin, osteopontin, bone sialoprotein, fibronectin, TSP-1
α2β1 Collagen I, laminin
α4β1 (VLA-4) VCAM-1 fibronectin, osteopontin
αvβ1 Fibronectin, vitronectin
αvβ5 Vitronectin, osteonectin, bone sialoprotein, fibronectin
αIIbβ3 Fibrinogen
β2 VCAM-1, ICAM-1, fibrinogen
α1β1 Collagen
α5β1 Fibronectin
α9β1 TSP1
α6β4 Laminin, TSP-1
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Several integrins are involved in OC binding to bone, including
αvβ3 (osteopontin, vitronectin, bone sialoprotein), αvβ5 (fibronec-
tin), and α2β1 (collagen) [73,74]. Of these, αvβ3 is the predominant
integrin found on OCs, and antibody inhibition of αvβ3 inhibits OC
attachment to the bone matrix as well as OC mediated bone
resorption [75]. In addition, mice with targeted disruption of β3
integrin (β3−/−) have defective OC function [76] and are protected
from tumor-associated osteolysis [77]. αvβ3 is responsible for
mediating OC-bone recognition [53,75,78,79] and subsequent attach-
ment to the bone matrix [75,80], signaling to create the characteristic
resorptive ruffled membrane, regulation of OC spreading, and overall
organization of the cytoskeleton [76,81]. Activation of αvβ3 regulates
OC adhesion and migration on osteopontin, important for OC
polarization and bone resorption [82]. Osteopontin ligand binding of
αvβ3 causes a reduction of OC cytosolic calcium, inducing podosome
formation and subsequent resorption [83]. In addition,αvβ3 is critical
for the activation of c-Src, c-Cbl, and GTPases Rho and Rac, signaling
that is necessary for the cytoskeletal reorganization important in OC
function [81,84,85].
OC targeted therapy is a standard of care for the treatment of
bone metastasis and myeloma bone disease. Tumor cells recruit OCs
resulting in bone destruction and pain [3,86,87]. Because of its
known role in OC function and its high expression in skeletal
metastatic tumors much research has focused on αvβ3 integrin and
its ligands. An important characteristic of αvβ3 mediated cell
adhesion, both in OCs and tumor cells, is the requirement of
osteopontin, an αvβ3 ligand [58]. Osteopontin is a non-collagenous
bone matrix protein that is produced by OBs, OCs, and macrophages
and is found in the ECM adjacent to calcified bone [88–90].
Expression of osteopontin in both the tumor cell and in the bone
microenvironment can promote skeletal metastasis [91,92]. Osteo-
pontin-deficient mice have reduced bone metastasis and tumor-
induced osteolysis than wild type controls in a mouse model of
tumor metastasis using syngeneic B16 melanoma cells [93,94],
confirming a role for host cell osteopontin expression during bone
metastasis. Recombinant osteopontin induces cell migration of B16
cells that is inhibited by repressing the ERK/MAPK pathway,
suggesting that the ERK/MAPK pathway regulates bone microenvi-
ronment osteopontin levels [91]. Overexpression of osteopontin in
B16 melanoma cells increases cell proliferation and migration,
indicating that the ligand also plays an important role in the tumor
cell itself [91]. It has been demonstrated using a prostate cancer cell
line overexpressing osteopontin that tumor cell osteopontin
regulates MMP-9 secretion and the subsequent CD44/MMP-9
interaction, important for the migration of prostate cancer cells,
contributing to metastatic potential [95]. Osteopontin-producing
tumor cells enhance osteopontin production by OBs [96] and OCs
[97], stimulating osteoclastogenesis, OC adherence, migration, and
bone resorption via host αvβ3 binding [88,98]. Osteopontin
activation of αvβ3 integrin leads to downstream activation of
FAK, c-Src kinase, and Ras-ERK, among other signaling molecules,
resulting in cytoskeletal reorganization, focal adhesion formation,
basolateral membrane differentiation, and osteoclastic resorption
[59,99].
CD47, integrin associated protein, is expressed constitutively
and interacts with integrins, including αvβ3, as part of inside-out
signaling cascades and also operates in an integrin-independent
manner. CD47 plays a role in OC and macrophage biology and
CD47−/− mice have decreased OC number and function [100,101]
which can be rescued in vitro by inhibiting nitric oxide synthase
[101]. CD47−/− mice have decreased bone metastases and tumor-
associated osteolysis compared to wild type [101]. During the early
stages of osteoclastogenesis, namely, macrophage fusion, CD47
binds with SIRP1α, a molecule that is transiently induced in
myeloid cells and that likely participates in early fusion events
[102]. In the event of tumor cell metastasis to bone, however, it
has been reported that cancer cells may utilize this macrophage
self-recognition signaling to fuse with macrophages [103], leading
to mature OCs with tumor cell nuclei and subsequent over-
expression of OC stimulation factors, thus leading to increased OC
function [104].
These data underscore the importance of integrins, especially
αvβ3, and its adaptor proteins in OC biology and bone metabolism
and point to the role of OC integrins in regulating growth of cancer
cells in the bone.
Integrins and tumor neovasculature and bone metastasis
Tumor neovascularization is essential for tumor cell invasion and
metastasis. Access to the host blood supply provides the tumor cells
with nutrients and connects the tumor to the circulation, facilitating the
dissemination of metastatic cells. The angiogenic process begins with
the de-stabilization and de-differentiation of local vessels, followed by
activation of endothelial cells (EC), EC migration and proliferation into
the tumor ECM, and finally organization of ECs into functional vessels.
The ability of tumor cells to activate the normally quiescent vasculature
is proposed to be controlled by an “angiogenic switch” mechanism,
whereby tumor or stromal cells induce changes in the relative balanceof
inducers (e.g. vascular endothelial growth factor (VEGF) or TGFβ, PDGF,
TNFα, bFGF) and inhibitors (e.g. thrombospondin-1 [TSP-1]) of
angiogenesis reviewed in [41,105–109]. Activated platelets, tumor
cells, andfibroblasts secretemany of these pro-angiogenic factors. It has
recently been appreciated thatmacrophage lineage cells play important
roles in promoting tumor-associated angiogenesis [110–113]. Bone
metastasis and bone residing tumors like myeloma also modify and
recruit ECs to enhance neoangiogenesis [114,115].
Many integrin heterodimers have been implicated in tumor-
associated angiogenesis [41,105–109,116]. The first integrin found to
regulate angiogenesis, αvβ3, is expressed at high levels on tumor-
associated vasculature [117,118] and tumor-associated angiogenesis
can be inhibited by β3 integrin neutralizing antibodies [119–122].
αvβ3 has been specifically implicated in the angiogenesis associated
with prostate cancer bone metastases; antibody inhibition of αvβ3
decreases tumor-associated blood vessels in mice [123]. Interestingly,
Reynolds et al. demonstrated enhanced (not reduced) tumor-
associated angiogenesis in subcutaneous tumors in β3−/− mice
[124]. Elevated levels of VEGFR2 were found on tumor-associated
blood vessels in β3−/−mice, and a VEGFR2 inhibitor could block the
enhanced blood vessel formation [125]. It should be noted that an
inhibitor of integrin binding and signaling might have different
consequences than loss of integrin expression. For example, apoptotic
machinery is activated in certain cells expressing integrins that are
not ligand-bound [126–129]. Recent reports that low dose integrin
antagonists can increase tumor growth and angiogenesis while higher
doses suppress tumor growth and angiogenesis [130] underscore the
complexity of targeting β3 integrins for angiogenesis and cancer
therapy.
Another αv integrin, αvβ5, also shows increased expression on
tumor-associated vasculature, and αvβ5 antibodies inhibit VEGF-
induced tumor-associated angiogenesis [131]. In contrast, the β3/
β5−/− double knockout mice show enhanced tumor-associated
angiogenesis, as was seen in β3−/− mice [125]. Several hypoth-
eses have been proposed that reconcile the contradictory results
involving the αv integrin family that outline the roles of the
integrins as pro-angiogenic, anti-angiogenic, and/or working
through different pathways as reviewed in [41,108]. It is clear,
however, that αvβ3 and αvβ5 have distinct roles in regulation of
tumor-associated angiogenesis and associated metastasis. The bone
targeted bisphosphonate, zoledronic acid, alters EC integrin-
mediated adhesion by reduced expression of αvβ3 and αvβ5
integrin on ECs in vitro in one observation [132]. This observation
provides a possible mechanism for OC-independent anti-tumor
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actions for bisphosphonates that have been reported in animal
models [133–135] and clinically [136–139]. Evaluation of the
effects of bisphosphonates on integrin signaling in the tumor–
bone microenvironment is underway.
While much of the research in integrin-mediated angiogenesis has
been focused on the αv integrins, there is evidence that other
heterodimers play a role in angiogenic regulation, particularly the β1
and β4 families. The β1 integrin family (α1β1, α2β1, α5β1, and
α4β1) has a critical role in angiogenesis with β1−/− mice having
severe vascular defects. α1β1 (a collagen receptor) and α2β1 (a
laminin receptor) have been shown to be important for mediating cell
adhesion in VEGF-stimulated ECs [140]. In vivo, function-blocking
antibodies to α1 and α2 significantly inhibited VEGF-induced
angiogenesis, indicating a positive regulatory role for α1β1 and
α2β1 expression in tumor-associated angiogenesis [141]. Genetic
data further support a role for the integrin α1β1 as a positive
regulator of angiogenesis as α1-deficient mice show reduced
angiogenesis [142].
Fibronectin receptor α5β1 has also been implicated as a positive
regulator of angiogenesis: α5β1 antagonists inhibit tumor-associated
angiogenesis in mice by inhibition of EC migration and regulating
proliferation and apoptosis [143,144]. Importantly, the α5β1 antago-
nists did not inhibit angiogenesis induced by VEGF, indicating that the
integrin α5β1 (together with αvβ3) may act in a VEGF-independent
pathway [144]. α4β1, together with its ligand, VCAM-1, expressed in
vessel mural cells, plays an important role in adhesion of ECs and
vascular smooth muscle cells during blood vessel formation [145].
Both anti-α4β1 antibodies and anti-VCAM-1 antibodies inhibit
angiogenesis in vivo. Another integrin, laminin receptor α6β4 is
reported to regulate several aspects of tumor angiogenesis. Genetic
studies revealed that α6β4 promotes endothelial cell migration in
culture; in addition, the integrin is involved in the translational
regulation of VEGF, having a pro-angiogenic effect [146,147].
In many cases, integrins influence angiogenesis through their
interaction with the integrin ligand thrombospondin 1 (TSP-1). Mice
with a TSP-1 deficiency have increased tumor burden and tumor-
associated vasculature, both in capillary size and number, while mice
that overexpress TSP-1 have delayed or absent tumor growth and
reduced tumor-associated vasculature [148]. These data indicate that
TSP-1 can contribute to tumor burden via negative regulation of
angiogenesis. In contrast, in a human breast cancer cell line, TSP-1
stimulation up-regulates both integrin subunit α6 mRNA levels and
protein levels which leads to increased adhesion to ECM protein
laminin in vitro, suggesting that TSP-1 facilitates pathogenic angio-
genesis [149]. TSP-1 also interacts with α9β1 via its N-terminal
domain and has a positive effect on proliferation and motility in
culture and on angiogenesis in vivo that can be reduced by α9β1
inhibitors. This binding of the microvasculature-associated integrin in
ECs with TSP-1 activates signaling cascades including ERK and
paxillin. Thus, TSP-1 can play both pro- and anti-angiogenic roles,
depending on its specific integrin interaction.
The roles of integrins in tumor-associated angiogenesis are
complex, not only involving integrin ligand interactions and associ-
ated signaling pathways, but also specific temporal regulation and
indirect effects through proteins such as TSP-1, and are important for
the progression of angiogenesis and eventual metastasis.
Integrin-hematopoietic cell interactions: tumor-induced
mobilization and modulation of bone marrow cells
The bone marrow is the primary site of hematopoiesis in the adult.
OBs and bone marrow stromal cells regulate hematopoietic stem cell
(HSC) growth, differentiation and bone marrow retention through
numerous signaling pathways including integrin VLA-4/VCAM [150],
chemokine SDF-1/CXCR4, BMPs and Notch [151–156]. Hematopoietic
progenitors and stem cells express the integrin VLA-4 and the
chemokine receptor CXCR4. OB and bone marrow stromal cells
produce VCAM-1, SDF-1 and osteopontin, all important components
of the “HSC niche” [157–159]. Integrin and chemokine signaling work
in concert to promote HSC and progenitor cell homing and
mobilization in the bone marrow [160]. Disruption of VLA-4/VCAM-
1 and SDF-1/CXCR4 interactions results inmobilization of HSC into the
circulation [159]. G-CSF mobilization of HSC acts in part through
disruption of VLA-4/VCAM-1 and CXCR4/SDF1 interactions [158,161].
OC resorption can also regulate HSC mobilization and the stem cell
niche [162].
Diverse integrins are expressed on hematopoietic progenitor cells
in specific patterns and at distinct time points [163]. Integrins not only
mediate the binding of normal progenitor cells to stroma and matrix
molecules, but may also regulate expansion, maturation and differ-
entiation of those cells [164,165]. For example, α4β1 integrin
regulates hematopoietic progenitor cell fate through changes in
integrin expression and activity levels during cell maturation and
differentiation into erythrocytes and neutrophils [165–167]. α4
containing integrins mediate adhesion of hematopoietic progenitors
to stromal cells likely through binding to matrix components such as
fibronectin [168] or cellular receptors such as VCAM-1 [169]. The
integrin subunits α5, α6 and α9 have also been shown to be
expressed by progenitor cells [170–172]. Studies using blocking
antibodies demonstrated that α6 subunit cooperates in collaboration
with theα4 subunit in regulating the homing of progenitor cells [171].
α9β1 integrin is also important for adhesion of progenitor cells to OBs
in the bone marrow [172], illustrating the fact that hematopoiesis
takes place in three dimensional matrices, the so-called bone marrow
niches. These niches are located at the endosteum near OBs and in the
vascular niche close to marrow blood vessels [173].
Tumor cells both in the bone microenvironment and at distant sites
canmodulate andmobilize hematopoietic progenitor and immune cells
to promote bone and visceral metastasis and local tumor growth.
Tumor-induced mobilization of VEGFR+ and Sca+kit-bone marrow
derived cells has been implicated in enhancing distant tumor and
metastatic growth [174]. These mobilized VEGFR+ cells also express
α4β1 and can migrate to sites of increased synthesis of matrix
components such as fibronectin and establish a “pre-metastatic niche”
that can favor tumormetastasis and growth [174]. β2 integrins on bone
marrow derived endothelial progenitors can also mediate the adhesion
and VEGF-induced migration of the progenitors to the mature
endothelium of actively remodeling vasculature [175].
Tumor cells from a primary lesion can act at a distance to influence
bone marrow hematopoiesis through secreted factors such as the
integrin ligand, osteopontin [176]. Primary epithelial tumors can
instigate growth of indolent tumors through modulation of the bone
marrowmicroenvironment andmobilization and recruitment of bone
marrow cells to distant tumor sites [176,177]. McAllister et al. found
that tumor secretion of osteopontin is necessary but not sufficient in
xenograft models to modulate the bone microenvironment and
promote bone marrow cell recruitment to tumor metastasis [176].
Pazolli et al. found that osteopontin secreted by senescent fibroblasts
promoted tumorigenesis in animal models of skin cancer [178].
Thus tumors cells both in bone and at distant sites can modulate
hematopoiesis in part through osteopontin and bone marrow cell
integrins resulting in the mobilization and recruitment of bone
marrow derived cells that will enhance local and metastatic tumor
growth.
Integrins and tumor cell homing/colonization of bone
The site of metastasis is tumor cell specific depending on their
integrin, chemokine receptor and cytokine/receptor expression
profiles [50,179–181]. At the metastatic site, normal physiology is
changed towards increased secretion of cytokines and activation of
integrins to support recruitment, survival and growth of tumor cells.
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Metastasizing cancer cells can co-opt the same mechanisms used in
physiological hematopoietic progenitor cell homing to bone through
expression of integrins and chemokines [150,152,153]. CXCR4
expressed on cancer cells can direct those cells to bone [181–186].
The migration of myeloma cells to and across bone marrow stromal
cells is in part regulated by SDF-1α/CXCR4 ligation and up-regulation
of α4β1 (VLA-4) results in adhesion of myeloma cells to the
underlying bone marrow stroma [187]. Likewise, CXCR4 ligation can
increase αvβ3 expression and aggressiveness of metastatic prostate
cancer cells, and disruption of CXCR4 can inhibit prostate cancer bone
metastases [183–185].
It has recently been shown that β3 integrin activity on circulating
CXCR4-positive bone marrow derived cells is important for their
migration and recruitment to sites of angiogenesis. In mice with
mutated tyrosine residues “knocked in” to the β3 integrin locus to
inhibit proper phosphorylation (DiYF mice) [188], CXCR4-positive
bone marrow derived cells were higher in number and defective in
recruitment to subcutaneously implanted tumors or wounds, where
SDF-1 levels were also lower [189]. These data demonstrate that β3
integrin on bone marrow derived cells may be critical for the CXCR4/
SDF-1 gradient, and thus may be important for localization of tumor
cells to the bone microenvironment and also localization of myeloid/
ECs to tumors. Interestingly, CXCR4 deletion on bonemarrow cells can
enhance OC activity which could counteract some of the beneficial
effects of CXCR4 inhibition on bone metastases [9].
Integrins expressed by tumor cells, in concert with bone
microenvironment chemokine secretion and further integrin activa-
tion, determine the osteotropic characteristics of metastasizing cancer
cells and represent an ideal target for skeletal metastatic cancer
therapy.
Integrins and myeloid/immune cell function during tumor
growth in bone
Myeloid cell integrins are involved in tumor escape from immune
responses and tumor-induced angiogenesis. Bone marrow derived
myeloid cells (macrophages, monocytes, myeloid derived suppressor
cells, andmyeloid dendritic cells) migrate to tumors and contribute to
tumor growth, invasion and angiogenesis [190–194]. Macrophages
within tumors, called tumor-associated-macrophages (TAM) [127],
are recruited by chemoattractants such as MCP-1 [195] secreted by
the tumor and then differentiate into tissue macrophages [196]. The
anti-tumor M1 phenotype represents a classical activation that is
induced by pathogens, lipopolysaccharides (LPS) or interferon gamma
resulting in secretion of proinflammatory cytokines such as tumor
necrosis factor α (TNFα), interleukin 1β (IL-1 β) and others. M1
macrophages can act in an anti-tumor fashion by secretion of
cytotoxic cytokines and antigen presentation to lymphocytes [197].
The pro-tumor M2 phenotype, represents alternative activation
induced by IL-4 or IL-10 [198]. M2 polarized macrophages promote
tumor cell proliferation and survival, suppress immune responses and
drive tumor neoangiogenesis [197,199–201]. Studies have shown that
the TAM content of tumors and prognosis of patients are inversely
correlated [192,202,203].
β2 integrins are involved in monocyte/myeloid cell migration
through endothelium and in phagocytosis, while β1 integrins mediate
adhesion to matrix proteins and the induction of inflammatory genes
[204]. α4β1 and αvβ3 integrins have been implicated in myeloid cell
homing, adhesion and migration to tumors. α4β1 promotes endo-
thelial progenitor cells and monocyte homing and adhesion to sites of
active pathological angiogenesis [205]. Inhibition of α4β1 leads to
suppressed monocyte and macrophage colonization of tumors and
associated vasculature and decreased angiogenesis [194].
The αvβ3 integrin is down-regulated during differentiation of bone
marrow myeloid progenitor cells to monocytes but induced in
macrophages during inflammation [206,207]. αvβ3 promotes myeloid
homing, adhesion and migration of bone marrow derived cells through
the endothelium to sites of tumor angiogenesis [189]. β3 integrins are
involved in phagocytosis of apoptotic cells [208,209] and limit the
secretion of inflammatory mediators [207]. Defective macrophage
tumor infiltration is observed in TAM from β3−/− bone marrow,
myeloid specific β3KOM−/− mice and in the signaling defective DiYF
β3mice (micewith twomutated tyrosine residues) [111,189,210–213],
suggesting that defective cytoskeletal reorganization or lack of
appropriately polarized macrophages [212] within tumors may be due
to β3 integrin deficiency.
Myeloid derived suppressor cells (MDSC) [214] represent a
subpopulation of immature myeloid cells that are roughly character-
ized by GR1+ and by the αMβ2(CD11b) integrin adhesion marker
[214]. The MDSC suppress T-cell antigen receptor mediated immune
responses [190] and can promote TAM M2 polarization [215]. MDSC
from myeloma bearing mice had a greater capacity to become bone
resorbing cells compared toMDSC from control mice [191]. The role of
integrins in MDSC differentiation, recruitment and function is under
investigation. Integrins are involved in monocyte/macrophage differ-
entiation and recruitment to tumors and can influence local and
metastatic tumor growth.
Integrins and tumor recruited platelets and bone metastasis
Cancer cells co-exist with platelets and mononuclear hematopoi-
etic cells in thrombi located throughout the organs of patients with
metastatic cancer [216–218]. Platelet aggregation and activation
enhances tumor growth and metastasis to bone [77,219]. Platelets
are anuclear metabolically active cells that are formed from bone
marrowmegakaryocytes. Platelet aggregation is stimulated by soluble
factors such as ADP and thromboxane (TXA2), membrane proteins,
collagen or von Willebrand factor that are produced by injured
endothelial, inflammatory and tumor cells. αIIbβ3 plays a central role
in the initiation of arterial thrombosis and platelet aggregation
[220,221]. αIIbβ3 integrins are expressed on the surface of mega-
karyocytes and platelets and are undetectable on any other non-
cancerous cell type. Mice globally deficient for the β3 integrin have
prolonged bleeding times, defects in platelet aggregation and clot
retraction and cutaneous and gastrointestinal bleeding, all character-
istics of Glanzmann's thrombasthenia, [222] a disease characterized by
functional reduction or absence of αIIbβ3 in humans. Targeting β3
integrins by monoclonal antibodies to the receptor (abciximab/
Reopro) or by inhibiting the binding of the ligand fibrinogen to the
receptor (tirofiban/Integrilin) are used in patientswith acute coronary
and cerebral vascular syndromes but have significant bleeding risks
that prevent their usefulness for chronic uses such as cancer.
Tumor cell lines have been shown to induce platelet aggregation
and adhesion in vitro through mechanisms involving αIIbβ3 integrin,
ADP, thrombin, vonWillebrand factor and selectins [77,223–229]. The
metastatic potential of tumor cell lines is markedly diminished in
mice with defective platelet aggregation (β3 integrin−/−, Gaq−/−,
Par4−/−, NFE2−/− and fibrinogen−/−) [77,219,223,226,228–244].
β3−/− mice are protected from bone metastasis in part through a
mechanism involving defective platelet aggregation [77]. Additional-
ly, tumor cells engineered to respond to platelet-derived lysopho-
sphatidic acid (LPA) have enhanced bone metastatic potential in mice
[219]. Platelets also represent a significant source of pro-angiogenic
(VEGF) and anti-angiogenic factors (TSP-1) and are recruited to tumor
sites where their aggregation could affect local tumor growth [245].
Platelet-specific integrin targeting is a promising therapeutic ap-
proach for inhibiting bone metastasis, especially to prevent or slow
metastasis.
In contrast to platelets, bone marrow megakaryocytes can inhibit
prostate cancer tumor growth in bone [246]. Megakaryocytes can
indirectly inhibit bone resorption by inhibiting OC formation [247].
The negative effect of megakaryocytes on bone resorption is likely
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mediated in part through the OC inhibitory factor osteoprotegrin that
is contained in secretory granules of platelets and megakaryocytes
[248,249]. Adhesion of mature polyploid megakaryocytes to fibro-
nectin is also mediated by β1 subunit containing integrins [250,251].
Megakaryocytes may also influence bone remodeling and resorption
through effects on OB proliferation that are mediated by the α3β1,
α5β1 and glycoprotein IIb integrins [252]. Given the location of
maturemegakaryocytes at vascular sinusoids, they are also among the
first cells to physically encounter cancer cells as they enter the bone
marrow, so a direct mechanism of action involving integrin-mediated
signal transduction could be involved. Interestingly, bisphosphonates
(BP) increase megakaryocyte proliferation and increase the platelet
concentration of the anti-angiogenic integrin ligand TSP-1 [253–255]
which suggests non-OC mechanisms of BPs' action in decreasing
tumor growth in bone. Thus, platelets and their megakaryocytic
precursors interact with cancer cells before, during and after
metastasis to bone through interactions mainly determined by
integrins and their ligands.
Integrins and bone metastasis: Therapeutic aspects
Because of the wide range of functions in physiological and
pathological processes, the integrin family of adhesion receptors has
been adopted as a promising target for metastatic bone diseases.
Several tumor cell types express an abnormal integrin profile
compared to non-tumor cells [41,51,256], providing an opportunity
for specific targeting. Targeting integrins on both tumor and/or host
cells has proven to be effective not only in blocking local cancer
progression, but also in reducing tumor cell detachment from their
primary site in preclinical models [257–259].
In recent years, integrins on the tumor cells and the endothelium
have been targeted by monoclonal antibodies and RGD peptides in
order to reduce tumor angiogenesis [109,260]. Integrin antagonists,
including humanized monoclonal antibodies, small molecule antago-
nists and cyclic peptides, have been developed based on the
recognition sequences of integrin physiological ligands [261]. Several
compounds are already in clinical use or undergoing their clinical
evaluation for various diseases.
For the future treatment of skeletal metastasis, the αvβ3 integrin
has become an attractive target because of its expression in tumor and
angiogenic cells, its role in OC differentiation and function and its role
in tumor cell homing to bone [53,60,61,183,262–267]. The multiple
expected beneficial effects on endothelial, cancer and osteoclastic
cells instigated a significant effort to develop drug candidates that
target the αvβ3 integrin for therapy of skeletal complications of
cancer. These strategies resulted predominantly in antagonists of
αvβ3, αvβ5 and αIIβ3 integrins that showed efficacy in animal
models. Peptidomimentic antagonists of theαvβ3 andαvβ5 integrins
were successfully used to inhibit OC in vitro and to reduce bone loss in
a rat osteoporosis model [268]. An active nonpeptide αvβ3 integrin
antagonist and anti-αvβ3 antibodies were shown to hinder cancer
induced bone loss [79,268–270]. It is possible that the current
treatment for bone metastasis, BPs, may also exert an effect on
αvβ3 on both ECs [132] as well as OCs in a similar manner.
Many drugs candidates targeting integrin αvβ3 have advanced to
the clinic for the treatment of osteoporosis and cancer, though none
have specifically targeted patients with bone metastases. A lipophilic
isoester of RGD (L000845704), developed by Merck, is effective in
increasing bone mineral density (BMD) in postmenopausal women
[271]. Another inhibitor, RGD-mimetic cyclic peptide Cilengitide
(EMD-1219974) directed at both αvβ3 and αvβ5 [272] and currently
investigated by MerckSerono, is in advanced stages of clinical testing
for the treatment of glioblastoma multiforme and is under investiga-
tion for the treatment of squamous cell carcinoma, prostate cancer,
and lung cancer (Phase II).
Clinical trials of function-blocking antibodies are also ongoing,
including Vitaxin (LM609), a humanized monoclonal IgG1 antibody
against the extracellular domain of the αvβ3 integrin heterodimer.
Vitaxin had substantial anti-angiogenic effects in preclinical models
[119,262] and has shown direct anti-tumor effects as well as impaired
bone resorption by inhibiting OC attachment to the bone surface
[273]. Another monoclonal antibody (CNTO95), directed against the
αv subunit, is under development by Centocor and is in phases I–II
testing for solid tumors. Two other additions to this therapeutic family
are planned to be more specifically evaluated for their effects on bone
metastasis [62], organic small molecule GLPG0187 [62] and peptide
antagonist S247 [257].
Given the participation of the OCs, blood vessels and platelets in
bone metastases, it may be beneficial to block both αvβ3 and αIIβ3
integrins on host cells. This concept of combination inhibition relies
on the common RGD ligand binding domains of αvβ3, αvβ5 and
αIIbβ3. In fact, many of the synthetically designed αvβ3 integrin
inhibitors display some selectivity towards αvβ5 integrin, and, in
the case of Cilengitide, this dual antagonism is part of the
mechanism to treat cancer by inhibiting neoangiogenesis as well
as invasion [274,275]. The strategy to combine multiple targets also
bears some risks with regards to the desired high therapeutic
specificity and low off-target toxicity. This issue is further
complicated by the differential function of the integrins as
determined by their location, expression level, activation status
and ligand binding. Studies in animal models and xenograft tumor
models have demonstrated that low concentrations of αvβ3
integrin antagonists can act as integrin agonists [130,276,277].
Further research is necessary to identify optimal drug dosing and
targeting that overcome the problem of generalized integrin
inhibition to reduce or prevent skeletal metastasis.
Another area of active research in bone metastasis therapeutics
is the specific targeting of integrins on HSCs or progenitors that
prepare the metastatic niche and enhance bone marrow coloniza-
tion by cancer cells which then instigate the vicious cycle of bone
metastasis [278,279]. Interfering with integrin-mediated homing of
cancer cells to the cells to the bone represents an early option for
intervention. siRNA against the αv integrin subunit was used to
prevent the progression of prostate cancer to bone by interfering
with the ECM–integrin interaction [280]. In another approach, a
disintegrin and a neutralizing antibody to VCAM-1 or its receptor
α4β1 integrin reduced metastasis of melanoma cells and dimin-
ished osteolysis by decreasing OC activity in a myeloma in vitro
model [69,281]. These strategies, however, are not yet in clinical
trials. An exciting new approach to cancer therapy takes advantage
of the fact that cancer cells use CXCR4 and VLA-4 to home to and
engraft in the marrow. HSC mobilizing agents such as AMD3100 and
anti-VLA-4 targeted agents can be used to mobilize leukemia and
myeloma cells into the blood from the bone marrow leading to
increased sensitivity to chemotherapy [282–284] in mice. This
approach is now being tested in clinical trials.
Future perspectives
Despite the high level of complexity of the integrin family, the
β3 integrin remains a major target in the search for effective
therapies for skeletal metastasis. In recent years, a steady increase
in knowledge has led to clinical testing of several interesting
compounds. There remains, however, a lack of clarity concerning
the exact roles of the integrins in different cell types. In the initiated
clinical studies using αvβ3 integrin antagonists, the overall effect in
reducing tumor growth and pathological angiogenesis in fast
progressing deadly tumors may outweigh potential undesired
effects in tissues or cells other than tumor or endothelial origin.
Drugs designed to tackle skeletal complications of cancer must be
targeted to the bone microenvironment. This fact is underscored by
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the clinical successes of the bone matrix targeted bisphosphonates
and the OC targeted denosumab in treating and preventing skeletal
complications of bone metastases and myeloma. A detailed
understanding of the role of integrin regulation in both the
metastatic tumor cells and the tumor-associated stroma will allow
for a more targeted and focused approach to treat bone metastases.
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